---
document_datetime: 2023-09-21 20:19:12
document_pages: 127
document_pathfilename: www.ema.europa.eu/en/documents/variation-report/kyprolis-h-c-3790-ii-0045-epar-assessment-report-variation_en.pdf
document_name: kyprolis-h-c-3790-ii-0045-epar-assessment-report-variation_en.pdf
version: success
processing_time: 196.7919392
conversion_datetime: 2025-12-30 21:59:03.512139
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
<!-- image -->

12 November 2020 EMA/CHMP/593622/2020 Committee for Medicinal Products for Human Use (CHMP)

## Assessment report

## Kyprolis

International non-proprietary name: carfilzomib

Procedure No. EMEA/H/C/003790/II/0045

## Note

Variation assessment report as adopted by the CHMP with all information of a commercially confidential nature deleted.

<!-- image -->

<div style=\"page-break-after: always\"></div>

## Table of contents

| 1. Background information on the procedure..............................................                                   | 5                                                                                                         |
|----------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------|
| 1.1. Type II variation ..................................................................................................5 |                                                                                                           |
| 1.2. Steps taken for the assessment of the product                                                                         | ........................................................5                                                 |
| 2. Scientific discussion................................................................................                   | 6                                                                                                         |
| 2.1. Introduction                                                                                                          | ........................................................................................................6 |
| 2.1.1. Problem statement                                                                                                   | ............................................................................................6             |
| 2.1.2. About the product                                                                                                   | .............................................................................................8            |
| 2.1.3. The development programme/compliance with CHMP guidance/scientific                                                  | advice........8                                                                                           |
| 2.1.4. General comments on compliance with GLP, GCP                                                                        | ..................................................9                                                       |
| 2.2. Non-clinical aspects..............................................................................................9   |                                                                                                           |
| 2.2.1. Introduction......................................................................................................9 |                                                                                                           |
| 2.2.2. Ecotoxicity/environmental risk assessment...........................................................9               |                                                                                                           |
| 2.2.3. Discussion on non-clinical aspects                                                                                  | ..................................................................... 10                                  |
| 2.2.4. Conclusion on the non-clinical aspects                                                                              | ............................................................... 11                                        |
| 2.3. Clinical aspects                                                                                                      | .................................................................................................. 11     |
| 2.3.1. Introduction....................................................................................................    | 11                                                                                                        |
| 2.3.2. Pharmacokinetics ............................................................................................       | 11                                                                                                        |
| 2.3.3. Pharmacodynamics..........................................................................................          | 30                                                                                                        |
| 2.3.4. PK/PD modelling                                                                                                     | ............................................................................................. 34          |
| 2.3.5. Discussion on clinical pharmacology...................................................................              | 41                                                                                                        |
| 2.3.6. Conclusions on clinical pharmacology.................................................................               | 42                                                                                                        |
| 2.4. Clinical efficacy                                                                                                     | .................................................................................................. 43     |
| 2.4.1. Main study(ies)                                                                                                     | ............................................................................................... 43        |
| 2.4.2. Discussion on clinical efficacy............................................................................         | 80                                                                                                        |
| 2.4.3. Conclusions on the clinical efficacy                                                                                | .................................................................... 85                                   |
| 2.5. Clinical safety                                                                                                       | .................................................................................................... 85   |
| 2.5.1. Discussion on clinical safety............................................................................           | 115                                                                                                       |
| 2.5.2. Conclusions on clinical safety..........................................................................            | 117                                                                                                       |
| 2.5.3. PSUR cycle                                                                                                          | ................................................................................................... 117   |
| 2.6. Risk management plan                                                                                                  | ..................................................................................... 118                 |
| 2.7. Update of the Product information......................................................................               | 121                                                                                                       |
| 2.7.1. User consultation                                                                                                   | .......................................................................................... 121            |
| 3. Benefit-Risk Balance...........................................................................                         | 121                                                                                                       |
| 3.1. Therapeutic Context                                                                                                   | ......................................................................................... 121             |
| 3.1.1. Disease or condition                                                                                                | ...................................................................................... 121                |
| 3.1.2. Available therapies and unmet medical need.....................................................                     | 121                                                                                                       |
| 3.1.3. Main clinical studies.......................................................................................        | 122                                                                                                       |
| 3.2. Favourable effects............................................................................................        | 122                                                                                                       |
| 3.3. Uncertainties and limitations about favourable effects...........................................                     | 122                                                                                                       |
| 3.4. Unfavourable effects.........................................................................................         | 123                                                                                                       |
| 3.5. Uncertainties and limitations about unfavourable effects                                                              | ....................................... 124                                                               |
| 3.6. Effects Table....................................................................................................     | 125                                                                                                       |
| 3.7. Benefit-risk assessment and discussion...............................................................                 | 126                                                                                                       |

<div style=\"page-break-after: always\"></div>

| 3.7.1. Importance of favourable and unfavourable effects............................................                   |   126 |
|------------------------------------------------------------------------------------------------------------------------|-------|
| 3.7.2. Balance of benefits and risks ..........................................................................        |   126 |
| 3.8. Conclusions ..................................................................................................... |   126 |
| 4. Recommendations...............................................................................                      |   126 |

<div style=\"page-break-after: always\"></div>

## List of abbreviations

| CR       | complete response                                             |
|----------|---------------------------------------------------------------|
| CrCl     | creatinine clearance                                          |
| DOR      | duration of response                                          |
| ECOG     | Eastern Cooperative Oncology Group                            |
| EU       | European Union                                                |
| GHS      | Global Health Status                                          |
| HR       | hazard ratio                                                  |
| IMiD     | immunomodulatory drug                                         |
| IMWG-URC | International Myeloma Working Group Uniform Response Criteria |
| IRC      | Independent Review Committee                                  |
| ISS      | International Staging System                                  |
| IV       | intravenous(ly)                                               |
| IxRS     | Interactive voice/web response system                         |
| Kd       | carfilzomib and dexamethasone                                 |
| KdD      | carfilzomib, dexamethasone, and daratumumab                   |
| MRD[-]CR | minimal residual disease negative-complete response           |
| ORCA     | Onyx Response Computational Assessment                        |
| ORR      | overall response rate                                         |
| OS       | overall survival                                              |
| PFS      | progression-free survival                                     |
| QLQ-C30  | Quality of Life Core Module                                   |
| QOL      | Quality of Life                                               |
| SAP      | statistical analysis plan                                     |
| SFLC     | serum free light chain                                        |
| SPEP     | serum protein electrophoresis                                 |
| UPEP     | urine protein electrophoresis                                 |
| US       | United States                                                 |

<div style=\"page-break-after: always\"></div>

## 1. Background information on the procedure

## 1.1. Type II variation

Pursuant to Article 16 of Commission Regulation (EC) No 1234/2008, Amgen Europe B.V. submitted to the European Medicines Agency on 12 February 2020 an application for a variation.

The following variation was requested:

| Variation requested   | Variation requested                                                                                                            | Type    | Annexes affected   |
|-----------------------|--------------------------------------------------------------------------------------------------------------------------------|---------|--------------------|
| C.I.6.a               | C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one | Type II | I and IIIB         |

Extension of existing indication to include combination of Kyprolis with daratumumab and dexamethasone; as a consequence, sections 4.1, 4.2, 4.8 and 5.1 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 12.0 of the RMP has also been submitted.

The variation requested amendments to the Summary of Product Characteristics and Package Leaflet.

## Information relating to orphan designation

Kyprolis, was designated as an orphan medicinal product EU/3/08/548 on 3 June 2008. Kyprolis was designated as an orphan medicinal product in the following indication: 'Kyprolis in combination with either lenalidomide and dexamethasone or dexamethasone alone is indicated for the treatment of adult patients with multiple myeloma who have received at least one prior therapy'

## Information on paediatric requirements

Pursuant to Article 8 of Regulation (EC) No 1901/2006, the application included (an) EMA Decision(s) P/0171/2019 on the granting of a (product-specific) waiver.

## Information relating to orphan market exclusivity

## Similarity

Pursuant to Article 8 of Regulation (EC) No. 141/2000 and Article 3 of Commission Regulation (EC) No 847/2000, the application included a critical report addressing the possible similarity with authorised orphan medicinal products.

## Protocol assistance

The MAH did not seek Protocol Assistance at the CHMP.

## 1.2. Steps taken for the assessment of the product

The Rapporteur and Co-Rapporteur appointed by the CHMP were:

Rapporteur:

Blanca Garcia-Ochoa

Co-Rapporteur:

Alexandre Moreau

<div style=\"page-break-after: always\"></div>

29 October 2020

| Timetable                                                                                                | Actual dates     |
|----------------------------------------------------------------------------------------------------------|------------------|
| Submission date                                                                                          | 12 February 2020 |
| Start of procedure:                                                                                      | 29 February 2020 |
| CHMP Rapporteur Assessment Report                                                                        | 14 May 2020      |
| CHMP Co-Rapporteur Assessment Report                                                                     | 30 April 2020    |
| CHMP members comments                                                                                    | 18 May 2020      |
| Updated CHMP Rapporteur(s) (Joint) Assessment Report                                                     | 23 May 2020      |
| Request for supplementary information (RSI)                                                              | 28 May 2020      |
| CHMP Rapporteur Assessment Report                                                                        | 22 October 2020  |
| PRAC Rapporteur Assessment Report                                                                        | 19 October 2020  |
| PRAC members comments                                                                                    | 21 October 2020  |
| Updated PRAC Rapporteur Assessment Report                                                                | 23 October 2020  |
| PRAC Outcome                                                                                             | 29 October 2020  |
| CHMP members comments                                                                                    | 3 November 2020  |
| Updated CHMP Rapporteur Assessment Report                                                                | 6 November 2020  |
| Opinion                                                                                                  | 12 November 2020 |
| The CHMP adopted a report on similarity of Kyprolis with Imnovid, Farydak, Darzalex, Ninlaro and Blenrep | 12 November 2020 |

## 2. Scientific discussion

## 2.1. Introduction

## 2.1.1. Problem statement

## Disease or condition

Kyprolis in combination with daratumumab and dexamethasone, either with lenalidomide and dexamethasone , or with dexamethasone alone is indicated for the treatment of adult patients with multiple myeloma who have received at least 1 prior therapy.

## Epidemiology

Multiple myeloma, an oligoclonal neoplastic proliferation of plasma cells, is the second most common hematologic malignancy with an estimated incidence worldwide in 2018 of 159 985 persons (Ferlay et al, 2018).  The 5-year prevalence of multiple myeloma worldwide was estimated at 376 005 persons.

<div style=\"page-break-after: always\"></div>

Multiple myeloma may represent less than 1 % of all cancer diagnoses but contributes to significant disease burden with over 2 million disability-adjusted life-years (Cowan et al, 2018; Bray et al, 2013). Despite recent therapeutic advances which have prolonged survival, multiple myeloma remains a fatal disease with nearly 100 000 annual deaths worldwide (1 % of cancer deaths) (Cowan et al, 2018; Kazandjian, 2016; Ferlay et al, 2015). Multiple myeloma is a disease of older adults, with a median age at diagnosis of 69 years (Surveillance, Epidemiology, and End Results Cancer Stat Facts, 2019).

## Biologic features, clinical presentation, diagnosis

Multiple myeloma is characterized by a recurring pattern of remission and relapse (Laubach et al, 2016; Durie et al, 2012; Jakubowiak et al, 2012). With each successive line of treatment, patients have lower response rates and a shorter duration of response (Kumar et al, 2012), remissions become increasingly transient, and the disease eventually becomes refractory (nonresponsive to the most recent therapy or progression within 60 days of discontinuation from the most recent therapy) (Laubach et al, 2016).  Thus, a need exists for new combination regimens to treat relapsed or refractory multiple myeloma.

## Management

The primary goals of treatment for relapsed or refractory multiple myeloma are to achieve deep and durable response and subsequently longer survival with an acceptable level of toxicity.  Additional goals are to prevent or delay disease-related morbidity (including bone fractures and renal insufficiency), to provide relief from pain and other disease-related symptoms, and to maintain the best possible quality of life (World Health Organization, 2019; Landgren and Iskander, 2017; Durie, 2010; Durie, 2005).

Regimens used and/or approved for the treatment of multiple myeloma incorporate conventional agents such as alkylating agents, anthracyclines, and corticosteroids, as well as novel agents including immunomodulatory drugs (IMiDs), proteasome inhibitors, monoclonal antibodies, and histone deacetylase inhibitors (National Comprehensive Cancer Network [NCCN], 2020; Moreau et al, 2017).  The novel and conventional agents are typically combined as doublet or triplet regimens and are sequenced across multiple lines of therapy.  Treatments for relapsed or refractory multiple myeloma that are either NCCN preferred regimens or European Society for Medical Oncology (ESMO) major regimens are listed in table 1.

Table 1.  NCCN Preferred and ESMO Major Regimens for Relapsed or Refractory Multiple Myeloma

| Regimens                                 | NCCN Category   | ESMO Major Regimen, Levels of Evidence and Grade of Recommendation   |
|------------------------------------------|-----------------|----------------------------------------------------------------------|
| Carfilzomib/dexamethasone (twice-weekly) | 1 - Preferred   | Major, II, A                                                         |
| Carfilzomib/lenalidomide/dexamethasone   | 1 - Preferred   | Major, II, A                                                         |
| Daratumumab/bortezomib/dexamethasone     | 1 - Preferred   | Major, II, A                                                         |
| Daratumumab/lenalidomide/dexamethasone   | 1 - Preferred   | Major, II, A                                                         |
| Ixazomib/lenalidomide/dexamethasone      | 1 - Preferred   | Major, II, A                                                         |
| Elotuzumab/lenalidomide/dexamethasone    | 1 - Preferred   | Major, II, B                                                         |
| Panobinostat/bortezomib/dexamethasone    | 1 - Other       | Major, II, C                                                         |

<div style=\"page-break-after: always\"></div>

| Carfilzomib/dexamethasone (once-weekly)   | 2A - Preferred   |
|-------------------------------------------|------------------|
| Bortezomib/lenalidomide/dexamethasone     | 2A - Preferred   |

ESMO = European Society for Medical Oncology; NCCN = National Comprehensive Cancer Network; -= not applicable ESMO level of evidence II = small randomized trials or large randomized trials with a suspicion of bias (lower methodological quality) or meta-analyses of such trials or of trials demonstrated heterogeneity strong

ESMO grade of recommendation:  A = strong evidence for efficacy with a substantial clinical benefit, strongly recommended; B = or moderate evidence for efficacy but with a limited clinical benefit, generally recommended; C = insufficient evidence for efficacy or benefit does not outweigh the risk or disadvantages (adverse events, costs, etc), optional

Source:  NCCN, 2020 and Moreau et al, 2017

Current treatment guidelines by NCCN and ESMO recommend regimens containing an IMiD for frontline therapy as well as lenalidomide for maintenance therapy, which has become standard of care (NCCN, 2020; Facon et al, 2018; Pulte et al, 2018; Moreau et al, 2017; McCarthy et al, 2017).

Despite recent therapeutic advances, relapse is virtually inevitable and patients can become refractory to IMiDs (Nijhof et al, 2018; Sonneveld et al, 2017; Cornell and Kassim, 2016).  Outcomes tend to be worse for patients who are refractory to lenalidomide than the overall population (Moreau et al, 2019.

## 2.1.2. About the product

Carfilzomib, a tetrapeptide epoxyketone, is a highly selective, irreversible second generation proteasome inhibitor. The epoxyketone pharmacophore of carfilzomib forms an irreversible, covalent adduct with the N-terminal threonine residue of the chymotrypsin-like active site of the 20S proteasome, while sparing nonproteosomal sites.  As a result, proteasome substrates accumulate, ultimately stimulating arrest and apoptosis of tumor cells.

Kyprolis (carfilzomib), is currently approved in the EU for the following indication:

'Kyprolis in combination with either lenalidomide and dexamethasone or dexamethasone alone is indicated for the treatment of adult patients with multiple myeloma who have received at least one prior therapy (see section 5.1)'.

The purpose of this marketing application is to support a new indication for carfilzomib, dexamethasone, plus daratumumab (KdD) in the treatment of adult patients with multiple myeloma who have received at least 1 prior therapy.  The key clinical study that contributed to the development of the KdD dose regimen is CANDOR, a phase 3, open-label, randomized study comparing KdD 20/56 mg/m 2  twice-weekly versus Kd 20/56 mg/m 2  twice-weekly in subjects with relapsed or refractory multiple myeloma who have received 1 to 3 lines of therapy.

## 2.1.3. The development programme/compliance with CHMP guidance/scientific advice

Scientific advice on the CANDOR study design was not obtained from regulatory authorities within the EU. However, a Type B pre-phase 3 meeting was held with the US Food and Drug Administration on 20 October 2016.

<div style=\"page-break-after: always\"></div>

## 2.1.4. General comments on compliance with GLP, GCP

Not applicable

## 2.2. Non-clinical aspects

No new non-clinical data have been submitted in this application, which was considered acceptable by the CHMP. The only new data submitted were related to ERA.

## 2.2.1. Introduction

A new ERA for Carfilzomib is submitted to update the data related to the variation (EMEA/H/C/003790/II/0001/G). In this variation, Carfilzomib is used in combination with dexamethasone for the treatment of patients with relapsed or refractory multiple myeloma.

## 2.2.2. Ecotoxicity/environmental risk assessment

An ERA was submitted based on the EMA guideline on the Environmental Risk Assessment of Medicinal Products for Human Use. Accordingly, Phase I was conducted by calculating both PBT and PECsw.

Screening for Persistence, Bioaccumulation and Toxicity (PBT)

Octanol-water partition coefficient was calculated in an OECD107 study. The final report was submitted in a previous variation (EMEA/H/C/003790/II/0001/G) in december2015 (table below).

| Buffer solution   |   Pow |   log Pow |
|-------------------|-------|-----------|
| pH 4              |  3580 |       3.6 |
| pH 7              | 40100 |       4.6 |
| pH 9              | 29000 |       4.5 |

Given that the value for Pow was above 4.5, an initial PBT assessment was performed via OECD308 test (Aerobic and Anaerobic Transformation in Aquatic Sediment Systems). The results of this test were submitted in a type IB variation (EMEA/H/C003790/IB/0014). In this test, Carfilzomib showed a DT50 of 0.5 days and a DT90 &lt;2 days. Two degradation products were identified (metabolite K and 2morpholineacetic acid). The degradation kinetics is shown below:

| Compound           | Compartment   | Calwich Abbey Lake system (silt loam 2% organic carbon)   | Calwich Abbey Lake system (silt loam 2% organic carbon)   | Swiss lake system (loamy sand 6.7% organic carbon)   | Swiss lake system (loamy sand 6.7% organic carbon)   |
|--------------------|---------------|-----------------------------------------------------------|-----------------------------------------------------------|------------------------------------------------------|------------------------------------------------------|
| Compound           | Compartment   | DT 50                                                     | DT 90                                                     | DT 50                                                | DT 90                                                |
| Carfilzomib        | Water         | 0.5                                                       | 1.7                                                       | 0.5                                                  | 1.7                                                  |
| Carfilzomib        | Sediment      | 0.4                                                       | 1.2                                                       | 0.3                                                  | 0.9                                                  |
| Carfilzomib        | Total system  | 0.5                                                       | 1.8                                                       | 0.5                                                  | 1.8                                                  |
| 2-morpholinoacetic | Water         | 85                                                        | 282                                                       | 117                                                  | 389                                                  |
| 2-morpholinoacetic | Sediment      | n.d.                                                      | n.d.                                                      | n.d.                                                 | n.d.                                                 |

<div style=\"page-break-after: always\"></div>

|              | Total system   |   111 |   369 |   142 |   472 |
|--------------|----------------|-------|-------|-------|-------|
| Metabolite K | Water          |   7.1 |    24 |  16   |    54 |
| Metabolite K | Sediment       |  11   |    36 |   2.7 |     9 |
| Metabolite K | Total system   |   8.5 |    28 |  16   |    53 |

However, bound residues and carbon dioxide accounted for 37.5% after 29 days and 43.1% after 99 days, which would indicate the extensive mineralization of Carfilzomib in natural biotic systems.

Calculation of the Predicted Environmental Concentration (PEC)

PEC surface water calculation was based on a revised Fpen, according to Questions and Answers EMA guidance document. The value of Pregion (prevalence) for a worst-case estimation was 3.72 people in 10000, taken from the Orphan Maintenance Report to the Committee for Orphan Medicinal Products.

<!-- image -->

The result of the estimation of total prevalence (0.0000795) was incorporated to the PECsw calculation, resulting in a value of 0.0049 µ g/L.

<!-- image -->

DOSEai = maximum recommended daily dose of active ingredient for the indication (123 mg/inh*day) Fprevalence = prevalence obtained from the previous formula (0.0000795) WasteWinhab = amount of wastewater discharged per person in a population per day (assumed to be 200 L) DILUTION = surface water dilution (assumed to be 10)

PECsurfacewater=0.0049 µ g/L

## 2.2.3. Discussion on non-clinical aspects

In the context of the extension of indication an updated ERA for Carfilzomib was presented by the Applicant.

Phase I assessment was reported and  resulted in a PECsw surface water value below the action limit of 0.01, so no additional studies would be required. As for PBT assessment, although logKow value was 4.6, further tests (OECD308) showed that carfilzomib is extensively degraded in aquatic systems.

The transformation product (TP) 2-morpholino-acetic-acid is rapidly formed to an extent of 85% and just slowly degraded (DT50 values of 237 und 303 d after normalization to 12°C). However, it is noted that although the TP 2-morpholino-acetic acid is classified as very persistent, it shows a logKOW of -0.955. Consequently, no further B assessment is required and the PBT assessment can stop at this stage.

<div style=\"page-break-after: always\"></div>

Testing the B-criteria for the active ingredient itself is not required.

## 2.2.4. Conclusion on the non-clinical aspects

Considering the above data, Carfilzomib should be used according to the precautions stated in the SPC in order to minimize any potential risks to the environment.

## 2.3. Clinical aspects

## 2.3.1. Introduction

The clinical data to support the extension of indication of carfilzomib 'in combination with daratumumab and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one  prior  therapy'  is  supported  by  a  randomized,  Open-label,  Phase  3  Study  Comparing  Carfilzomib, Dexamethasone, and Daratumumab (KdD) to Carfilzomib and Dexamethasone (Kd) : the CANDOR study.

## GCP

This study was conducted in accordance with International Council for Harmonisation (ICH) Good Clinical Practice (GCP) regulations/guidelines. Essential documents will be retained in accordance with ICH GCP.

## · Tabular overview of clinical studies

CFZ=carfilzomib;MM=multiplemyeloma;CSR=ClinicalStudyReport

<!-- image -->

| Typeof Study              | Protocol Number   | Study Objectives   | Study Design and Type of Control        | Drug combination/Dose schedule                                                              | Numberof Subjects                                                 | Subject Population        | Study Status; TypeofReport(s)              |
|---------------------------|-------------------|--------------------|-----------------------------------------|---------------------------------------------------------------------------------------------|-------------------------------------------------------------------|---------------------------|--------------------------------------------|
| Controlled Clinical Study | 20160275 (CANDOR) | Efficacy,safety    | Phase 3, randomized, active- controlled | Carfilzomib+ daratumumab+ dexamethasone (KdD)vscarfilzomib+ dexamethasone(Kd) CFZ20/56mg/m2 | 466subjects randomized (312intheKdD and 154 subjectsinthe Kd arm) | Relapsedand refractory MM | Ongoing; primary CSR (cutoff 14 July 2019) |

## Analytical Methods

A summary of biopharmaceutics for carfilzomib is provided in ASPIRE PFS Primary Analysis Module 2.7.1, Summary of Biopharmaceutics Studies and Related Analytical Methods. No updated information is provided for this submission

## 2.3.2. Pharmacokinetics

The provided documentation consists of two population-PK studies one dedicated to the investigation of carfilzomib (Report 153199) and the second for the investigation of daratumumab (Report JNJ54767414). Both analyses contributed to the update of previously models by the incorporation of PK data collected in study CANDOR.

The main PK properties of the components of the combination (carfilzomib and daratumumab) are reported below consistently with their respective SPCs.

<div style=\"page-break-after: always\"></div>

## Absorption

The Cmax and AUC following a 2 to 10 minute intravenous infusion of 27 mg/m 2  was 4,232 ng/mL and 379 ng·hr/mL, respectively. Following repeated doses of Kyprolis at 15 and 20 mg/m 2 , systemic exposure (AUC) and half-life were similar on days 1 and 15 or 16 of cycle 1, suggesting there was no systemic carfilzomib accumulation. At doses between 20 and 56 mg/m 2 , there was a dose-dependent increase in exposure.

A 30 minute infusion resulted in a similar half-life and AUC, but 2- to 3-fold lower Cmax compared to that observed with a 2 to 10 minute infusion of the same dose. Following a 30 minute infusion of the 56 mg/m 2  dose, the AUC (948 ng·hr/mL) was approximately 2.5-fold that observed at the 27 mg/m 2  level, and Cmax (2,079 ng/mL) was lower compared to that of 27 mg/m 2  over the 2 to 10 minute infusion.

## Distribution

The mean steady-state volume of distribution of a 20 mg/m 2  dose of carfilzomib was 28 L. When tested in vitro , the binding of carfilzomib to human plasma proteins averaged 97% over the concentration range of 0.4 to 4 micromolar.

## Biotransformation

Carfilzomib was rapidly and extensively metabolised. The predominant metabolites measured in human plasma and urine, and generated in vitro by human hepatocytes, were peptide fragments and the diol of carfilzomib, suggesting that peptidase cleavage and epoxide hydrolysis were the principal pathways of metabolism. Cytochrome P450 mediated mechanisms played a minor role in overall carfilzomib metabolism. The metabolites have no known biologic activity.

## Elimination

Following intravenous administration of doses ≥ 15 mg/m 2 , carfilzomib was rapidly cleared from the systemic circulation with a halflife of ≤ 1 hour on day 1 of cycle 1. The systemic clearance ranged from 151 to 263 L/hour, and exceeded hepatic blood flow, suggesting that carfilzomib was largely cleared extrahepatically. Carfilzomib is eliminated primarily via metabolism with subsequent excretion of its metabolites in urine.

## Pharmacokinetics of daratumumab

The pharmacokinetics (PK) of daratumumab following intravenous administration of daratumumab monotherapy were evaluated in patients with relapsed and refractory multiple myeloma at dose levels from 0.1 mg/kg to 24 mg/kg.

In the 1 to 24 mg/kg cohorts, peak serum concentrations (Cmax) after the first dose increased in approximate proportion to dose and volume of distribution was consistent with initial distribution into the plasma compartment. Following the last weekly infusion, Cmax increased in a greater than doseproportional manner, consistent with target mediated drug disposition. Increases in AUC were more than dose-proportional and clearance (CL) decreased with increasing dose. These observations suggest CD38 may become saturated at higher doses, after which the impact of target binding clearance is minimised and the clearance of daratumumab approximates the linear clearance of endogenous IgG1. Clearance also decreased with multiple doses, which may be related to tumour burden decreases.

<div style=\"page-break-after: always\"></div>

Terminal half-life increases with increasing dose and with repeated dosing. The mean (standard deviation [SD]) estimated terminal half-life of daratumumab following the first 16 mg/kg dose was 9 (4.3) days. The estimated terminal half-life of daratumumab following the last 16 mg/kg dose increased, but there are insufficient data for a reliable estimation. Based on population PK analysis, the mean (SD) half-life associated with non-specific linear elimination was approximately 18 (9) days; this is the terminal half-life that can be expected upon complete saturation of target mediated clearance and repeat dosing of daratumumab.

At the end of weekly dosing for the recommended monotherapy schedule and dose of 16 mg/kg, the mean (SD) serum Cmax value was 915 (410.3) micrograms/mL, approximately 2.9-fold higher than following the first infusion. The mean (SD) predose (trough) serum concentration at the end of weekly dosing was 573 (331.5) micrograms/mL.

## Pharmacokinetics in the target population

## Daratumumab

Exploratory data analysis

<div style=\"page-break-after: always\"></div>

Table l: Overriew of Studies and Data Included in the Population Pharmacokinetics Analysis

<!-- image -->

| Study No.         | Study Title and Design (including doses administered)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | Brief Description of PK Data (including how many subjects, rich or sparsely sampled)                                                                                                                                                                                                                                                                                                                                                                                                                                        |
|-------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| CANDOR (20160275) | A Randomized, Open-label, Phase 3 Study Comparing Carfilzomib,Dexamethasone, and Daratumumab to Carfilzomib and Dexamethasone for the Treatment ofPK: Patients With Relapsedor Refiactory Multiple Myeloma Daratumumab: Dose: 16 mg/kg Dose Schedule: Every week for Cycles l and 2 followed by every 2 weeks for Cycle 3 to 6, then every 4 weeks thereafter. A cycle is 4 weeks. Carfilzomib: Dose Schedule: Carfilzomib dosed twice weekly as an IV infusion.                                                                                                                   | 300 subjects (plamned) Sparse sampling for all subjects. One sample before infusion for Day 1 of Cycles 1, 3, 7 and 12. One sample at 30 days and 8 weeks post the last daratumumab administration.                                                                                                                                                                                                                                                                                                                         |
| MMY1001 (DKd am)  | An Open-label, Multicenter, Phase 1 Study ofS5 subjects Darahumumab InCombination with Backbone Regimens for the Treatment Of Subjects with Mulhiple Split first dose: 75 subjects Myeloma Daratumumab: Dose: 16 mg/kg. Split first dose, 8 mg/kg on Cycle 1 Days 1 and 2, 16 mg/kg thereafter Single first dose, 16 mg/kg on Cycle 1 Day 1 and thereafter. Dose Schedule: Every week for Cycles l and 2 followed by every weeks for Cycle 3 to 6, then every 4 weeks thereafter. A cycle is 4 weeks. Carfilzomib: Dose Schedule: Carfilzomib dosed once weekly as an IV infusion. | Single first dose: 10 subjects PK: Split first dose: One sample before infusion for Day l of Cycles 1, 2, 3 and 4. One sample after infusion for Day 1 of Cycles 1, 2, 3, and 4. One sample before infision for Day 2 of Cycle 1. One sample after infusion for Day 2 of Cycle 1. Single first dose: One sample before infusion for Day O of Cycle 1. One sample after infusion for Day 0 of Cycle 1. One sample before infusion for Day 1 of Cycles 2, 3 and 4. One sample after infusion for Day l of Cycles 2, 3, and 4. |

The final PPK dataset contains measurable 1,556 daratumumab PK samples from 375 subjects. The lower limit of quantification for daratumumab is 0. 2 μg/mL. The percentage of BQL sample out of total number of post-treatment PK samples (excluding 'Not done' samples) is &lt;3%. As prespecified in the analysis plan (Appendix 2), they were excluded from the PPK analysis.

<div style=\"page-break-after: always\"></div>

Table 4: Descriptive Statistics of Baseline Continuous Covariates

|                               | Study MMIY1001 (N=85)   | Study CANDOR (N=308)   | Combined (N=393)   |
|-------------------------------|-------------------------|------------------------|--------------------|
| Age (years)                   |                         |                        |                    |
| N                             | 85                      | 308                    | 393                |
| Median                        | 66.0                    | 64.0                   | 64.0               |
| Mean (SD)                     | 64.2 (9.32)             | 62.9 (10.0)            | 63.2 (9.88)        |
| IQR                           | 60.0- 71.0              | 57.0 - 70.0            | 57.0 - 70.0        |
| Range                         | 38.0-85.0               | 29.0-84.0              | 29.0 -85.0         |
| Baseline body weight (kg)     |                         |                        |                    |
| N                             | 85                      | 308                    | 393                |
| Median                        | 70.0                    | 74.4                   | 74.0               |
| Mean (SD)                     | 75.5 (20.0)             | 76.6 (17.0)            | 76.4 (17.7)        |
| IQR                           | 61.0-85.0               | 65.0 - 85.0            | 64.0 -85.0         |
| Range                         | 45.0 - 161              | 43.3 - 152             | 43.3 - 161         |
| Creatinine clearance (mL/min) |                         |                        |                    |
| N                             | 85                      | 308                    | 393                |
| Median                        | 76.3                    | 84.4                   | 83.0               |
| Mean (SD)                     | 83.5 (37.7)             | 86.2 (33.0)            | 85.6 (34.0)        |
| IQR.                          | 59.3 - 101              | 62.5 -105              | 61.8 -105          |
| Range                         | 15.3 - 236              | 17.5 -299              | 15.3 - 299         |
| Albumin (g/L)                 |                         |                        |                    |
| N                             | 85                      | 308                    | 393                |
| Median                        | 38.7                    | 40.5                   | 40.0               |
| Mean (SD)                     | 38.3 (5.07)             | 40.0 (5.34)            | 39.6 (5.32)        |
| IQR.                          | 35.0-41.8               | 37.0 - 44.0            | 37.0 -43.0         |
| Range                         | 21.0 -48.1              | 24.0- 53.0             | 21.0-53.0          |
| Alanine transaminase (U/L)    |                         |                        |                    |
| N                             | 85                      | 308                    | 393                |
| Median                        | 17.0                    | 17.0                   | 17.0               |
| Mean (SD)                     | 22.7 (19.6)             | 20.5 (12.3)            | 21.0 (14.2)        |
| IQR                           | 13.0 -24.0              | 13.0 -24.3             | 13.0 - 24.0        |
| Range                         | 6.00 - 131              | 6.00-81.0              | 6.00 - 131         |
| Aspartate transaminase (U/L)  |                         |                        |                    |
| N                             | 85                      | 308                    | 393                |
| Median                        | 21.0                    | 20.0                   | 20.0               |
| Mean (SD)                     | 26.0 (16.6)             | 22.2 (9.48)            | 23.0 (11.5)        |
| IQR.                          | 17.0-28.0               | 16.0 - 25.0            | 16.0 -26.0         |
| Range                         | 7.00 - 101              | 9.00 - 74.0            | 7.00 -101          |
| Alkaline phosphatase (U/L)    |                         |                        |                    |
| N                             | 85                      | 308                    | 393                |
| Median                        | 63.0                    | 62.0                   | 62.0               |
| Mean (SD)                     | 71.6 (35.8)             | 68.4 (41.0)            | 69.1 (39.9)        |
| IQR                           | 53.0-80.0               | 48.0 - 77.0            | 49.0 - 77.0        |
| Range                         | 30.0 - 261              | 25.0-552               | 25.0 - 552         |
| Total bilirubin (umol/L)      |                         |                        |                    |
| N                             | 85                      | 308                    | 393                |
| Median                        | 7.35                    | 7.00                   | 7.00               |
| Mean (SD)                     | 9.05 (5.94)             | 7.94 (3.92)            | 8.18 (4.45)        |
| IQR.                          | 6.00-10.3               | 5.00-10.0              | 5.00 -10.0         |
| Range                         | 3.00-42.8               | 3.00 -27.0             | 3.00-42.8          |
| Totalprotein (g/L)            |                         |                        |                    |
| N                             | 85                      | 308                    | 393                |
| Median                        | 72.0                    | 79.0                   | 78.0               |
| Mean (SD)                     | 77.8 (20.1)             | 82.0 (16.5)            | 81.1 (17.4)        |
| IQR.                          | 62.0-86.0               | 72.0-89.0              | 70.0-88.0          |
| Range                         | 52.0 - 141              | 52.0 - 170             | 52.0 - 170         |

Table 4: DescriptiveStatisticsofBaselineContinuous Covariates

|                                                      | Study MINIY1001 (N=85)   | Study CANDOR (N=308)   | Combined (N=393)   |
|------------------------------------------------------|--------------------------|------------------------|--------------------|
| Estimated glomerular filtration rate (mL/min/l.73m²) |                          |                        |                    |
| N                                                    | 85                       | 308                    | 393                |
| Median                                               | 74.1                     | 77.6                   | 77.4               |
| Mean (SD)                                            | 76.2 (26.0)              | 77.0 (23.0)            | 76.8 (23.6)        |
| IQR                                                  | 57.5 - 92.7              | 62.3 - 91.8            | 60.6 - 92.1        |
| Range                                                | 18.4-147                 | 12.9-147               | 12.9 - 147         |

<div style=\"page-break-after: always\"></div>

Table 5: Descriptive Statistics of Baseline Categorical Covariates

Abbreviations: CRCL=creatinine clearance; ECOG=Eastem Cooperative Oncology Group:

|                                                  | Study MMIY1001 (N=85)   | Study CANDOR (N=308)   | Combined (N=393)   |
|--------------------------------------------------|-------------------------|------------------------|--------------------|
| Age category n (%)                               |                         |                        |                    |
| 275 yr                                           | 77 (90.6)               | 280 (90.9)             | 357 (90.8)         |
| ≥75 yr                                           | 8 (9.4)                 | 28 (9.1)               | 36 (9.2)           |
| Sex n (%)                                        |                         |                        |                    |
| Male                                             | 46 (54.1)               | 174 (56.5)             | 220 (56.0)         |
| Female                                           | 39 (45.9)               | 134 (43.5)             | 173 (44.0)         |
| Race n (%)                                       |                         |                        |                    |
| White, not Hispanic or Latino                    | 64 (75.3)               | 233 (75.6)             | 297 (75.6)         |
| Black or Afican American, not Hispanic or Latino | 3 (3.5)                 | 7 (2.3)                | 10 (2.5)           |
| White, Hispanic or Latino                        | 4 (4.7)                 | 7 (2.3)                | 11 (2.8)           |
| Asian, not Hispanic or Latino                    | 3 (3.5)                 | 46 (14.9)              | 49 (12.5)          |
| Other                                            | 11 (12.9)               | 15 (4.9)               | 26 (6.6)           |
| Baseline ECOG score n (%)                        |                         |                        |                    |
| 0                                                | 32 (37.6)               | 134 (43.5)             | 166 (42.2)         |
| 1                                                | 46 (54.1)               | 161 (52.3)             | 207 (52.7)         |
| 2                                                | 7 (8.2)                 | 13 (4.2)               | 20 (5.1)           |
| Hepatie dysfunetion n (%)                        |                         |                        |                    |
| Normal                                           | 71 (83.5)               | 282 (91.6)             | 353 (89.8)         |
| Mild dysfimetion                                 | 12 (14.1)               | 26 (8.4)               | 38 (9.7)           |
| Moderate dysfiumction                            | 2(2.4)                  | 0 (0.0)                | 2 (0.5)            |
| CRCL category n (%)                              |                         |                        |                    |
| ≥90 mL/min                                       | 29 (34.1)               | 132 (42.9)             | 161 (41.0)         |
| 60 and ~90 mL/min                                | 33 (38.8)               | 107 (34.7)             | 140 (35.6)         |
| ≥30 amd ≤60 mL/min                               | 20 (23.5)               | 64 (20.8)              | 84 (21.4)          |
| 15 amd<30 mL/min                                 | 3 (3.5)                 | 5 (1.6)                | 8 (2.0)            |
| Region n (%)                                     |                         |                        |                    |
| Other                                            | 71 (83.5)               | 287 (93.2)             | 358 (91.1)         |
| North America                                    | 14 (16.5)               | 21 (6.8)               | 35 (8.9)           |
| Type of myeloma n (%)                            |                         |                        |                    |
| IgG                                              | 40 (47.1)               | 175 (56.8)             | 215 (54.7)         |
| Non-IgG                                          | 45 (52.9)               | 133 (43.2)             | 178 (45.3)         |

IgG=immunoglobulin G; N=maximum mumber of subjects with data; SD=standard deviation.

<div style=\"page-break-after: always\"></div>

Figure 3: Daratumumab Serun Concentration-time Profiles in Study CANDOR on a Semi-logarithmic Seale in Comparison With MIMY100l at 16 mg/kg Intravenous Infusion

CANDOR

MMY1001

(DKd cohort)  (DKd cohort)

<!-- image -->

Abbreviations: DKd=daratumumab-carfilzomib-dexamethasone. Key: Black dashed line represents the lower limit of quantification at 0.2 μg/mL

Dose schedule: once weekly for S weeks, followed by every 2 weeks for 16 weeks, and every 4 weeks thereafter.

<div style=\"page-break-after: always\"></div>

Figure 4: Daratumumab Serum Concentration-time Profiles in Studies CANDOR and MIMIYl00l (DKd), on a Semi-logarithmic Scale in Comparison With Monotherapy Study (MIMfY2002) at 16 mg/kg Intravenous Infusion

- Daratumumab in cohort of DKd Daratumumab monotherapy (studies MMY1001 and CANDOR)  (study MMY2002)

<!-- image -->

Abbreviations:DKd=darahumumab-carfilzomib-dexamethasone. Key: Black dashed line represents the lower limit of quantification at O.2 μg/mL Dose schedule: once weekly for S weeks, followed by every 2 weeks for 16 weeks, and every 4 weeks thereafter.

## Base PK model

The previously developed final structural and covariate model for daratumumab IV monotherapy was used to fit the concentration-time data of daratumumab in RRMM patients who received DKd combination therapy (Study 20160725 and MMY1001 DKd arm). These models have been successfully implemented in subjects with RRMM following both daratumumab monotherapy and other combination therapies.

The developed base PPK model for IV administration included 2-compartment structure with parallel linear and Michaelis-Menten nonlinear elimination pathways.14 The model structure for daratumumab PK is provided in Figure 2.

<div style=\"page-break-after: always\"></div>

## Figure 2: Michaelis-MfentenPharmacolineticsMfodel forDaratumumab

<!-- image -->

Abbreviations: A=daratumumab amount in the central compartment; Az=darahumumab amoumt in the peripheral compartment; CL=linear clearance; K,=Michaelis-Menten constant; Q=intercompartmental clearance; V=volume of dishibution in the cental compartment; V=volume of dishibution in the peripheral compartment; Va.=maximum velocity of the satuable clearance process, which decreases over time through a first-order rate (KDes).

The linear clearance represents the nonspecific clearance for IgG and the Michaelis-Menten elimination represents the saturable target-mediated clearance. Due to the treatment effect of daratumumab, the total target (CD38) level decreased over time. This was investigated using an empirical function:

<!-- image -->

in which TDVM represents the time-dependent maximum capacity of the saturable clearance and KDES represents first-order rate constant, describing the decrease of the maximum velocity of the saturable clearance process (Vmax) over time (t).

The IIV in structural parameters was modeled with an exponential term to ensure positive values of individual parameters. Because the serum concentrations were log-transformed, an additive model was used to model residual variability.

The final covariate model based on the daratumumab IV studies developed previously includes body weight, albumin, type of myeloma, and sex as statistically significant (but not clinically relevant) covariates.14 In case some parameters could not be reliably estimated, due to limited sparse sampling in Studies CANDOR and MMY1001, the models (eg, number of random-effects parameters) were reduced to avoid over-parameterization.

The previous PPK analysis showed that the PK of daratumumab could be adequately described by a 2compartment PPK model with parallel linear and nonlinear (Michaelis-Menten) elimination pathways following both monotherapy and combination therapies.

The serum concentration-time profiles for daratumumab are similar between subjects in Studies CANDOR and MMY1001 (Figure 3) and subjects in monotherapy studies and other combination studies (Figure 4 and Figure 5, respectively), further confirming the hypothesis and validating the applicability of the previously developed PPK model for the analysis herein. To stabilize the model fitting, the body weight effect on clearance and volume of distribution in the central compartment (V1) were fixed to the plausible allometric scaling exponent of 0.75 and 1, respectively, in the base model.

<div style=\"page-break-after: always\"></div>

Basic Goodness-of-Fit Plots for PK Base Model

<!-- image -->

## Final PK model

After the based model was confirmed (eg, plausible PPK parameters estimates and adequate goodnessof-fit), a final model was established by including those significant covariates that were identified from the previous daratumumab PPK analysis. In the meantime, the model was further fine-tuned with the goal of obtaining a parsimonious model.

The estimated linear clearance (0.00393 L/h) was similar to the clearance of nonspecific endogenous IgG reported in the literature and the estimated V1 (4.47 L) approached plasma volume. The model-derived geometric mean (coefficient of variation %) half-life associated with linear elimination was 23.8 (16%) days, comparable to the estimated half-lives derived from the previous monotherapy and combination therapy data (an average of 15 to 23 days).

The IIV of was 43.7% and 38.3% for linear clearance and V1, respectively. The associated ETA shrinkage was 7.63% and 27.9% for linear clearance and V1, respectively, suggesting that individual estimates for these 2 parameters were adequately characterized without shrinking to the population mean.

The condition number of the final model is 30.67, indicating the final covariate model is appropriately parameterized (ie, no issues of over-parameterization).

<div style=\"page-break-after: always\"></div>

Table 7: Parameter Estimates of Daratumumab for theFinal Population Pharmacokinetics Mfodel (Run1005)

| Parameter, unit   |   Estimate | RSE (%)   | IIV (%C1)   | RSE (%)   |
|-------------------|------------|-----------|-------------|-----------|
| CL (L/h)          |   0.00393  | 5.52      | 43.7        | 3.80      |
| ALBon CL          |  -1.19     | 11.7      |             |           |
| WT on CL          |   0.75     | FIX       |             |           |
| TPMM on CL        |   0.449    | 18.6      |             |           |
| V (L)             |   4.47     | 4.65      | 38.4        | 5.88      |
| WT on V,          |   1        | FIX       |             |           |
| SEX on V          |  -0.164    | 29.8      |             |           |
| V(L)              |   3.51     | 4.67      |             |           |
| Q (Lb)            |   0.0752   | 14.2      |             |           |
| Vmx (mg/h)        |   1.3      | 3.25      |             |           |
| Kpes (1/h)        |   0.000124 | 3.77      |             |           |
| K, (μg/mL)        |   1.91     | 31.6      |             |           |
| ADD ERR (%CV)     |  21.3      | 1.05      |             |           |

Abbreviations: ALB=serum albumin concenhation; ADD ERR=additive eror term on the log-scale; CL=linear clearance; CV=coefficient of variation; FIX=Not Estimated; IIV=interindividual variability: IgG=immunoglobulin G; K=Michaelis-Menten constant; Kpes=first-order rate for decrease of Vmx PK=pharmacokinetics; Q=intercompartmental clearance; RSE=relative standard eiror; SEX=gender (female V5 male); TPMM=type of myeloma (IgG vs non-IgG); TV=typical values; TVCL=Iypical Value of Clearance; TVV=Typical Value of Volume of Dishibution; V=volume of distibution in the central compartment; V=volume of distibution in the peripheral compartment; Vmm=maximum velocity of the sahuable clearance process; W'T=body weight.

Note: The objective function value=-1833.6230. Condition mumber=30.67. Condition number was caleulated as the ratio of the largest to smallest eigenvalue of corelation mahix of estimate.

The TV of PK parameters, TVCL = 0.00393 ALB 1.19 · TPMMeL where TPMMe is a shift factor of l

SEXy1, where SEXy is a shift factor of 1 for male and 1-0.164 for female.

For IIV, RSE% is given in %CV and is an approximate value.

Attachment 6 includes the basic goodness-of-fit plots for the final PK model. The plots of population and individual predictions versus observations show that the individual predictions fitted well along the identity line and the conditionally weighted residuals were generally centered along the zero line with homogenous variation relative to the population predictions and time, suggesting an adequate fit of the final model to the overall study data.

<div style=\"page-break-after: always\"></div>

Basic Goodness-of-Fit Plots forPK Final Model

<!-- image -->

Attachment7:VisualPredictiveCheckof theFinalPPKMfodel UsingTime

<!-- image -->

Abbreviations:PPK=population pharmacokinehics.

Key: The blue open circles represent individual observations. The red solid and dashed lines represent the median and 2.5th and 97.5th percentiles of the observations, respectively; the shaded red and blue areas represent the 95% confidence interval of the median and 2.5th and 97.5th percentiles predicted by the model, respectively.

<div style=\"page-break-after: always\"></div>

Attachment 8:Visual Predictive Check of the Final PPK Model Using Time Stratified by Weight Group Body weight ≤74 kg By 2 146aw. Apog

<!-- image -->

Abbreviations:PPK=population pharmacokinetics.

Key: The blue open circles represent individual observations. The red solid and dashed lines represent the median and 2.5th and 97.5th perceniles of the observations, respectively; the shaded red and blue areas represent the 95% confidence interval of the median and 2.5th and 97.5th percentiles predicted by the model, respectively

Attachment 9:Visual Predictive Check of the Final PPK Model Using Time Stratified by Sex

Male

Femalle

<!-- image -->

Abbreviations:PPK=population pharmacokinetics.

Key: The blue open circles represent individual observations. The red solid and dashed lines represent the median and 2.5th and 97.5th percentiles of the observations, respectively; the shaded red and blue areas represent the 95% confidence interval of the median and 2.5th and 97.5th percentiles predicted by the model, respectively

<div style=\"page-break-after: always\"></div>

AttachmentlO:Visual Predictive Checkof theFinal PPKMfodel UsingTimeStratified byAlbumin Levels Albumin ≤$9 g/L Albumin ≥49 g/L

<!-- image -->

Abbreviations: PPK=population pharmacokinetics.

Key: The blue open circles represent individual observations. The red solid and dashed lines represent the median and 2.5th and 97.5th percentiles of the observations, respectively; the shaded red and blue areas represent the 95% confidence interval of the median and 2.5th and 97.5th percentiles predicted by the model, respectively

Comparison of daratumumab exposure in subpopulations was based on simulation assuming that all subjects received 16 mg/kg daratumumab in the same dose schedules as in Study CANDOR. Figure 6 shows the forest plot of subgroup analyses on the exposure metrics of predicted maximal trough concentrations (preinfusion concentration of the first dose of the Q2W dose schedule, ie, Cycle 3 Day 1 [C3D1]) in the same dose schedule as in Study CANDOR. The selection of this exposure metric was based on the cumulative knowledge of its clinical relevance found in the prior E-R analysis for daratumumab.

<div style=\"page-break-after: always\"></div>

Figure 6: Forest Plot of Subgroup Analyses on the Predicted Preinfusion Daratumunab Concentration at C3Dl According to Study CANDOR Dose Schedule

<!-- image -->

Geometric mean of predicted C3D1 trough concentration (μg/mL)

Abbreviations:C3D1=Cycle 3 Day l; DKd=darahumumab-carfilzomib-dexamethasone; ECOG=Eastem Cooperative Oncology Group; IgG=immunoglobulin G; Q2W=once every 2 weeks; Q4W=once every 4 weeks. Key: Solid blue circle represents geometric mean and short horizontal bar represents 95% confidence interval. Dashed line represents the geometic mean value (591.28 μg/mL) of all subjects. Numbers represent percentage of change and the associated confidence interval.

Note: Analyses assumed that all subjects in cohort of DKd in Studies CANDOR and MMY100l with evaluable pharmacokineties received 16 mg/kg weekly for 8 weeks (8 doses), Q2W for 16 weeks (8 doses), and then Q4W thereafter. The mumber of subjects in the reference group for each covaniate: age &lt;75 years (N=340); male (N=210); non-white (N=84); body weight 65 to 85 kg (N=181); albumin concentration ≥40 g/L (N=205); normal hepatic fumction (N=338); normal renal fmction (N=151); EC0G=0 (N=164); non-IgG myeloma (N=166).The mumber of subjects with moderate hepatic dysfimction (N=2) or severe renal impainment (N=7) is ≤2% of the total number of subjects in the analysis, therefore they are not included in the comparison.

<div style=\"page-break-after: always\"></div>

Figure 7: Forest Plot of Subgroup Analyses on Percent Change Relative to Reference Value for Predicted Preinfusion Daratumumab Concentration at C3Dl According to Study CANDOR Dose Schedule

<!-- image -->

Abbreviations: C3D1=Cycle 3 Day 1; DKd=daratumumab-carfilzomib-dexamethasone; ECOG=Eastem Cooperative Oncology Group; IgG=immumoglobulin G; Q2W=once every 2 weeks; Q4W=once every 4 weeks. Key: Solid blue circle represents percentage change of geometic mean and short horizontal bar represents 95% confidence interval. Dashed line represents reference value of zero. Numbers represent percentage of change and the associated confidence interval.

Note: Analyses assumed that all subjects in cohort of DKd in Studies CANDOR and MMYl00l with evaluable pharmaeokineties received 16 mg/kg weekly for 8 weeks (8 doses), Q2W for 16 weeks (8 doses), and then Q4W thereafter. The number of subjects in the reference group for each covaniate: age ≤75 years (N=340); male (N=210); non-white (N=84); body weight 65 to 85 kg (N=181); albumin concentration ≥40 g/L (N=205); normal hepatic fumction (N=338); normal renal fumction (N=151); EC0G=0 (N=164); non-IgG myeloma (N=166). The number of subjects with moderate hepatie dysfiumction (N=2) or severe renal impairment (N=7) is &lt;2% of the total number of subjects in the analysis, therefore they are not included in the companison.

## Carfilzomib

## Exploratory data analysis

Carfilzomib was administered as monotherapy in studies PX-171-003 - Part 2 (A1), PX-171-004, PX-171005, CFZ001, and CFZ002; in combination with lenalidomide and dexamethasone in studies PX-171-006 and PX-171-009; as monotherapy or in combination with low-dose dexamethasone in PX-171-007, 2011003, 2012-002, 20140355, 20140242 and the control arm of 20160275; in combination with low dose dexamethasone and daratumumab in the experimental arm of 20160275 and in the carfilzomib + dexamethasone and daratumumab arm of MMY1001 (Amgen Study 20190252). The pooled dataset contained 8279 plasma concentrations of carfilzomib from 1318 subjects.

In the pooled dataset, the median age of subjects was 64 years and ranged from 21 to 89 years. The median body weight was 76 kg and ranged from 36 to 165 kg. In total, 770 male and 548 female subjects were included in the analysis, and 74.05% were white, 9.45% Asian, 6.37% black, 0.68% Hispanic, and 9.45% other.

## Final PK model

<div style=\"page-break-after: always\"></div>

Based on a previously published model of carfilzomib (Ou, 2017), a two-compartment pharmacokinetic model with intravenous (IV) infusion and first order elimination processes, with an effect of BSA on clearance, was expected to sufficiently characterize the carfilzomib pharmacokinetic disposition. The twocompartment model was parameterized in terms of systemic clearance (CL), volume of distribution for the central compartment (V1), volume of distribution for the peripheral compartment (V2), intercompartmental clearance between central and peripheral compartment (Q). Since the updated dataset consists mostly of data from Phase 3 studies with sparse PK sampling, which are not designed to characterize the PK behaviour of carfilzomib, the published model was used as the base model.

A separate error model between intense and sparse sampling studies was used in the base structural PK model. Incorporation of a full block OMEGA matrix led to a decrease in the objective function value and therefore the structure was retained in the base model.

The two-compartment model with IIVs estimated for CL, V1, V2, Q, and covariate effect of BSA on CL deemed appropriate as the structural population PK model. All PK parameters were estimated with good precision (RSE% &lt; 20%). The shrinkage on CL, V1, V2, and Q were 26.7%, 34.4, 33%, and 32%, respectively. Figure 2 shows the goodness-of-fit plots for the structural model. As shown in the upper panels, there was good agreement of the observed and the individual-level as well as population-level predicted concentrations. Also, CWRES showed random normal scatter around zero with no specific trends of bias across the range of predicted values and over time. Of note, the distribution of conditional weighted residuals versus time remains constant, which indicates the absence of time-dependent pharmacokinetics. Following the development of the base model, the effects of subject specific covariates on the random effects in the base structural model were explored graphically on key PK parameters. No new covariate relationship was found on any of the ETAs and therefore no further changes were made to the model.

<div style=\"page-break-after: always\"></div>

| Parameter                                                                                                 |   Estimate | RSE %     | IIV CV %   | Shrinkage %   |
|-----------------------------------------------------------------------------------------------------------|------------|-----------|------------|---------------|
| Clearance (L/h)                                                                                           |    251     | 5.7       | 56         | 26.7          |
| Central volume (L)                                                                                        |     25.1   | 7.7       | 107        | 34.4          |
| Peripheral volume (L)                                                                                     |     21.6   | 15.3      | 207        | 33            |
| Inter-compartment clearance (L/h)                                                                         |     14.5   | 13.1      | 199        | 32            |
| Exponent of BSA effect on clearance                                                                       |      0.472 | 22.9      |            |               |
| SD of additive residual error on log- transformed data Intensive sampling studies Sparse sampling studies |      1.43  | 0.68 0.83 |            |               |

| Comelation matrix   |   IIV CL (%) | IIV V1 (%)   | IIV V2 (%)   | IV Q (%)   |
|---------------------|--------------|--------------|--------------|------------|
| IV CL (%)           |         95   |              |              |            |
| IV V1 (%)           |         90   | 107          |              |            |
| IV V2 (%)           |         81.4 | 87.6         | 207          |            |
| IV Q (%)            |         87.3 | 93.5         | 98.8         | 199        |

<!-- image -->

## Special populations

## Daratumumab

## Body weight

When daratumumab was administered on a mg/kg basis, no clinically important differences (ie, &lt;20%) in the exposure to daratumumab were observed in subjects with a low body weight (&lt;65 kg, n=99) or high body weight ( ≥ 85 kg, n=95) compared to those with a body weight ranging from 65 to 85 kg (n=181).

## Age

No clinically important influence of age on the exposure to daratumumab was observed. The exposure to daratumumab in older subjects (age ≥ 75 years, n=35) was similar to younger subjects (age &lt;75 years, n=340) with a percent difference of &lt;20%.

## Sex

No clinically important influence of sex on the exposure to daratumumab was observed. The exposure to daratumumab in males (n=210) was similar to that in females (n=165).

<div style=\"page-break-after: always\"></div>

## Race

Because the majority of subjects were white and there were only limited sample sizes in other race categories, the effect of race was evaluated as white (n=291) and non-white (n=84). No clinically important influence of race on the exposure to daratumumab was observed. The exposure to daratumumab in white subjects was similar to non-white subjects.

## Renal impairment

No formal studies of daratumumab in patients with renal impairment have been conducted. Creatinine clearance is not a significant covariate on daratumumab clearance. No clinically important differences (&lt;20%) in the exposure to daratumumab were observed between subjects with renal impairment and those with normal renal function.

## Hepatic impairment

No formal studies of daratumumab in patients with hepatic impairment have been conducted. No subjects had severe hepatic impairment (TB &gt;3× upper limit of normal [ULN] and any AST), and only 2 subjects had moderate hepatic impairment (TB &gt;1.5× to 3.0× ULN, as defined using the National Cancer Institute criteria of hepatic dysfunction). Therefore, the effect of hepatic impairment was evaluated in categories of normal hepatic function (TB and AST ≤ ULN, n=338) and mild hepatic impairment (TB 1.0× to 1.5× ULN or AST &gt;ULN, n=35). No clinically important differences in the exposure to daratumumab (&lt;20%) were observed between subjects with mild hepatic impairment and those with normal hepatic function.

## Baseline Albumin

No clinically important differences in the exposure to daratumumab were observed between subjects with different albumin levels. The exposure to daratumumab in subjects with albumin level below median value (&lt;40 g/L, n=170) was 15% lower than that in subjects with albumin level above median value ( ≥ 40 g/L, n=205).

## Type of Myeloma

The exposure to daratumumab was approximately 22% (95% confidence interval: 27% - 16%) lower in subjects with IgG myeloma (n=209) compared with subjects with non-IgG myeloma (n=166), consistent with previous study results. As the treatment effect on efficacy endpoints was similar for subjects with IgG and non-IgG myeloma, this is considered not a clinically important effect.

## Carfilzomib

## Renal impairment

The pharmacokinetics of carfilzomib was studied in two dedicated renal impairment studies. The first study was conducted in 50 multiple myeloma patients with normal renal function (CrCL &gt; 80 mL/min, n = 12), mild (CrCL 50-80 mL/min, n = 12), moderate (CrCL 30-49 mL/min, n = 10), and severe (CrCL &lt; 30 mL/min, n = 8) renal impairment, and patients on chronic dialysis (n = 8). Kyprolis, as a single agent, was administered intravenously over 2 to 10 minutes at doses up to 20 mg/m 2 . Pharmacokinetic data were collected from patients following the 15 mg/m 2  dose in cycle 1 and the 20 mg/m 2  dose in cycle 2. The second study was conducted in 23 relapsed multiple myeloma patients with creatinine clearance ≥ 75 mL/min (n = 13) and patients with end stage renal disease (ESRD) requiring dialysis (n = 10). Pharmacokinetic data were collected from patients following administration of a 27 mg/m 2  dose as a 30 minute infusion on cycle 1, day 16 and the 56 mg/m 2  dose on cycle 2, day 1.

Results from both studies show that renal function status had no marked effect on the exposure of carfilzomib following single or repeat-dose administration. The geometric mean ratio in AUClast at the 15 mg/m 2  dose cycle 1, day 1 for mild, moderate, severe renal impairment and chronic dialysis versus

<div style=\"page-break-after: always\"></div>

normal renal function were 124.36%, 111.07%, 84.73% and 121.72%, respectively. The geometric mean ratios in AUClast at the 27 mg/m 2  dose cycle 1, day 16 and at the 56 mg/m 2  dose cycle 2, day 1 for ESRD versus normal renal function were 139.72% and 132.75%, respectively. In the first study the M14 metabolite, a peptide fragment and the most abundant circulating metabolite, increased 2- and 3-fold in patients with moderate and severe renal impairment, respectively, and 7-fold in patients requiring dialysis (based on AUClast). In the second study, the exposures for M14 were greater (approximately 4fold) in subjects with ESRD than in subjects with normal renal function. This metabolite has no known biological activities. Serious adverse events related to worsening renal function were more common in subjects with baseline renal dysfunction.

## Hepatic impairment

A pharmacokinetic study evaluated 33 patients with relapsed or progressive advanced malignancies (solid tumours; n = 31 or haematologic malignancies; n = 2) who had normal hepatic function (bilirubin ≤ upper limit of normal [ULN]; aspartate aminotransferase [AST] ≤ ULN, n = 10), mild he patic impairment (bilirubin &gt; 1-1.5 × ULN or AST &gt; ULN, b ut bilirubin ≤ ULN, n = 14), or moderate hepatic impairment (bilirubin &gt; 1.5-3 × ULN; any AST, n = 9). The pharmacokinetics of carfilzomib has not been studied in patients with severe hepatic impairment (bilirubin &gt; 3 × ULN and any AST). Kyprolis, as a single agent, was administered intravenously over 30 minutes at 20 mg/m 2  on days 1 and 2 and at 27 mg/m 2  on days 8, 9, 15 and 16 of cycle 1. If tolerated, patients received 56 mg/m 2  starting in cycle 2. Baseline hepatic function status had no marked effect on the total systemic exposure (AUClast) of carfilzomib following single or repeat-dose administration (geometric mean ratio in AUClast at the 27 mg/m 2  dose in cycle 1, day 16 for mild and moderate impairment versus normal hepatic function were 144.4% and 126.1%, respectively; and at the 56 mg/m 2  dose in cycle 2, day 1 were 144.7% and 121.1%). However, in patients with mild or moderate baseline hepatic impairment, all of whom had solid tumours, there was a higher subject incidence of hepatic function abnormal ities, ≥ grade 3 adverse events and serious adverse events compared with subjects with normal hepatic function.

## 2.3.3. Pharmacodynamics

## Mechanism of action

As from studies submitted in the context of the original MAA, carfilzomib, a tetrapeptide epoxyketone, is a highly selective, irreversible second-generation proteasome inhibitor that preferentially targets the chymotrypsin-like (CT-L) activity of the 20S proteasome compared with the trypsin-like (T-L) and caspase-like (C-L) proteasome activities.  The 20S proteasome exists in 2 forms:  the constitutive proteasome, expressed ubiquitously throughout the body, and the immunoproteasome, expressed primarily in hematopoietic cells or in cytokine-exposed nonhematopoietic cells (Nandi et al, 1996; Glynne et al, 1991; Martinez and Monaco, 1991).  The 3 different catalytic activities of constitutive proteasome are encoded by the β 5, β 2, and β 1 subunits based on their substrate specificity for the CT-L, T-L, and C-L activities, respectively.  In the immunoproteasome, low-molecular mass polypeptide 2 and 7 and multicatalytic endopeptidase complex-like 1 replace β 1, β 5, and β 2, respectively.  It has been shown that multiple myeloma cells express both constitutive and immunoproteasomes (Lee et al, 2016; Parlati et al, 2009).

The epoxyketone pharmacophore of carfilzomib forms an irreversible, covalent adduct with the N-terminal threonine residue of the CT-L active site of the 20S proteasome, while sparing nonproteosomal sites.  As a result, proteasome substrates accumulate, ultimately stimulating arrest and apoptosis of tumor cells (see SmPC section 5.1).

<div style=\"page-break-after: always\"></div>

With regard to carfilzomib and daratumumab, no formal PK investigations of the DDI potential has been performed (see discussion of Clinical Pharmacology.

## Potential for drug-drug interaction of the KdD combination

No formal investigations of the DDI potential between the components of the combination were performed.

## Primary and secondary pharmacology

## Daratumumab

None of the samples from subjects treated with KdD (300 subjects) were positive for antibodies to daratumumab, indicating a low risk of immunogenicity to daratumumab with this combination. Thus, immunogenicity is not expected to have an impact on daratumumab exposure, efficacy or safety.

## Exposure-efficacy

The ORR increased rapidly to a maximum value with the increase of daratumumab exposure when daratumumab 16 mg/kg was coadministered with Kd based on the data from Studies CANDOR and MMY1001. In both studies, the ORR was very similar in Ctrough,max Q2-Q4 (ie, &gt;90%), while the ORR in Ctrough,max Q1 was somewhat lower (Figure 12). There is no apparent impact of carfilzomib dosage regimen (56 mg/m2 twice weekly [BIW; 20 mg/m2 for the first 2 doses] in Study CANDOR and 70 mg/m2 QW [20 mg/m2 for the first dose] in MMY1001) on daratumumab E-R relationship for ORR.

Figure l2: Rate of Responders in Relation to Daratumumab Maximum Trough Concentrations (Crhmw. by Quartile) When Daratumumab Was Coadiministered With Carfilzomib of 20/56 mg/m² Q2W or 20/70 mg/m² Q1W

<!-- image -->

Abbreviations: Cmouph,maxpredicted maximal trough (preinfusion) concentation; Pr-probability; Q=quartile; BIW=twice weekly; Q2W=once every 2 weeks; QW=once weekly.

- The quartiles for Cough,mx in Study MMY1001 were: fust quartile (≤465 μg/mL), second quartile (465 to 572 μg/mL), third quartile (572 to 74l μg/mL), and fouth quartile (741 to 1,150 μg/mL).

The quartiles for Cmughm in Study CANDOR were: first quartile (≤471 μg/mL), second quatile (471 to 595 μg/mL), third quartile (595 to 701 μg/mL), and fouth quartile (701 to 1,280 μg/mL).

## Carfilzomib

## Exposure-efficacy

<div style=\"page-break-after: always\"></div>

Exposure-response analysis with the efficacy endpoints were conducted in subjects with multiple myeloma. The efficacy endpoints per Independent Review Committee (IRC) in all the studies included in this analysis:

- Overall response rate (ORR), defined as the proportion of subjects achieving a best overall response of stringent complete response (sCR), complete response (CR), very good partial response (VGPR), or partial response (PR). ORR was analyzed both for each study separately and for the pooled data.
- Progression-free survival (PFS), defined as duration in months from randomization to the earlier of documented progressive disease (PD) or death due to any cause. Subjects who did not have disease progression or death were censored. PFS was analyzed for each study separately and for the pooled data.
- MRD[-]CR at 12 months, defined as the proportion of subjects with a best overall response of complete response or better and minimal residual disease negative status in bone marrow aspirates at 12 (  4) months as determined by next-generation sequencing

## Exposure-safety

Exposure-response analyses of safety endpoints were conducted in subjects with multiple myeloma and solid tumors using data from CANDOR alone as well as pooled data of all clinical studies. The following safety endpoints were analyzed:

- Overall adverse events
- o Any grade adverse event leading to study drug (carfilzomib) discontinuation
- o Any ≥ grade 3 adverse event
- Specific adverse events of interest
- o Any grade cardiac failure, broad grouping (SMQB) - adverse event with preferred term included in SMQB of cardiac failure
- o Any grade cardiac failure, SMQ, narrow grouping (SMQN) - adverse event with preferred term included in SMQN of cardiac failure
- o Any grade ischemic heart disease
- o Any grade hepatic adverse events
- o Any grade transaminase elevation
- o Any grade hepatic event (hepatic adverse events or transaminase elevation)
- o Any grade dyspnea
- o Any grade pulmonary hypertension
- o Any grade interstitial lung disease
- o Any grade and ≥ grade 3 acute renal failure based on broad and narrow grouping SMQB and SMQN, any grade and&gt;=grade 3 chronic kidney disease based on broad and narrow grouping SMQB and SMQN
- o Any grade and ≥ grade 3 hypertension based on narrow grouping SMQNLaboratory abnormalities
- o Alanine transaminase (ALT) elevation ≥ 3 × upper limit of normal (ULN)

<div style=\"page-break-after: always\"></div>

## o Aspartate transaminase (AST) elevation ≥ 3 × ULN

## QTc analysis

In the analysis dataset (N=382), the median age of subjects was 64 years and ranged from 29 to 84 years. The median body weight was 75.4 kg and ranged from 36 to 143 kg. In total, 221 male and 161 female subjects were included in the analysis. The summary statistics and distributions of body weight and age by gender are presented in Table 2. The summary statistics for the included PK and QTcF data are shown in T able 3. There were 628 pairs with median (range) concentration ΔQTcF values of 2.4 msec (-114 to 169 msec). The median predicted carfilzomib concentration was 1.60 ng/mL and ranged from 0 .00 to 15444.23 ng/mL. ΔQTcF values vs time after last dose are prese nted in Figure 1.

A linear mixed effect model was used to characterize the carfilzomib concentration and ΔQTcF relationship,. The parameter estimates are summarized in Table 4. The slope of the relationship for plasma concentration of carfilzomib and QTcF change is 0.0009 msec/ng/mL. The 90% confidence interval for the slope is (-0.0007, 0.0027 msec/ng/mL), which includes 0 suggesting lack of QTcFexposure effect for carfilzomib. The intercept was estimated to be -21.55 msec. The p value for the slope of ΔQ TcF vs carfilzomib concentration is &gt;0.05 indicating lack of linear relationship between carfilzomib plasma concentration and ΔQTcF.

Figure 2 AQTcF versus Predicted Carfilzomib Concentration

<!-- image -->

Note: LLOQ: Lower limit of quantification (0.1 ng/mL)

## Summary of data below LLoQ

| Study             | >= LL0Q (%)   | <LL0Q (%)   |
|-------------------|---------------|-------------|
| CANDOR (20160275) | 342 (54)      | 286 (46)    |

<div style=\"page-break-after: always\"></div>

Table 4ParameterEstimates for the Relationshipbetween Predicted Carfilzomib Concentration and AQTcF

| Parameter                |   Estimate | Standard Error   | p-value   | 5%      | 95%     |
|--------------------------|------------|------------------|-----------|---------|---------|
| Intercept (msec)         |   -21.55   | 2.75             | 0.000     | -26.94  | -16.15  |
| DrugEffect (msec/ng/mL)  |     0.0009 | 0.0008           | 0.268     | -0.0007 | 0.0027  |
| Baseline QTcF (msec)     |    -0.1004 | 0.0107           | 0.000     | -1.1214 | -0.0795 |
| Variance(lliV_Intercept) |   181.98   | NA               | NA        | NA      | NA      |
| ResidualVariance         |   404.41   | NA               | NA        | NA      | NA      |

## 2.3.4. PK/PD modelling

## Daratumumab

## Exposure-efficacy

An apparent maximal effect relationship was observed between the relative hazard of disease progression or death and daratumumab systemic exposures (Figure 9). The relative hazard for progression or death decreased rapidly with increasing daratumumab systemic exposure. For both Ctrough,1st and predicted maximal trough concentration (Ctrough,max) of daratumumab, when these numbers were greater than their respective first quartile (Q1) , the risk of progression or death was reduced by approximate 50% as compared to the control Kd group, indicating that the maximum effect on PFS had been attained for the majority of the subjects at the 16 mg/kg dose.

Figure 9: Relative Hazard of Progression-free Survival at Different Predicted Exposures

<!-- image -->

Abbreviations: Kd=carfilzomib-dexamethasone; ISS=Intemational Staging System. Key: The solid red line is the point estimate, and gray shaded areas represent 95% confidence interval. Blue vertical dotted lines separate the quartiles of trough concentrations after the fist dose (Ctmgh,1a) and maximal trough concenhation (Cmmgh.m). The contol group (Kd treatment) was used as the reference (ie, Comhma=0). Hazard ratio and its 95% confidence interval were estimated based on shatified Cox regression models. The shatifieation factors included ISS staging (I, Il, Il), and high cytogenetie nisk. The quartiles for Cuogh,lawere: first quartile (≤89 μg/mL), second quartile (S9 to 104 μg/mL), third quartile (104 to 119 μg/mL), and fouth quartile (119 to 198 μg/mL). The quartiles for Croughmax were: furst quartile (≤470 μg/mL), second quartile (470 to 595 μg/mL), third quartile (595 to 701 μg/mL), and fouth quartile (701 to 1,282 μg/mL).

A case-control analysis was conducted using the weighted Mahalanobis metric method to match the identified risk factors.15 After matching, a group of subjects in the Kd group with similar risk factors (Q1 Kd match) as in the Q1 DKd group (Q1 DKd match) were identified, and the differences in the risk factors

<div style=\"page-break-after: always\"></div>

were minimized (Attachment 17 and Attachment 18). The 2 matched treatment groups, Q1 DKd match and Q1 Kd match, appeared to be balanced. The results for the matched case-control analysis are shown in Figure 11.

Figure 1l: Kaplan-Meier Curves for the Matched Subgroups (Progression-free Survival)

<!-- image -->

Abbreviations: Dara=daratumumab; D-Kd=daratumumab-carfilzomib-dexamethasone; Kd=carfilzomib-dexamethasone; Ql=first quartile. Note: First trough is trough concenhation after the furst infusion

The improvement in PFS was observed in the majority of the daratumumab-treated subjects (exposure quartiles: Q2-Q4, 75%). In the case-control analysis, the improvement of PFS was apparent in the 'Q1 DKd match' group compared with the 'Q1 Kd match' group for both first trough concentrations and maximum trough concentrations.

In summary, the E-R analysis on efficacy data suggests that the maximum daratumumab effect on PFS had been attained for the majority of the subjects at the studied 16 mg/kg dose, and it appeared that subjects in the DKd arm of Study CANDOR benefited from the treatment with daratumumab evidenced by a lower relative risk of disease progression/death across the studied daratumumab concentration range compared with the subjects in the Kd arm.

## Exposure-safety

There was no apparent E-R relationship between Cpeak,max and IRR, thrombocytopenia, anemia, neutropenia, lymphopenia, and infections and infestations within the studied drug concentration range (Table 10).

<div style=\"page-break-after: always\"></div>

Table 10: Comparison of Treatment-emergent AdverseEvent RatesAcrossPredicted DaratumumabExposure

Abbreviations: CI=confidence interval; Cpak,mxpredicted maximal end-of-infusion concentration; DKd=daratumumab-carfilzomib-dexamethasone;

|                           | % (95% C1) N=153   | Kd DKd Exposure quartiles, % (95% C1)   | Kd DKd Exposure quartiles, % (95% C1)   | Kd DKd Exposure quartiles, % (95% C1)   | Kd DKd Exposure quartiles, % (95% C1)   |
|---------------------------|--------------------|-----------------------------------------|-----------------------------------------|-----------------------------------------|-----------------------------------------|
| TEAE                      |                    | Q1 N=93                                 | Q2 6=N                                  | Q3 N=93                                 | Q4 N=93                                 |
| IRR                       | 0 (0 -0)           | 37.6 (28.2-47.7)                        | 42.4 (32.6-52.6)                        | 39.8 (30.2-49.9)                        | 38.7 (29.2-48.8)                        |
| Grade ≥3                  | 0(0-0)             | 8.6 (4-15.4)                            | 12 (6.4 - 19.6)                         | 5.4 (2 -11.2)                           | 8.6 (4-15.4)                            |
| Thrombocytopenia          | 30.1 (23.2-37.6)   | 53.8 (43.6 - 63.7)                      | 46.7 (36.7 -56.9)                       | 43(33.2-53.2)                           | 34.4 (25.3 -44.4)                       |
| Grade≥3                   | 16.3 (11.1 - 22.7) | 40.9(31.2-51)                           | 29.3 (20.7-39.1)                        | 16.1 (9.6- 24.5)                        | 16.1 (9.6-24.5)                         |
| Neutropenia               | 17(11.6-23.5)      | 31.2 (22.4-41)                          | 22.8 (15.1-32.1)                        | 35.5(26.2 -45.5)                        | 26.9 (18.6 -36.4)                       |
| Grade ≥3                  | 11.8 (7.3 - 17.5)  | 24.7 (16.7 - 34.1)                      | 18.5 (11.5 -27.2)                       | 21.5(14-30.6)                           | 17.2 (10.5-25.7)                        |
| Anemia                    | 32.7 (25.6-40.4)   | 50.5 (40.5 -60.6)                       | 40.2 (30.6 - 50.4)                      | 32.3 (23.3-42.1)                        | 30.1 (21.4-39.9)                        |
| Grade ≥3                  | 14.4 (9.4 - 20.5)  | 39.8 (30.2-49.9)                        | 16.3 (9.7 - 24.7)                       | 7.5 (3.3 -14)                           | 7.5 (3.3 - 14)                          |
| Lymphopenia               | 7.8 (4.3-12.8)     | 7.5 (3.3 - 14)                          | 12 (6.4 - 19.6)                         | 20.4 (13.1-29.4)                        | 15.1 (8.8-23.2)                         |
| Grade≥3                   | 7.2 (3.8 -12)      | 7.5 (3.3 -14)                           | 9.8 (4.8-16.9)                          | 14 (7.9 - 22)                           | 12.9 (7.1 -20.7)                        |
| InfectionsandInfestations | 66.7 (59 -73.8)    | 77.4 (68.2 -85.1)                       | 81.5 (72.8-88.5)                        | 83.9 (75.5-90.4)                        | 88.2 (80.6-93.7)                        |
| Grade >3                  | 32.7 (25.6-40.4)   | 45.2(35.3-55.3)                         | 33.7 (24.6-43.7)                        | 25.8(17.6-35.3)                         | 35.5 (26.2-45.5)                        |

Kd=carfilzomib-dexamethasone;IRR=infusion-related reaction; N=maximum nuber of subjects with data; Q=quartile;TEAE=hreatment-emergent adverse event.

The quartiles for Cueak.max were: first quartile (≤731 μg/mL), second quartile (731 to S80 μg/mL), third quartile (S80 to 1,010 μg/mL), and fouth quartile (1,010 to 1,650 μg/mL).

Key: Ccek max was used as the exposure measwre for analyses on alladverse events.

## Carfilzomib

## Exposure-efficacy

The summary of the exposure metrics (AUC and Cmax) available from Study 20160275 (CANDOR) based on individual PK parameter estimates from the final population PK model and individual dosing history is presented The time-to-event analysis for PFS was performed in subjects based on carfilzomib exposure (AUC or Cmax).

The exposure-response analysis of efficacy endpoints in subjects from Study 20160275 alone, in which all subjects received a 20/56 mg/m2 dose of carfilzomib, with or without daratumomab, did not show any statistically significant relationship between carfilzomib exposure and the primary efficacy endpoints, PFS, ORR and MRD[-]CR. Therefore, no further multivariate analysis with the additional covariates was done. Coadministration of daratumumab was found to have a positive effect (p &lt; 0.05) with the efficacy endpoints PFS, ORR, and MRD[-]CR at 12 months.

When combining data from all the studies in a pooled exposure response analysis of efficacy endpoints, the analysis did not show any statistically significant relationship between carfilzomib exposure and the primary efficacy endpoints, PFSand ORR. Therefore, no further multivariate analysis with the additional covariates was done. Coadministration of daratumumab was found to have a positive effect (p &lt; 0.05) with the efficacy endpoints PFS and ORR.

<div style=\"page-break-after: always\"></div>

Figure 3.Logistic Regression of the Probability of Overall ResponseVersus AUC of carfilzomib (CANDoR Analysis) in the presence (A) and absence (B) of daratumumab

(A)

<!-- image -->

(B)

<!-- image -->

## CarfilzomibExposure-ORRinabsenceofDaratumumab

STUDYID1CANDOR(Kd)

AUC = area under the concentration-time curve; AUC.clavg = average AUC in cycle 1; ORR = overall responserate

Blue line indicates predicted probability of response. Gray ribbon indicates 95% confidence interval of predicted response. Black circles, vertical error bars and numbers indicated the observed response rate (mean and 95% confidence interval) within each quartile of exposure. Quartiles of exposure are separated by dashed lines.Individual exposure values from each study are shown as colored points.

<div style=\"page-break-after: always\"></div>

Figure 4.Logistic Regression of the Probability of Overall ResponseVersus AUC of carfilzomib (Pooled Analysis) in the presence (A) and absence (B) of daratumumab

(A)

<!-- image -->

(B)

<!-- image -->

STUDYD1oCANDOR（Kd+Dara)+MMY1001

## CarfilzomibExposure-ORRinabsenceofDaratumumab

STUDYID1ARROW20/70+CANDOR（Kd）

AUC = area under the concentration-time curve; AUC.ciavg = average AUC in cycle 1; ORR = overall response rate

Blue line indicates predicted probability of response. Gray ribbon indicates 95% confidence interval of predicted response. Black circles, vertical error bars and numbers indicated the observed response rate (mean and 95% confidence interval) within each quartile of exposure. Quartiles of exposure are separated by dashed lines.Individual exposure values from each study are shown as colored points.

<div style=\"page-break-after: always\"></div>

Figure 5.Logistic Regression of the Probability of MRD Response Versus AUC

(CANDoR Analysis) in the presence (A) and absence (B) of daratumumab (A)

<!-- image -->

(B)

<!-- image -->

AUC = area under the concentration-time curve; AUC.ciavg = average AUC in cycle 1; MRD = MRD[H-]CR at 12 months

Blue line indicates predicted probability of response. Gray ribbon indicates 95% confidence interval of predicted response. Black circles, vertical error bars and numbers indicated the observed response rate by dashed lines. Individual exposure values from each study are shown as colored points.

## Exposure-safety

The results of the bivariate logistic regression analysis in both datasets, evaluating the effect of carfilzomib exposure and concomitant administration of daratumumab, for the safety endpoints on the

<div style=\"page-break-after: always\"></div>

exposure-response dataset indicated that there was a statistically significant relationship between exposure of carfilzomib and ischemic lung disease. only a small number of subjects had interstitial lung disease in CANDOR (7 of 445 subjects) and in the pooled dataset (9 out of 508). A relationship (p &lt; 0.05) was also identified between coadministration of daratumumab and grade ≥ 3 adverse ev ents.

Table 2: Summary of adverse events by study

Table 3. Summary of Adverse Events by Study

<!-- image -->

| Variable                  | ARROW 20/70 (n=53) n (%)   | CANDOR (KdD) (n=297) n (%)   | CANDOR (Kd) (n=148) n (%)   | MMY1001 (n = 10) n (%)   | All (n=508) n (%)   |
|---------------------------|----------------------------|------------------------------|-----------------------------|--------------------------|---------------------|
| Discontinuation           | 7 (13.2%)                  | 64 (21.6%6)                  | 35 (23.6%)                  | 0 (0%)                   | 106 (20.9%)         |
| Cardiac failure (broad)   | 11 (20.8%)                 | 63 (21.2%)                   | 33 (22.3%)                  | 4 (40%)                  | 111 (21.9%)         |
| Cardiac failure (narrow)  | 2 (3.8%6)                  | 21 (7.1%)                    | 14 (9.5%)                   | 2 (20%)                  | 39 (7.7%6)          |
| Ischemic heart disease    | 2 (3.8%6)                  | 13 (4.4%)                    | 5(3.4%6)                    | 0 (0%)                   | 20 (3.9%6)          |
| Hepatic failure           | 0 (1.196)                  | (%0) 0                       | 0 (0%)                      | 0 (0%)                   | 0(0%)               |
| Transaminase elevation    | 2 (3.8%6)                  | 20 (6.79)                    | 8 (5.496)                   | 0 (0%)                   | 30 (5.996)          |
| Hepatic event             | 2 (3.8%6)                  | 20 (6.79%)                   | 8 (5.4%6)                   | 0 (0%)                   | 30 (5.9%6)          |
| Dyspnea                   | 3 (5.7%)                   | 88 (22.9%6)                  | 37 (25%6)                   | 3 (30%)                  | 111 (21.9%)         |
| Pulmonary hypertension    | 1 (1.9%)                   | 5 (1.79%)                    | 4 (2.7%)                    | 0 (0%)                   | 10 (2%)             |
| Interstitial lung disease | 1 (1.9%6)                  | 6 (2%)                       | 1 (0.7%)                    | 1 (10%)                  | 9 (1.8%)            |
| ALT elevation             | 1 (1.9%)                   | 13 (4.4%)                    | 4 (2.7%)                    | 0 (0%)                   | 18 (3.5%6)          |
| AST elevation             | 0 (0%)                     | 5 (1.7%)                     | 1 (0.7%6)                   | 0 (0%)                   | 6 (1.2%)            |
| Any 2 grade 3             | 35 (66%)                   | 243 (81.8%6)                 | 109 (73.696)                | 8 (80%)                  | 395 (77.8%6)        |

Table 3.Summary of Adverse Events by Study

<!-- image -->

| Variable                                | ARROW 20/70 (n=53) n (%)   | CANDOR (KdD) (n=297) n (%)   | CANDOR (Kd) (n=148) n (%)   | MMY1001 (n = 10) n (%)   | All (n=508) n (%)   |
|-----------------------------------------|----------------------------|------------------------------|-----------------------------|--------------------------|---------------------|
| Acute renal failure (broad)             | 5 (9.4%)                   | 23 (7.79%)                   | 23 (15.5%)                  | 4 (40%)                  | 55 (10.8%)          |
| Acute renal failure (broad, 2 grade 3)  | (%0) 0                     | 3 (1%)                       | 3 (2%)                      | 0 (0%)                   | 6 (1.2%)            |
| Acute renal failure (narrow)            | 3 (5.7%)                   | 17 (5.7%)                    | 12 (8.1%)                   | 4 (40%)                  | 36 (7.1%)           |
| Acute renal failure (narrow, 2 grade 3) | (%0) 0                     | 8 (2.7%)                     | 10 (6.8%)                   | (9%0) 0                  | 18 (3.5%)           |
| Hypertension (narrow)                   | 13 (24.5%)                 | 94 (31.6%)                   | 47 (31.8%)                  | 0 (0%)                   | 154 (30.3%)         |
| Hypertension (narrow, 2 grade 3)        | 2 (3.8%)                   | 53 (17.8%)                   | 23 (15.5%)                  | 0 (0%)                   | 78 (15.4%)          |

ALT = alanine transaminase; AsT = aspartate transaminase

Hepatic event -- combined hepatic failure or transaminase elevation.

Number within parentheses reflect the proportion of patients for which effect was observed in each study.

<div style=\"page-break-after: always\"></div>

## 2.3.5. Discussion on clinical pharmacology

## Pharmacokinetic in the target population

The Applicant has applied a population-based analysis to describe the time-course of daratumumab and carfilzomib in patients with relapsed or refractory multiple myeloma. The structural PK models used were developed for the original MAA and successfully fitted to the observed data. The modelling strategy, model selection and model evaluation procedures are endorsed.

The final dataset of daratumumab consisted in 1556 samples from 375 patients. 723 samples were excluded.

In relation to the PK model of daratumumab, the estimated final parameters and the included covariates are reasonable. They have been estimated with adequate precision and the inter-individual variability is moderate. The goodness-of-fit graphs show a description of the observations. Differences are more notable in patients with body weights less than 74 kg, in women, and in patients with albumin levels less than 40 g/L, where a slight under-prediction in the higher range of Ctrough and Cmax values is observed. In addition, the elimination of the monoclonal antibody has been described using a linear and non-linear mechanisms able to account for the nonspecific clearance for IgG and the saturable target-mediate clearance, respectively. The reduction in the maximum velocity of the saturable process has been justified by the presence of a target-mediated drug disposition for daratumumab affecting together the total target amount in patients with multiple myeloma once receiving daratumumab. No differences were detected in terms of efficacy due to clinically relevant changes in exposure (&gt;20%) in patients with different type of myeloma, with mild hepatic impairment, weight &gt; 85 kg and moderate renal impairment.

The population PK model of carfilzomib was adapted from a previous publication in patients with multiple myeloma. Linear pharmacokinetic processes were assumed to describe the time-course of carfilzomib after intravenous administration. The final PK model incorporates a BSA effect on clearance. However, the inter-individual variability associated to each of the PK parameters (CL, Vc, Q and Vp) was considerably high (&gt;95%). The justification of sparse sampling as a consequence that may limit the identification of covariate effects and increase the inter-individual variability of PK parameters is reasonable.

## Potential drug-drug interaction of KdD combination

No formal investigations of the DDI potential between the components of the combination were performed and this could be considered acceptable. The use of dexamethasone in combination with either carfilzomib or daratumumab is already approved. The absence of clinically significant interaction between dexamethane and respectively carfilzomib and daratumumab already established.

The absence of clinically significant interaction between dexamethane and respectively carfilzomib and daratumumab already established. With regard to carfilzomib and daratumumab, the elimination pathways for are mainly mediated by ubiquitous enzymes (non-cytochrome P450 enzymes). According to the applicant, the pharmacokinetic drug interaction potential is expected to be low between carfilzomib and daratumumab. This is supported by the rapid and extensive elimination of carfilzomib by noncytochrome P450 mechanisms (epoxide hydrolases, peptidases). The drug interaction potential between carfilzomib and daratumumab is also low based on the unlikely interactions between small molecules and biologics, mainly attributed to differences in each clearance mechanism. Based on the metabolic pathways of carfilzomib (epoxide hydrolases, peptidases). Also, Clinical pharmacokinetic assessments of daratumumab in combination with lenalidomide, pomalidomide, thalidomide, bortezomib and dexamethasone indicated no clinically-relevant drug-drug interaction between daratumumab and these small molecule medicinal products. Furthermore, the covariate analyses in the PPK studies, identified no

<div style=\"page-break-after: always\"></div>

clinically significant intrinsic factors (eg, sex, race, disease, organ dysfunctions) or extrinsic factors (eg, drug-drug interactions) impacting carfilzomib or daratumumab pharmacokinetics have been identified.

Therefore, the potential for DDI is limited and the lack of formal PK investigations is acceptable.

## Secondary pharmacology

The evaluation of the QTc prolongation was performed using data after carfilzomib administration in combination with dexamethasone and daratumumab, or in combination with dexamethasone alone in 382 patients. A joint analysis revealed the lack of any QTc prolongation. A lack of linear relationship has been demonstrated for each treatment arm (Kd and DKd), suggesting no clinically relevant change in QTcF due to the exposure of carfilzomib.

## Exposure-efficacy

An exposure-efficacy relationship was established between trough and maximal trough concentrations of daratumumab and the relative hazard of disease. A significant improvement was observed when the exposure of daratumumab was greater than Q1. The improvement over the Kd group is minimal as long the exposure of daratumumab increases from Q1, indicating a saturable relationship. The Kaplan-Meir analysis shows a slight improvement in PFS in patients receiving DKd vs Kd group.

No exposure-efficacy relationship was found when carfilzomib average AUC in cycle 1 was related to the overall response rate or MRD response. Nevertheless, the results showed a higher overall response rate and MRD scores for the DKd groups vs the Kd group, confirming the improvement in terms of efficacy.

## Exposure-safety

No daratumumab exposure was available in the Kd group, which limited the comparison between Kd and DKd groups in terms of the exposure-safety analysis. Several inverse relationships were observed between daratumumab exposure and the incidence of adverse events, which do not indicate any exposure-safety relationship. A exposure-safety relationship was found between exposure of carfilzoib and ischemic lung disease, which was also observed when daratumumab is coadministered. The statistical relationship between carfilzomib exposure and interstitial lung disease showed limited impact in the number of patients with safety issues. No differences were provided in the incidence of interstitial lung disease between Kd and DKd groups. However, due to the limited number of patients (7 of 445) showing the disease, the comparison lacks clinical relevance.

The clinical pharmacology data included in this application did not necessitate an update of the SmPC.

## 2.3.6. Conclusions on clinical pharmacology

The population pharmacokinetic models adequately account for the daratumumab and carfilzomib longitudinal observations. The QTc analysis indicates the lack of any QTc prolongation when carfilzomib is co-administered with dexamethasone and daratumumab. The exposure-efficacy analysis shows a reduction in the hazard of disease for the combination group

(carfilzomib+dexamethasone+daratumumab) compared to carfilzomib+dexamethasone.

<div style=\"page-break-after: always\"></div>

## 2.4. Clinical efficacy

## 2.4.1. Main study(ies)

## Title of Study

CANDOR: A Randomized, Open-label, Phase 3 Study Comparing Carfilzomib, Dexamethasone, and Daratumumab to Carfilzomib and Dexamethasone for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma

## Methods

Figure 8-1. Study Design and Treatment Schema

<!-- image -->

Ab=antibody;CD38=clusterdifferentiation antigen38;CR=completeresponse;d=dexamethasone;D=daratumumab;ISS=International Staging System; survival;PFS=progression-freesurvival;Pl=proteasomeinhibitor.

a For patients with baseline chronic hepatic impairment (mild, moderate),the starting and subsequent doses of carfilzomib were reduced by 25%(ie,15 mg/m2 day 1 and 2 of cycle 1 and 42 mg/m2 day 8 cycle 1 and thereafter).

## Study participants

## Inclusion Criteria

- Relapsed or progressive multiple myeloma after last treatment
- Males or females ≥ 18 years of age
- Measurable disease with at least 1 of the following assessed within 21 days prior to randomization:
- IgG multiple myeloma: serum monoclonal paraprotein (M-protein) level ≥ 1.0 g/dL,
- IgA, IgD, IgE multiple myeloma: serum M-protein level ≥ 0.5 g/dL,

<div style=\"page-break-after: always\"></div>

- urine M-protein ≥ 200 mg/24 hours,
- in subjects without measurable serum or urine M-protein, serum free light chain (SFLC) ≥ 100 mg/L (involved light chain) and an abnormal serum kappa lambda ratio
- Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) of 0 to 2
- Patients must have at least PR to at least 1 line of prior therapy
- Received at least 1 but not more than 3 prior lines of therapy for multiple myeloma (induction therapy followed by stem cell transplant and consolidation/maintenance therapy will be considered as 1 line of therapy). Prior therapy with carfilzomib or anti-CD38 antibodies is allowed.
- Left ventricular ejection fraction ≥ 40% as assessed by transthoracic echocardiogram (TTE)
- Adequate hepatic function within 21 days prior to randomization:
- bilirubin &lt; 1.5 times the upper limit of normal (ULN)
- aspartate aminotransferase (AST) and alanine aminotransferase (ALT) &lt; 2.5 times the ULN
- Absolute neutrophil count (ANC) ≥ 1 x 109/L within 21 days prior to randomization.
- Hemoglobin ≥ 80 g/L within 21 days prior to randomization.
- Platelet count ≥ 75 x 109/L ( ≥ 50 x 109/L if myeloma involvement in the bone marrow is ≥ 50%) within 21 days prior to randomization.
- creatinine clearance (CrCl) of ≥ 20 mL/min within 21 days prior to randomization
- Females of childbearing potential (FCBP) must have a negative serum pregnancy test within 15 days prior to first dose of study drug and a negative urine pregnancy test within the 24 hours prior to first dose and must agree to use highly effective method(s) of contraception
- Male subjects who are sexually active with an FCBP must agree to use condoms (unless they have had a vasectomy with medical confirmation of surgical success) during carfilzomib and/or daratumumab treatment and for additional 90 days following the last carfilzomib and/or daratumumab administration.
- Male subjects must agree to not donate sperm, during treatment and for an additional 90 days following the last carfilzomib and/or daratumumab administration
- Subject has provided informed consent/assent prior to initiation of any study specific activities/procedures.

## Exclusion Criteria

- Waldenström macroglobulinemia
- Multiple myeloma of IgM subtype
- POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, and skin changes)
- Plasma cell leukemia (&gt; 2.0 x 109/L circulating plasma cells by standard differential)
- Myelodysplastic syndrome
- History of other malignancy within the past 5 years except:
- Adequately treated carcinoma in situ of the cervix without evidence of disease

<div style=\"page-break-after: always\"></div>

- Prostate cancer with a Gleason score &lt; 6 with undetectable prostate specific antigen (PSA) over 12 months
- Ductal breast carcinoma in situ with full surgical resection (ie, negative margins) and without evidence of disease
- Treated medullary or papillary thyroid cancer
- Adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease
- Adequately treated urothelial papillary noninvasive carcinoma or carcinoma in situ
- Similar neoplastic conditions with an expectation of &gt; 95% five-year disease-free survival
- Malignancy treated with curative intent and with no known active disease present for ≥ 3 years before randomization and felt to be at low risk for recurrence by the treating physician
- Primary amyloidosis (patients with multiple myeloma with asymptomatic deposition of amyloid plaques found on biopsy would be eligible if all other criteria are met)
- Immunotherapy with potential anti-myeloma activity within 21 days prior to randomization
- Chemotherapy with approved or investigational anticancer therapeutic within 21 days prior to randomization
- Glucocorticoid therapy within 14 days prior to randomization that exceeds a cumulative dose of 160 mg of dexamethasone or equivalent dose of other corticosteroids
- Focal radiation therapy within 7 days prior to randomization. Radiation therapy to an extended field involving a significant volume of bone marrow within 21 days prior to randomization (ie, prior radiation must have been to less than 30% of the bone marrow)
- Major surgery (except kyphoplasty) within 28 days prior to randomization
- Contraindication to dexamethasone
- Known history of allergy to Captisol (a cyclodextrin derivative used to solubilize carfilzomib)
- Contraindication to use daratumumab or any of its components: allergies, hypersensitivity, or intolerance to mannitol, monoclonal antibodies or human proteins or excipients (refer to Daratumumab's IB), or known sensitivity to mammalian-derived products.
- Prior participation in a Janssen daratumumab phase 3 study (with exception of subjects in control arm that have withdrawn consent from study participation)
- Contraindication to any of the required concomitant drugs or supportive treatments, including hypersensitivity to antiviral drugs
- Intolerance to hydration due to preexisting pulmonary or cardiac impairment
- Active congestive heart failure (New York Heart Association [NYHA] Class III to IV), symptomatic ischemia, uncontrolled arrhythmias, clinically significant electrocardiogram (ECG) abnormalities, screening ECG with corrected QT interval (QTc) of &gt; 470 msec, pericardial disease, or myocardial infarction within 4 months prior to randomization
- Infiltrative pulmonary disease, known pulmonary hypertension
- Active infection within 14 days prior to randomization requiring systemic antibiotics, antiviral (except antiviral therapy directed at hepatitis B) or antifungal agents. Such infection must be fully resolved prior to initiating study treatment.

<div style=\"page-break-after: always\"></div>

- Pleural effusions requiring thoracentesis within 14 days prior to randomization
- Ascites requiring paracentesis within 14 days prior to randomization
- Uncontrolled hypertension, defined as an average systolic blood pressure &gt; 159 mmHg or diastolic &gt; 99 mmHg despite optimal treatment (measured following European Society of Hypertension/European Society of Cardiology [ESH/ESC] 2013 guidelines; Appendix F)
- Known chronic obstructive pulmonary disease (COPD) with a forced expiratory volume in 1 second (FEV1) &lt; 50% of predicted normal.
- Subjects with confirmed FEV1 &lt; 50% of predicted.
- Known moderate or severe persistent asthma within the past 2 years (see Appendix G), or currently has uncontrolled asthma of any classification or at time of screening has an FEV1 of &lt; 50%. (Note that subjects who currently have controlled intermittent asthma or controlled mild persistent asthma are allowed in the study).
- Known cirrhosis
- Known human immunodeficiency virus (HIV) infection, hepatitis C infection (subjects with hepatitis C that achieve a sustained virologic response following antiviral therapy are allowed), or hepatitis B infection (subjects with hepatitis B surface antigen [HBsAg] or core antibody that achieve sustained virologic response with antiviral therapy directed at hepatitis B are allowed)
- Currently receiving treatment in another investigational device or drug study, or less than 28 days since ending treatment on another investigational device or drug study(ies). Other investigational procedures while participating in this study are excluded.
- Pregnant or breastfeeding women, or women who are planning to become pregnant or breastfeed during treatment and for an additional 30 days after discontinuing treatment.
- Ongoing graft-versus-host disease
- Autologous stem cell transplant less than 90 days prior to randomization
- Vaccination with live attenuated vaccines within 4 weeks prior to randomization
- Subject likely to not be available to complete all protocol required study visits or procedures, and/or to comply with all required study procedures (eg, Clinical Outcome Assessment [COAs]) to the best of the subject and investigator's knowledge.
- History or evidence of any other clinically significant disorder, condition or disease (with the exception of those outlined above) that, in the opinion of the investigator or Amgen physician, if consulted, would pose a risk to subject safety or interfere with the study evaluation, procedures or completion
- Subjects with grade 3 or worse neuropathy within 14 days prior to randomization
- Allogeneic stem cell transplant less than 100 days prior to randomization
- Patients on any immunosuppressive therapy for graft versus host disease, even if it has resolved

## Treatments

Subjects were administered either KdD or Kd, as determined by randomization, in 28-day cycles. The treatment schedules for each treatment group are provided in Table 8-2.

<div style=\"page-break-after: always\"></div>

Table 8-2. Dosing Schedule

| Cycle(s)   | Days                  | Investigational Producta   | Dose     |
|------------|-----------------------|----------------------------|----------|
| 1          | 1 and 2               | carfilzomib                | 20 mg/m2 |
|            | 8, 9, 15, and 16      | carfilzomib                | 56 mg/m2 |
| 2+         | 1,2, 8, 9, 15, and 16 | carfilzomib                | 56 mg/m2 |
| 1          | 1 and 2               | daratumumab                | 8 mg/kg  |
| 1          | 8, 15, and 22         | daratumumab                | 16 mg/kg |
| 2          | 1,8, 15, and 22       | daratumumab                | 16 mg/kg |
| 3 to 6     | 1 and 15              | daratumumab                | 16 mg/kg |
| 7+         | 1                     | daratumumab                | 16 mg/kg |
| All        | 1,2, 8, 9, 15, and 16 | dexamethasone              | 20 mgb   |
| AIl        | 22                    | dexamethasone              | 40 mgb   |

## Justification for Investigational Product Dose

The dose schedule in the KdD group was based on the objective of evaluating the effect of the addition of daratumumab to a well characterized Kd regimen. The safety and efficacy of Kd 20/56 mg/m 2  twiceweekly has been established in randomized phase 3 Study 2011-003 (ENDEAVOR; Dimopoulos et al, 2017; Dimopoulos et al, 2016a).

Dosing of daratumumab in subjects with multiple myeloma was 16 mg/kg (weekly for 8 weeks, then every 2 weeks for 16 weeks, then every 4 weeks thereafter) as per the label (see Table 8-2). The dose selection was based on an acceptable safety profile, maximal clinical activity, and pharmacokinetics consistent with saturation of the target.

An antiviral was required concomitant medication for the duration of treatment with carfilzomib. A protonpump inhibitor (omeprazole or equivalent) was a required concomitant medication while taking dexamethasone.

## Pre- and Post-infusion Medications for Daratumumab

On daratumumab infusion days, subjects in the KdD group received paracetamol, antihistamine, and leukotriene inhibitor before daratumumab infusion.

In the absence of infusion-related adverse events after the first 3 infusions, post-infusion corticosteroids were administered per investigator discretion.

For subjects with a higher risk of respiratory complications an antihistamine, leukotriene inhibitor, shortacting β 2 adrenergic receptor agonist, and control medications for lung disease (eg, inhaled corticosteroids ± long-acting β 2 adrenergic receptor agonists for subjects with asthma; long-acting bronchodilators such as tiotropium or salmeterol ± inhaled corticosteroids for subjects with chronic obstructive pulmonary disease) were administered after daratumumab infusions.

## Optional and Allowed Concomitant Medications

The following medications/therapies were recommended per protocol-specified procedures, at the investigator's discretion:

<div style=\"page-break-after: always\"></div>

- anticoagulant for thromboprophylaxis
- approved uric acid-lowering agents (eg, allopurinol)
- concomitant bone health therapy
- pneumocystis jirovenci pneumonia prophylaxis
- antivirals
- hyperglycemia medical management
- prevention of constipation (eg, adequate hydration, high-fiber diet, and stool softeners, if needed)
- prophylactic antiemetics, with the exception of corticosteroids
- colony stimulating factors, erythropoietin, and transfusion of platelets and RBCs
- loperamide was recommended for the treatment of diarrhea
- additional hydration
- IV immunoglobulins

## Excluded Concomitant Medications

The following medications/therapies were not allowed while subjects received investigational product:

- therapy with a marketed or investigational anticancer therapeutic or radiation to large marrow reserves for either a palliative or therapeutic intent that was not required per the study protocol
- long-term corticosteroids for nonmalignant conditions (eg, asthma, inflammatory bowel disease) equivalent to a dexamethasone dose &gt; 4.0 mg/day or prednisone &gt; 20 mg/day
- plasmapheresis
- other investigational products or devices

<div style=\"page-break-after: always\"></div>

## Objectives Outcomes/endpoints

Table 3: objectives and endpoints in CANDOR trial

| Objectives                                                                                                                                                                                                                     | Endpoints                                                                                                                                                                                                                                                 |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Primary                                                                                                                                                                                                                        |                                                                                                                                                                                                                                                           |
| To compare carfilzomib dexamethasone, and daratumumab (KdD) to carfilzomib and dexamethasone (Kd) in terms of progression-free survival (PFS) in subjects with multiple myeloma who have relapsed after 1 to 3 prior therapies | PFS defined as time from randomization until disease progression or death from any cause. Disease progression was determined by a blinded Independent Review Committee (IRC)                                                                              |
| Key Secondary                                                                                                                                                                                                                  |                                                                                                                                                                                                                                                           |
| To compare the overall response rate (ORR) between the 2 groups                                                                                                                                                                | ORR, defined as the proportion of subjects with best overall response (BOR) of partial response (PR) or better by IRC                                                                                                                                     |
| To compare the rate of minimal residual disease negative-complete response (MRD[-]CR) in bone marrow aspirates at 12 months (± 4 weeks) as determined by next-generation sequencing (NGS) between the 2 groups                 | MRD[-]CR rate, defined as the proportion of subjects with BOR of complete response (CR) or better by IRC per International Myeloma Working Group Uniform Response Criteria (IMWG-URC) and MRD[-] status as assessed by NGS (at a 10-5 level) at 12 months |
| To compare the overall survival (OS) between the 2 groups                                                                                                                                                                      | OS, defined as time from randomization until death from any cause                                                                                                                                                                                         |

| Secondary               | Secondary                                                                                                                                                                                                                            |
|-------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| safety and tolerability | subject incidence of treatment-emergent adverse events safety laboratory values, left ventricular ejection fraction, forced expiratory volume in 1 second /forced vital capacity ratio, and vital signs at each scheduled assessment |

<div style=\"page-break-after: always\"></div>

| duration of response    | duration of response, defined as the time from first evidence of PR or better per IMWG-URC to the earliest of disease progression or death due to any cause for subjects with a best response of PR or better   |
|-------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| time to next treatment  | time to next treatment, defined as the time from randomization to the initiation of subsequent non-protocol anti-cancer treatment for multiple myeloma                                                          |
| time to progression     | time to progression, defined as the time from randomization to documented disease progression                                                                                                                   |
| time to response        | time to response, defined as the time from randomization to the earliest date a response of PR or better is first achieved and subsequently confirmed for subjects with a best response of PR or better         |
| persistence of MRD[-]CR | sustained MRD[-]CR, defined as the proportion of subjects who maintained MRD[-]CR for 12 months or more after achieving MRD[-]CR status                                                                         |
| complete response rate  | complete response rate, defined as the proportion of subjects with BOR of CR or better                                                                                                                          |
| MRD[-] rate             | MRD[-] rate, defined as the proportion of subjects with MRD[-] status as assessed by NGS (at a 10-5 level) at 12 months                                                                                         |
| quality of life         | Global Health Status/Quality of Life (GHS/QOL) measured by European Organisation for Research Treatment of Cancer (EORTC) Quality of Life Core Module (QLQ-C30) version 3 questionnaire                         |

## Hypothesis

The main hypothesis was that the carfilzomib, dexamethasone, and daratumumab (KdD) regimen would provide significant improvement in progression-free survival (PFS) over the carfilzomib and dexamethasone (Kd) regimen.

<div style=\"page-break-after: always\"></div>

## Sample size

One hundred eighty-eight PFS events were required to have at least 90% power to demonstrate superiority at an alternative hazard ratio (HR) of 0.6 (KdD group vs Kd group), using a log rank test at 1sided overall significance level of 0.025. The hypothesized HR of 0.6 corresponded to an increase in median PFS from 18 to 30 months (Dimopoulos et al, 2016a). With 450 subjects randomized (300 in the KdD group vs 150 in the Kd group), it was anticipated that 188 events would be accrued at approximately 27 months after the first subject was randomized assuming events followed an exponential distribution.

## Randomisation

Eligible subjects were randomized in a 2:1 ratio using an IxRS to receive either KdD or Kd. Eligible subjects were stratified at the time of randomization based on the following stratification factors:

1. original ISS stage at screening (stages 1 or 2 vs stage 3)
2. prior proteasome inhibitor exposure (yes vs no)
3. number of prior lines of therapy (1 vs ≥ 2)
4. prior CD38 antibody therapy (yes vs no)

## Blinding (masking)

This was an open-label study. However, the assessment of response and disease progression for the primary analysis was determined by an IRC in a blinded manner.

Sensitivity analyses of response and disease progression were determined centrally by the sponsor using a validated computer algorithm (Onyx Response Computational Assessment [ORCA]) in a blinded manner.

## Statistical methods

Before the analyses for this study report were conducted, the protocol-defined statistical analyses were detailed in the statistical analysis plan (SAP).

Analysis Sets, Subgroups and Covariates

## Analysis Sets

Analysis sets are described in Table 8-4.

## Table 8-4. Analysis Sets

<div style=\"page-break-after: always\"></div>

ITT = intent-to-treat; MRD = minimal residual disease

| Analysis Set                       | Definition                                                                                                                                                                                                                                               |
|------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Full analysis set                  | All randomized subjects. All subjects were analyzed according to the treatment to which they were randomized (ITT population).                                                                                                                           |
| Safety analysis set                | All randomized subjects who received at least 1 dose of any study treatment (ie, carfilzomib, dexamethasone, or daratumumab).Subjects were analyzed according to the treatment group corresponding to the actual treatment received (safety population). |
| Per protocol analysis set          | All randomized subjects who did not have any important protocol deviations that were considered tohave an effect on efficacy outcomes.                                                                                                                   |
| MRD evaluable analysis set         | All randomized subjectswhohad a baselineMRD sampleandpost-baselineMRDassessment.                                                                                                                                                                         |
| 12-month landmark MRD analysis set | All randomized subjects who had an MRD sample collectedatmonth12.                                                                                                                                                                                        |

## Subgroups

In addition to the stratification factors for randomization (eg, original ISS stage at screening, prior proteasome inhibitor exposure, number of prior lines of therapy, and prior CD38 antibody therapy), the following covariates were used to examine the primary and selected secondary endpoints in subgroups, as appropriate:

- baseline demographics and characteristics:
- o age (≤ 75, &gt; 75)
- o sex (female, male)
- o race (white, Asian and other/unknown)
- o region (North America, Europe, Asia Pacific)
- baseline organ function and comorbid conditions:
- o COG PS (0 to 1, 2)
- o baseline creatinine clearance (CrCl; 15 to 50, ≥ 50 to 80, ≥ 80 mL/mi n)
- baseline disease characteristics:
- o prior lenalidomide exposure (yes, no)
- o refractory to lenalidomide (yes, no)
- o prior bortezomib or ixazomib exposure (yes, no)
- o refractory to bortezomib or ixazomib (yes, no)
- o prior IMiD exposure (yes, no)
- o refractory to IMiD (yes, no)
- o revised ISS stage (stage 1 or 2, stage 3)
- o IgG vs non-IgG
- o determination of measurable disease at baseline (based on serum protein electrophoresis [SPEP] only, based on urine protein electrophoresis [UPEP] only or both SPEP and UPEP, based on SFLC only)

<div style=\"page-break-after: always\"></div>

- o β 2microglobulin level (&lt; 3.5, ≥ 3.5 and &lt; 5.5, ≥ 5.5 mg/L)
- o risk group as determined by genetic abnormality per IMWG (high risk, standard risk)
- o presence of soft tissue plasmacytoma (yes, no)

## Covariates

No covariates were planned.

## Planned Analyses

Summary statistics were provided for continuous variables. Frequency and percentage were summarized by treatment group for binary and categorical variables. Proportions and the corresponding 95% CI were based on Clopper-Pearson Method and the treatment comparison were based on Cochran-MantelHaenszel test. Exact tests were considered for subgroup analyses when the cell size was considered small. Time-to-event endpoints were estimated using the Kaplan-Meier method. Stratified log-rank test statistics and associated p-values were also calculated. Hazard ratios were estimated using stratified Cox proportional hazards models.

## Interim Analysis and Early Stopping Guidelines

No interim analysis of PFS was planned or performed. The first interim analysis of OS was tested at the time of primary analysis of PFS

## Primary Analysis

The primary analysis of PFS was event driven. The primary analysis, reported herein, was planned for when it was estimated that approximately 188 PFS events were observed. As IRC evaluations were not available in real time, blinded monitoring of cumulative PFS events was employed using ORCA assessed events to determine an initial data cutoff date for the planned primary analysis date. The primary analysis was to be conducted when at least 165 PFS events by IRC were observed.

## Final Analysis

The final analysis of the study will be conducted at approximately 230 OS events or 58 months after the first subject was enrolled, whichever is earlier. The results of the final analysis are not provided within this report.

## Planned Methods of Analysis

## Efficacy Analyses

Efficacy analyses were based on the ITT Population.

Testing of the primary and key secondary endpoints was performed using a fixed sequence hierarchical testing procedure in the order of PFS, ORR, MRD[-]CR rate at 12 months, and OS such that the overall Type I error rate was strongly controlled under 0.025 (1-sided). Overall survival was tested at a significance level of 0.001 for this primary analysis.

## Results

## Participant flow

<div style=\"page-break-after: always\"></div>

Figure 9-1. Subject Disposition (Intent-to-Treat Population)

<!-- image -->

FU = follow-up; KdD = carfilzomib, dexamethasone, and daratumumab; Kd = carfilzomib and dexamethasone; LTFU = long-term follow-up All percentages in this figure are relative to the number of subjects randomized in the specified treatment group.

Source: Table 14-1.1.1

## Table 9-1. Subject Disposition

|                                           | Kd n (%)   | KdD n (%)   | Total n (%)   |
|-------------------------------------------|------------|-------------|---------------|
| Number of subjects screened               |            |             | 569           |
| Subjects screened but not randomizeda     |            |             | 103 (18.1)    |
| Subjectsrandomizeda                       | 154        | 312         | 466 (81.9)    |
| Subjects randomized but not dosed - n (%) | 1 (0.6)    | 4 (1.3)     | 5 (1.1)       |
| Reasonsrandomized subjectsnotdosed        |            |             |               |
| Adverse event                             | 0 (0.0)    | 1 (0.3)     | 1 (0.2)       |
| Decision by sponsor                       | 1 (0.6)    | 2 (0.6)     | 3 (0.6)       |
| Death                                     | 0 (0.0)    | 1 (0.3)     | 1 (0.2)       |
| Investigational product accounting        |            |             |               |
| Carfilzomib                               |            |             |               |
| Subjects who received carfilzomib         | 153 (99.4) | 308 (98.7)  | 461 (98.9)    |
| Subjects continuing carfilzomib           | 46 (29.9)  | 129 (41.3)  | 175 (37.6)    |
| Subjects who discontinued carfilzomib     | 107 (69.5) | 179 (57.4)  | 286 (61.4)    |
| Ineligibility determined                  | 1 (0.6)    | 0 (0.0)     | 1 (0.2)       |
| Adverse event                             | 28 (18.2)  | 52 (16.7)   | 80 (17.2)     |
| Subject request                           | 10 (6.5)   | 15 (4.8)    | 25 (5.4)      |
| Disease progression                       | 60 (39.0)  | 80 (25.6)   | 140 (30.0)    |
| Lost to follow-up                         | 0 (0.0)    | 1 (0.3)     | 1 (0.2)       |
| Death                                     | 3 (1.9)    | 23 (7.4)    | 26 (5.6)      |
| Requirement for alternative therapy       | 1 (0.6)    | 3 (1.0)     | 4 (0.9)       |
| Other                                     | 4 (2.6)    | 5 (1.6)     | 9 (1.9)       |
| Daratumumab                               |            |             |               |
| Subjectswhoreceived daratumumab           | 0 (0.0)    | 308 (98.7)  | 308 (66.1)    |
| Subjects continuing daratumumab           | 0 (0.0)    | 157 (50.3)  | 157 (33.7)    |
| Subjectswho discontinued daratumumab      | 0 (0.0)    | 151 (48.4)  | 151 (32.4)    |
| Adverse event                             | 0 (0.0)    | 18 (5.8)    | 18 (3.9)      |
| Subject request                           | 0 (0.0)    | 16 (5.1)    | 16 (3.4)      |
| Disease progression                       | 0 (0.0)    | 88 (28.2)   | 88 (18.9)     |
| Death                                     | 0 (0.0)    | 22 (7.1)    | 22 (4.7)      |
| Requirement for alternative therapy       | 0 (0.0)    | 3 (1.0)     | 3 (0.6)       |
| Other                                     | 0 (0.0)    | 4 (1.3)     | 4 (0.9)       |

<div style=\"page-break-after: always\"></div>

| Dexamethasone                                |            |            |            |
|----------------------------------------------|------------|------------|------------|
| Subjectswhoreceived dexamethasone            | 153 (99.4) | 308 (98.7) | 461 (98.9) |
| Subjects continuing dexamethasone            | 45 (29.2)  | 147 (47.1) | 192 (41.2) |
| Subjects who discontinued dexamethasone      | 108 (70.1) | 161 (51.6) | 269 (57.7) |
| Ineligibility determined                     | 1 (0.6)    | 0 (0.0)    | 1 (0.2)    |
| Adverse event                                | 31 (20.1)  | 23 (7.4)   | 54 (11.6)  |
| Subject request                              | 9 (5.8)    | 16 (5.1)   | 25 (5.4)   |
| Disease progression                          | 58 (37.7)  | 85 (27.2)  | 143 (30.7) |
| Death                                        | 3 (1.9)    | 23 (7.4)   | 26 (5.6)   |
| Requirement for alternative therapy          | 0 (0.0)    | 3 (1.0)    | 3 (0.6)    |
| Other                                        | 6 (3.9)    | 11 (3.5)   | 17 (3.6)   |
| Study completion accounting                  |            |            |            |
| Subjects entered follow-up without PD (FU)b  | 42 (27.3)  | 26 (8.3)   | 68 (14.6)  |
| Continuing in FU                             | 11 (7.1)   | 10 (3.2)   | 21 (4.5)   |
| Completed or discontinued FU                 | 31 (20.1)  | 16 (5.1)   | 47 (10.1)  |
| Completed                                    | 5 (3.2)    | 2 (0.6)    | 7 (1.5)    |
| Subject request                              | 11 (7.1)   | 9 (2.9)    | 20 (4.3)   |
| Death                                        | 1 (0.6)    | 2 (0.6)    | 3 (0.6)    |
| Disease Progression                          | 11 (7.1)   | 3 (1.0)    | 14 (3.0)   |
| Other                                        | 3 (1.9)    | 0 (0.0)    | 3 (0.6)    |
| Subjects entered long-term follow-up (LTFU)c | 69 (44.8)  | 81 (26.0)  | 150 (32.2) |
| Continuing in LTFU                           | 50 (32.5)  | 63 (20.2)  | 113 (24.2) |
| Completed or discontinued LTFU               | 19 (12.3)  | 18 (5.8)   | 37 (7.9)   |
| Withdrawal of consent from study             | 2 (1.3)    | 0 (0.0)    | 2 (0.4)    |
| Lost to follow-up                            | 0 (0.0)    | 1 (0.3)    | 1 (0.2)    |
| Death                                        | 17 (11.0)  | 17 (5.4)   | 34 (7.3)   |
| Subjects continuing in study                 | 107 (69.5) | 233 (74.7) | 340 (73.0) |
| Subjects who discontinued study              | 47 (30.5)  | 79 (25.3)  | 126 (27.0) |
| Withdrawal of consent from study             | 9 (5.8)    | 14 (4.5)   | 23 (4.9)   |
| Decision by sponsor                          | 2 (1.3)    | 3 (1.0)    | 5 (1.1)    |
| Lost to Follow-up                            | 0 (0.0)    | 3 (1.0)    | 3 (0.6)    |
| Death                                        | 36 (23.4)  | 59 (18.9)  | 95 (20.4)  |

Kd=carfilzomiband dexamethasone;KdD=carfilzomib,dexamethasone,and daratumumab;

All percentages in this table are relative to the number of subjects randomized in each treatment group or in total, unless specified.

FU = follow-up; LTFU = long-term follow-up.

a Percentages are relative to the total number of subjects screened.

b Follow-up visits occurred 30 days (+ 3) and 8 weeks (± 7 days) after last dose of all study follow-up visits every 28 ± 7 days until PD.

cAllsubjectsentered LTFUforsurvival afterthe activefollow-upuntil thesubject hadwithdrawn consent, was lost to follow-up, had died, or the study had ended/closed, whichever was earliest. Source:Table 14-1.1.1

## Conduct of the study

The original protocol (dated 13 December 2016) was amended 4 times before the data cutoff date for this report (14 July 2019). Table 8-6 provides a summary of changes related to the conduct of the study.

<div style=\"page-break-after: always\"></div>

Table 8-6 Summary of Protocol Amendments

COA = clinical outcome assessment; CR = complete response; HBV =hepatitis B virus; IMWG-UC = International Myeloma Working Group Uniform Response Criteria; IRC = Independent Review Committee; ISS = International Staging System; pulmonary function test; Kd = carfilzomib plus dexamethasone; KdD = carfilzomib plus dexamethasone and daratumumab;OS=overallsurvival

| Amendment                                                                                         | Major Changes                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
|---------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Original Protocol 13 December2016 (12 subjects enrolled)                                          |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| Amendment 1 15 February 2017 (101 subjects enrolled)                                              | Included safety objectives and endpoints as additional secondary objectives and endpoints Updated and clarified the IMWG-URC Added additional exclusion criteria Updated list of countries participating in global study                                                                                                                                                                                                                                                                                                                                                  |
| Amendment 2 09 June 2017 (353 subjects enrolled)                                                  | Modified contraception language Modified primary and secondary endpoint analyses to include treatment-by subgroup analyses Clarified when confirmation of disease progression was needed.                                                                                                                                                                                                                                                                                                                                                                                 |
| Amendment 3 19 April 2018 (0 subjects enrolled betweenthisdateand the date of the next amendment) | Clarified timing of pregnancy tests before first dose of investigational product Clarified recommended action for congestive heart failure Clarified how dosing of 20 mg dexamethasone could be split in the KdD group Updated which laboratory assessments were to be performed at follow-up visits Clarified that for subjects who did not complete COAs on cycle 1 day1, further COAs were not collected. Clarified that COAs were collected electronically                                                                                                            |
| Amendment 4 17 May 2019 (0 subjects enrolled after this amendment)                                | Added 2interimreadoutsofOSat36and48months after the first subject enrolled, as well as, methods for the analyses and clarification of the timing of the OS final analysis Updated languagefor managementof HBVreactivation, safetyevaluations,anddoseinterruptionguidelinesfor daratumumab Updated dexamethasone dosing forsubjects who discontinued carfilzomib and for subjects with steroid intolerance Clarified recommended carfilzomib dose modifications for congestive heart failure Added the collection ofsubsequent antimyeloma therapy in long-term follow-up |

## Changes in Statistical Methods

The original SAP dated 31 July 2017 was amended once on 15 July 2019, before the database snapshot for the primary analysis, to add interim OS analyses.

## Protocol deviations

Overall, 132 subjects (28.3%) experienced important protocol deviations.

<div style=\"page-break-after: always\"></div>

| Table 4: Summary   | Deviations   | (Intent-to-Treat   | Population)   |
|--------------------|--------------|--------------------|---------------|

a Each occurrence was counted, including multiple events of the same important protocol deviations for a single subject.

Kd = carfilzomib and dexamethasone; KdD = carfilzomib, dexamethasone, and daratumumab; TA = received the wrong treatment or incorrect dose; TC = other treatment compliance b For 19 out of the 39 subjects (3 out of 7 subjects in the Kd group and 16 out of 32 subjects in the KdD group), local laboratory data or central laboratory test results received after enrollment showed that eligibility criteria were met such that neither subject safety nor efficacy assessments were impacted (Source: misc\\_dir.ipdlkup).

Source:Table14-3.1.1

## Baseline data

Subject demographics for the ITT population are presented in Table 9-4 and were generally consistent between treatment groups. Overall, 57.5 % of subjects were men, 78.5% were white, and the median age was 64 (range: 29 to 84) years. The percentage of subjects aged 75 to 84 years was lower in the KdD group (9.0%) than in the Kd group (14.3%).

Table 9-4. Baseline Demographics (Intent-to-Treat Population)

<div style=\"page-break-after: always\"></div>

|                              | Kd (N = 154)   | KdD (N = 312)   | Total (N = 466)   |
|------------------------------|----------------|-----------------|-------------------|
| Age at randomization (years) |                |                 |                   |
| Mean                         | 64.3           | 62.9            | 63.4              |
| SD                           | 9.6            | 10.0            | 9.9               |
| Median                       | 64.5           | 64.0            | 64.0              |
| Min, Max                     | 35, 83         | 29, 84          | 29, 84            |
| Age group - n (%)            |                |                 |                   |
| ≤75 years                    | 136 (88.3)     | 287 (92.0)      | 423 (90.8)        |
| > 75 years                   | 18 (11.7)      | 25 (8.0)        | 43 (9.2)          |
| Age group 2 -n (%)           |                |                 |                   |
| 18 - 64 years                | 77 (50.0)      | 163 (52.2)      | 240 (51.5)        |
| 65 - 74 years                | 55 (35.7)      | 121 (38.8)      | 176 (37.8)        |
| 75 - 84 years                | 22 (14.3)      | 28 (9.0)        | 50 (10.7)         |
| ≥ 85 years                   | 0 (0.0)        | 0 (0.0)         | 0 (0.0)           |
| Sex -n (%)                   |                |                 |                   |
| Male                         | 91 (59.1)      | 177 (56.7)      | 268 (57.5)        |
| Female                       | 63 (40.9)      | 135 (43.3)      | 198 (42.5)        |
| Ethnicity - n (%)            |                |                 |                   |
| Hispanic/Latino              | 1 (0.6)        | 7 (2.2)         | 8 (1.7)           |
| Not Hispanic/ Latino         | 146 (94.8)     | 291 (93.3)      | 437 (93.8)        |
| Missing                      | 7 (4.5)        | 14 (4.5)        | 21 (4.5)          |
| Race -n (%)                  |                |                 |                   |
| Asian                        | 20 (13.0)      | 46 (14.7)       | 66 (14.2)         |
| BlackorAfricanAmerican       | 2 (1.3)        | 7 (2.2)         | 9 (1.9)           |
| White                        | 123 (79.9)     | 243 (77.9)      | 366 (78.5)        |
| Other                        | 9 (5.8)        | 16 (5.1)        | 25 (5.4)          |

Kd = carfilzomib and dexamethasone; KdD = carfilzomib, dexamethasone, and daratumumab

Source:Table14-2.1.1

Study baseline characteristics are summarized in Table 9-5. Most subjects were enrolled in Europe (66.5%); subjects were also enrolled in Asia Pacific (26.4%) and North America (7.1%).

Disease characteristics were generally balanced between the treatment groups. The percentage of subjects who had previously received a lenalidomide-containing regimen was lower in the KdD group (39.4%) than in the Kd group (48.1%). The percentage of subjects who had a prior transplant was also higher in the KdD group (62.5%) than in the Kd group (48.7%).

Table 9-5. Baseline Characteristics (Intent-to-Treat Population)

<div style=\"page-break-after: always\"></div>

|                                                                        | Kd (N = 154)   | KdD (N = 312)   | Total (N = 466)   |
|------------------------------------------------------------------------|----------------|-----------------|-------------------|
| Geographic region - n (%)                                              |                |                 |                   |
| North America                                                          | 12 (7.8)       | 21 (6.7)        | 33 (7.1)          |
| Europe                                                                 | 103 (66.9)     | 207 (66.3)      | 310 (66.5)        |
| Asia Pacific                                                           | 39 (25.3)      | 84 (26.9)       | 123 (26.4)        |
| Frailty status - n (%)                                                 |                |                 |                   |
| Fit                                                                    | 68 (44.2)      | 176 (56.4)      | 244 (52.4)        |
| Intermediate fitness                                                   | 36 (23.4)      | 54 (17.3)       | 90 (19.3)         |
| Frail                                                                  | 9 (5.8)        | 10 (3.2)        | 19 (4.1)          |
| Not available                                                          | 37 (24.0)      | 66 (21.2)       | 103 (22.1)        |
| Missing                                                                | 4 (2.6)        | 6 (1.9)         | 10 (2.1)          |
| ECOG performance status - n (%)                                        |                |                 |                   |
| 0 or 1                                                                 | 147 (95.5)     | 295 (94.6)      | 442 (94.8)        |
| 2                                                                      | 7 (4.5)        | 15 (4.8)        | 22 (4.7)          |
| Missing                                                                | 0 (0.0)        | 2 (0.6)         | 2 (0.4)           |
| Time from initial diagnosis to randomization (months)                  |                |                 |                   |
| n                                                                      | 149            | 297             | 446               |
| Mean                                                                   | 44.03          | 47.86           | 46.58             |
| SD                                                                     | 36.57          | 34.69           | 35.34             |
| Median                                                                 | 34.60          | 37.50           | 36.70             |
| Min, Max                                                               | 0.5, 211.1     | 0.3, 221.9      | 0.3, 221.9        |
| Risk group as determined by fluorescent in situ hybridization - n (%)a |                |                 |                   |
| High risk                                                              | 26 (16.9)      | 48 (15.4)       | 74 (15.9)         |
| Standard risk                                                          | 52 (33.8)      | 104 (33.3)      | 156 (33.5)        |
| Unknown                                                                | 76 (49.4)      | 160 (51.3)      | 236 (50.6)        |
| ISS stage per IxRS at screening - n (%)                                |                |                 |                   |
| I or ll                                                                | 127 (82.5)     | 252 (80.8)      | 379 (81.3)        |
| III                                                                    | 27 (17.5)      | 60 (19.2)       | 87 (18.7)         |
| Beta-2 microglobulin (mg/L)                                            |                |                 |                   |
| n                                                                      | 154            | 311             | 465               |
| Mean                                                                   | 4.17           | 4.19            | 4.18              |
| SD                                                                     | 2.76           | 2.76            | 2.76              |
| Median                                                                 | 3.25           | 3.40            | 3.40              |
| Min, Max                                                               | 1.4, 18.0      | 1.2, 21.7       | 1.2, 21.7         |
| Beta-2 microglobulin level- n (%)                                      |                |                 |                   |
| <3.5 mg/L                                                              | 83 (53.9)      | 158 (50.6)      | 241 (51.7)        |
| ≥ 3.5 and <5.5 mg/L                                                    | 44 (28.6)      | 92 (29.5)       | 136 (29.2)        |
| ≥ 5.5 mg/L                                                             | 27 (17.5)      | 61 (19.6)       | 88 (18.9)         |
| Unknown                                                                | 0 (0.0)        | 1 (0.3)         | 1 (0.2)           |

<div style=\"page-break-after: always\"></div>

|                                                                      | Kd (N = 154)   | KdD (N = 312)   | Total (N = 466)   |
|----------------------------------------------------------------------|----------------|-----------------|-------------------|
| Number of subjects grouped by total number of prior regimens - n (%) |                |                 |                   |
| 1                                                                    | 70 (45.5)      | 144 (46.2)      | 214 (45.9)        |
| 2                                                                    | 46 (29.9)      | 99 (31.7)       | 145 (31.1)        |
| 3                                                                    | 37 (24.0)      | 69 (22.1)       | 106 (22.7)        |
| >3                                                                   | 1 (0.6)        | 0 (0.0)         | 1 (0.2)           |
| Received lenalidomide-including regimen - n (%)                      |                |                 |                   |
| Yes                                                                  | 74 (48.1)      | 123 (39.4)      | 197 (42.3)        |
| Refractory to any prior lenalidomide- including regimen              | 55 (35.7)      | 99 (31.7)       | 154 (33.0)        |
| Not refractory to any prior lenalidomide- including regimen          | 19 (12.3)      | 24 (7.7)        | 43 (9.2)          |
| No                                                                   | 80 (51.9)      | 189 (60.6)      | 269 (57.7)        |
| Received Pl-including regimen - n (%)                                |                |                 |                   |
| Yes                                                                  | 139 (90.3)     | 290 (92.9)      | 429 (92.1)        |
| Refractory to any prior Pl-including regimen                         | 55 (35.7)      | 102 (32.7)      | 157 (33.7)        |
| Not refractory to any prior Pl-including regimen                     | 84 (54.5)      | 188 (60.3)      | 272 (58.4)        |
| No                                                                   | 15 (9.7)       | 22 (7.1)        | 37 (7.9)          |
| Prior CD38 antibody therapy - n (%)                                  |                |                 |                   |
| Yes                                                                  | 0 (0.0)        | 1 (0.3)         | 1 (0.2)           |
| No                                                                   | 154 (100.0)    | 311 (99.7)      | 465 (99.8)        |
| Prior transplant - n (%)                                             |                |                 |                   |
| Yes                                                                  | 75 (48.7)      | 195 (62.5)      | 270 (57.9)        |
| No                                                                   | 79 (51.3)      | 117 (37.5)      | 196 (42.1)        |

Page 2 of 2

Kd = carfilzomib and dexamethasone; KdD = carfilzomib, dexamethasone, and daratumumab; ISS = International Staging System; IXRS = interactive voice/web response system; SPEP = chain; Pl = proteasome inhibitor.

a The high-risk group consists of the genetic subtypes t(4; 14), t(14; 16), or deletion17p. The standard-risk group consists of subjects without t(4; 14), t(14; 16), and deletion 17p. The unknown risk group is subjects with FlSH result not done, failed or quantity was not sufficient.

Source: Table 14-1.4.1; Table 14-2.2.1; Table 14-2.3.1

<div style=\"page-break-after: always\"></div>

## Additional Baseline Characteristics (Intent-to-Treat Population)

|                                                              | Kd (N = 154)   | KdD (N = 312)   | Total (N = 466)   |
|--------------------------------------------------------------|----------------|-----------------|-------------------|
| Received IMiD-including regimen - n (%)                      |                |                 |                   |
| Yes                                                          | 110 (71.4)     | 206 (66.0)      | 316 (67.8)        |
| Refractory to any prior IMiD-including regimenle]            | 65 (42.2)      | 130 (41.7)      | 195 (41.8)        |
| Not refractory to any prior IMiD-including regimen           | 45 (29.2)      | 76 (24.4)       | 121 (26.0)        |
| No                                                           | 44 (28.6)      | 106 (34.0)      | 150 (32.2)        |
| Best overall response to last prior systemic therapy - n (%) |                |                 |                   |
| Stringent complete response (sCR)                            | 5 (3.2)        | 17 (5.4)        | 22 (4.7)          |
| Complete response (CR)                                       | 20 (13.0)      | 57 (18.3)       | 77 (16.5)         |
| Very good partial response (VGPR)                            | 38 (24.7)      | 86 (27.6)       | 124 (26.6)        |
| Partial response (PR)                                        | 64 (41.6)      | 108 (34.6)      | 172 (36.9)        |
| Minimal response (MR)                                        | 5 (3.2)        | 13 (4.2)        | 18 (3.9)          |
| Stable disease (SD)                                          | 10 (6.5)       | 19 (6.1)        | 29 (6.2)          |
| Progressive disease (PD)                                     | 5 (3.2)        | 7 (2.2)         | 12 (2.6)          |
| Unknown                                                      | 7 (4.5)        | 5 (1.6)         | 12 (2.6)          |
| Refractory to the last prior line of therapylel - n (%)      |                |                 |                   |
| Yes                                                          | 95 (61.7)      | 165 (52.9)      | 260 (55.8)        |
| No                                                           | 59 (38.3)      | 147 (47.1)      | 206 (44.2)        |
| Prior transplant - n (%)                                     |                |                 |                   |
| Yes                                                          | 75 (48.7)      | 195 (62.5)      | 270 (57.9)        |
| Autologous                                                   | 75 (48.7)      | 194 (62.2)      | 269 (57.7)        |
| Allogeneic                                                   | 0 (0.0)        | 4 (1.3)         | 4 (0.9)           |
| No                                                           | 79 (51.3)      | 117 (37.5)      | 196 (42.1)        |

Medical history was most frequently reported (&gt; 25% of subjects) in the system organ classes (KdD, Kd) of vascular disorders (49.7%, 59.7%), musculoskeletal and connective tissue disorders (36.2%, 31.2%), nervous system disorders (29.2%, 26.6%), gastrointestinal disorders (28.8%, 29.2%), metabolism and nutrition disorders (29.5%, 26.6%), and surgical and medical procedures (27.2%, 25.3%).

Eighty-two subjects (26.2%) in the KdD group and 53 subjects (34.4%) in the Kd group had an abnormal, baseline electrocardiogram interpretation. The median (range) left ventricular ejection fraction was 62.0% (41, 84) for the KdD group and 62.0% (40, 82) for the Kd group. Median (range) CrCl was 82.80 (17.4, 291.0) mL/min for the KdD group and 80.40 (24.6, 217.8) mL/min for the Kd group at baseline. Most subjects in the KdD group (56.4%) and Kd group (50.0%) had a CrCl level ≥ 80 mL/min. A history of hypertension was noted at baseline for 135 subjects (43.3%) in the KdD group and 84 subjects (54.5%) in the Kd group.

Overall, 74 subjects (23.7%) in the KdD group and 70 subjects (45.5%) in the Kd group had at least 1 antimyeloma therapy after discontinuation of study treatment. The most frequent antimyeloma medications (&gt; 10% of subjects in either group) were (Kd, KdD): dexamethasone (25.3%, 14.1%,), lenalidomide (16.2%, 10.9%), and daratumumab (15.6%, 1.3%).

## Summary of New Antimyeloma Therapy Administered to ≥ 1% of Subjects in Either Group (ITT Population)

<div style=\"page-break-after: always\"></div>

| Category Preferred Term                              | Kd (N = 154) n (%)   | KdD (N = 312) n (%)   |
|------------------------------------------------------|----------------------|-----------------------|
| Number of subjects with any anti-myeloma therapy use | 70 (45.5)            | 74 (23.7)             |
| Dexamethasone                                        | 39 (25.3)            | 44 (14.1)             |
| Lenalidomide                                         | 25 (16.2)            | 34 (10.9)             |
| Pomalidomide                                         | 15 (9.7)             | 14 (4.5)              |
| Daratumumab                                          | 24 (15.6)            | 4 (1.3)               |
| Cyclophosphamide                                     | 8 (5.2)              | 19 (6.1)              |
| Bortezomib                                           | 8 (5.2)              | 5 (1.6)               |
| Etoposide                                            | 4 (2.6)              | 7 (2.2)               |
| Doxorubicin                                          | 6 (3.9)              | 5 (1.6)               |
| Cisplatin                                            | 4 (2.6)              | 6 (1.9)               |
| Ixazomib                                             | 2 (1.3)              | 6 (1.9)               |
| Dexamethasone W/Lenalidomide                         | 1 (0.6)              | 6 (1.9)               |
| Elotuzumab                                           | 2 (1.3)              | 5 (1.6)               |
| Dexamethasone W/Pomalidomide                         | 2 (1.3)              | 4 (1.3)               |
| Thalidomide                                          | 2 (1.3)              | 4 (1.3)               |
| Carfilzomib                                          | 3 (1.9)              | 3 (1.0)               |
| Melphalan                                            | 4 (2.6)              | 2 (0.6)               |
| Antineoplastic Agents                                | 3 (1.9)              | 2 (0.6)               |
| Bendamustine                                         | 3 (1.9)              | 2 (0.6)               |
| Monoclonal Antibodies                                | 3 (1.9)              | 1 (0.3)               |
| Isatuximab                                           | 2 (1.3)              | 0 (0.0)               |

Kd = carfilzomib and dexamethasone; KdD = carfilzomib, dexamethasone, and daratumumab Drugs were coded using WHO Drug Dictionary (version September 2017)

Source:Table14-8.4.2

## Numbers analysed

A total of 466 subjects were randomized 2:1 (312 subjects in the KdD group and 154 subjects in the Kd group) from 102 centers in 19 countries.  A total of 461 subjects received at least 1 dose of carfilzomib (308 subjects in the KdD and 153 subjects in the Kd group).

<div style=\"page-break-after: always\"></div>

Table 5: Summary of Analysis Populations

|                                                  | Kd (N = 154) n (%)   | KdD (N = 312) n (%)   | Total (N = 466) N (%)   |
|--------------------------------------------------|----------------------|-----------------------|-------------------------|
| Intent-to-Treat Population                       | 154 (100.0)          | 312 (100.0)           | 466 (100.0)             |
| Safety Population                                | 153 (99.4)           | 308 (98.7)            | 461 (98.9)              |
| Per-Protocol Population for PFS and ORR analysis | 139 (90.3)           | 280 (89.7)            | 419 (89.9)              |
| Per-Protocol Population for OS analysis          | 147 (95.5)           | 297 (95.2)            | 444 (95.3)              |
| MRD Evaluable Population                         | 133 (86.4)           | 258 (82.7)            | 391 (83.9)              |

PFS = progression-free survival

Reasons for exclusion from an analysis population are not mutually exclusive.

Source:Table 14-1.5.1

## Outcomes and estimation

## Primary Efficacy Endpoint

A statistically significant difference was observed for PFS (as assessed by the IRC) between the KdD and Kd groups (HR = 0.630; 95% CI: 0.464, 0.854; p = 0.0014) (Table 10-1). A Kaplan-Meier plot comparing PFS between treatment groups is provided in Figure 10-1.

## Table 10-1. Progression-free Survival as Assessed by the Independent Review Committee (Intent-to-Treat Population)

<div style=\"page-break-after: always\"></div>

|                                                  | Kd (N = 154)      | KdD (N = 312)                      | Treatment Difference   |
|--------------------------------------------------|-------------------|------------------------------------|------------------------|
| Subject status - n (%)                           |                   |                                    |                        |
| PFS Events                                       | 68 (44.2)         | 110 (35.3)                         |                        |
| Progressive disease                              | 62 (40.3)         | 82 (26.3)                          |                        |
| Death                                            | 6 (3.9)           | 28 (9.0)                           |                        |
| Censored                                         | 86 (55.8)         | 202 (64.7)                         |                        |
| Stratified Log-rank p-value (1-sided)a           |                   |                                    | 0.0014                 |
| StratifiedCoxmodelhazardratio (KdD/Kd) (95% CI)a |                   |                                    | 0.630 (0.464, 0.854)   |
| PFS (months)b                                    |                   |                                    |                        |
| 25th percentile (95% CI)                         | 7.4 (4.0, 9.3)    | 8.9 (6.5, 11.9)                    |                        |
| Median (95% CI)                                  | 15.8 (12.1, NE)   | NE (NE, NE)                        |                        |
| 75th percentile (95% Cl)                         | NE (NE, NE)       | NE (NE, NE)                        |                        |
| Min, Max (+ for censored)                        | 0+,22+            | 0+,23+                             |                        |
| PFS event-free rate (95% Cl) - %b                |                   |                                    |                        |
| 3 months                                         |                   | 87.5 (80.9, 92.0)91.2 (87.4, 93.9) |                        |
| 6 months                                         | 77.2 (69.4, 83.3) | 80.3 (75.3, 84.3)                  |                        |
| 12 months                                        | 60.3 (51.4, 68.2) | 69.6 (64.0, 74.5)                  |                        |
| 18 months                                        | 42.8 (32.4, 52.8) | 61.5 (55.4, 67.1)                  |                        |
| 24 months                                        | NE (NE, NE)       | NE (NE, NE)                        |                        |
| Follow-up time (months)c                         |                   |                                    |                        |
| 25th percentile (95% Cl)                         | 12.1 (7.7, 14.8)  | 15.9 (15.1, 16.2)                  |                        |
| Median (95% CI)                                  | 16.3 (15.9, 16.7) | 16.9 (16.7, 17.5)                  |                        |
| 75th percentile (95% Cl)                         | 17.6 (16.9, 18.6) | 18.6 (17.8, 18.9)                  |                        |
| Min, Max (+ for censored)                        | 0,22              | 0,23                               |                        |

Source: Table 14-4.2.1

Figure 10-1. Kaplan-Meier Plot -Progressive-free Survival as Assessed by the Independent Review Committee (Intent-to-Treat Population)

<div style=\"page-break-after: always\"></div>

<!-- image -->

Kd =carfilzomib and dexamethasone;KdD=carfilzomib,dexamethasone,and daratumumab; PFS = progression free survival.

The survival curves in this plot and the median PFS in this table are derived by Kaplan-Meier method, while other statistics reported in the table are from Cox proportional hazards model and logrank test stratified by randomization stratificationfactors.Stratificationfactors (as assessed at randomization):International Staging System stage at screening (stage 1 or 2 vs stage 3); prior proteasome inhibitor exposure (yes vs no); number of prior lines of therapy (1 vs ≥ 2).

Source:Figure 14-4.1.1

## Secondary Efficacy Endpoints

## Overall Response Rate

The ORR as assessed by IRC was 84.3% (95% CI: 79.8, 88.1) in the KdD group and 74.7% (95% CI: 67.0, 81.3) in the Kd group (odds ratio: 1.925 [95% CI: 1.184, 3.129]; p = 0.0040) (Table 10-3). The prespecified 1-sided significance level of 0.025 was met for ORR.

Table 10-3. Analysis of Best Overall Response as Assessed by the Independent Review Committee (Intent-to-Treat Population)

<div style=\"page-break-after: always\"></div>

|                                                  | Kd (N = 154) n (%)   | KdD (N = 312) n (%)   | Treatment Difference   |
|--------------------------------------------------|----------------------|-----------------------|------------------------|
| Best overall responsea - n (%)                   |                      |                       |                        |
| Complete responseb                               | 16 (10.4)            | 89 (28.5)             |                        |
| MRD[-]CRc,d                                      | 5 (3.2)              | 43 (13.8)             |                        |
| Very good partial response                       | 59 (38.3)            | 127 (40.7)            |                        |
| Partial response                                 | 40 (26.0)            | 47 (15.1)             |                        |
| Stable disease                                   | 18 (11.7)            | 19 (6.1)              |                        |
| Progressive disease                              | 4 (2.6)              | 4 (1.3)               |                        |
| Not evaluable                                    | 17 (11.0)            | 26 (8.3)              |                        |
| Overall response ratea                           |                      |                       |                        |
| Number of subjects who achieved overall response | 115                  | 263                   |                        |
| ORR (95% CI)d                                    | 74.7 (67.0, 81.3)    | 84.3 (79.8, 88.1)     |                        |
| Odds ratio (KdD/Kd) (95% CI)e                    |                      |                       | 1.925 (1.184, 3.129)   |
| 1-sided p-valuef                                 |                      |                       | 0.0040                 |

CR = complete response; IMWG-URC = International Myeloma Working Group Uniform Response Criteria; Kd = carfilzomib and dexamethasone; KdD = carfilzomib, dexamethasone, and daratumumab; MRD[-] = mean residual disease negative; MRD[-]CR = mean residual disease negative - complete response; NGS = next generation sequencing; ORR = overall response rate; PR = partial response; sCR = stringent complete response; VGPR = very good partial response.

Stratification factors (as assessed at randomization): International Staging System stage (Stage 1 or 2 vs Stage 3) at screening; prior proteasome inhibitor exposure (yes vs no); number of prior lines of therapy (1 vs ≥ 2).

- b sCR could not be differentiated due to lack of kappa/lambda ration by IHC
- a Overall response rate is defined as the proportion of subjects in each treatment group who achieve PR or better per the IMWG-URC as their best response.
- c MRD[-]CR (at a 10-5 level) is defined as achievement of CR per IMWG-URC and MRD[-] status as assessed by NGS at any time during the study.
- e Odds ratios and corresponding 95% Cls were estimated using the stratified Mantel-Haenszel method.
- d 95% Cls for proportions were estimated using the Clopper-Pearson method.
- f P-values were calculated using the stratified Cochran-Mantel-Haenszel Chi-Square test. Source:Table14-4.3.1

## Minimal Residual Disease Negative Complete Response

The MRD[-]CR rate at 12 months (at a 10-5 level) based on IRC assessment was 12.5% (95% CI: 9.0, 16.7) in the KdD group and 1.3% (95% CI: 0.2, 4.6) in the Kd group (odds ratio: 11.329 [95% CI: 2.703, 47.476]; p &lt; 0.0001) . The prespecified 1-sided significance level of 0.025 was met for MRD[-]CR at 12 months (at a 10-5 level).

## Table 10-4. Analysis of Minimal Residual Disease Negative Complete Response Rate as Assessed by the Independent Review Committee (Intent-to-Treat Population)

<div style=\"page-break-after: always\"></div>

|                                               | Kd (N = 154)   | KdD (N = 312)    | Treatment Difference   |
|-----------------------------------------------|----------------|------------------|------------------------|
| MRD[-]CR rate at 12 months (at a 10-5 level)a |                |                  |                        |
| Number of subjects who achieved MRD[-]CR      | 2              | 39               |                        |
| MRD[-]CR rate (95% CI)b                       | 1.3 (0.2, 4.6) | 12.5 (9.0, 16.7) |                        |
| Odds ratio (KdD/Kd) (95% CI)c                 |                |                  | 11.329 (2.703, 47.476) |
| 1-sided p-valued                              |                |                  | <0.0001                |

Kd = carfilzomib and dexamethasone; KdD = carfilzomib, dexamethasone, and daratumumab; MRD[-] = mean residual disease negative; MRD[-]CR = mean residual disease negative complete response.

a MRD[-]CR at 12 months was defined as achievement of CR (sCR could not be differentiated due to lack of kappa/lambda ration by IHC) per International Myeloma Working Group-Uniform Response Criteria and MRD[-] status as assessed byNGS at the 12 months landmark(8to 13 month window).

b 95% Cls for proportions were estimated using the Clopper-Pearson method.

method.

d P-values were calculated using the stratified Cochran-Mantel-Haenszel Chi-Square test. Source: Table 14-4.5.1

## Overall Survival

As of the data cutoff (14 July 2019), 59 subjects (18.9%) in the KdD group and 36 subjects (23.4%) in the Kd group had died (see table below).

Overall survival data were not mature and median OS was not reached in either treatment group by the data cutoff date (see table below). The HR for OS was 0.745 (95% CI: 0.491, 1.131; p = 0.0836). The OS distribution is shown in the Kaplan-Meier plot in Figure 10-5. The OS event-free rate was 84.5% in the KdD group and 85.2% in the Kd group at 12 months and 79.9% in the KdD group and 74.4% in the Kd group at 18 months (see table below). Median follow-up time was 17.2 months in the KdD group and 17.1 months in the Kd group.

## Table 10-5. Analysis of Overall Survival (Intent-to-Treat Population)

<div style=\"page-break-after: always\"></div>

|                                                      | Kd (N = 154)      | KdD (N = 312)     | Treatment Difference   |
|------------------------------------------------------|-------------------|-------------------|------------------------|
| Subject status                                       |                   |                   |                        |
| Death - n (%)                                        | 36 (23.4)         | 59 (18.9)         |                        |
| Censored - n (%)                                     | 118 (76.6)        | 253 (81.1)        |                        |
| Stratified Log-rank p-value (1-sided)a               |                   |                   | 0.0836                 |
| Cox model hazard ratio (KdD/Kd) (95% Cl) Stratifieda |                   |                   | 0.745 (0.491, 1.131)   |
| OS (months)b                                         |                   |                   |                        |
| 25th percentile (95% Cl)                             | 17.1 (12.7, NE)   | NE (17.7, NE)     |                        |
| Median (95% CI)                                      | NE (NE, NE)       | NE (NE, NE)       |                        |
| 75th percentile (95% Cl)                             | NE (NE, NE)       | NE (NE, NE)       |                        |
| Min, Max (+ for censored)                            | 0,22+             | 0+,24+            |                        |
| OS event free rate (95% Cl) - %b                     |                   |                   |                        |
| 6 months                                             | 92.0 (86.4, 95.4) | 91.2 (87.4, 93.9) |                        |
| 12 months                                            | 85.2 (78.4, 90.0) | 84.5 (79.9, 88.1) |                        |
| 18 months                                            | 74.4 (65.9, 81.1) | 79.9 (74.6, 84.2) |                        |
| 24 months                                            | NE (NE, NE)       | NE (NE, NE)       |                        |
| Follow-up time (months)c                             |                   |                   |                        |
| 25th percentile (95% Cl)                             | 16.2 (15.0, 16.4) | 16.3 (16.0, 16.6) |                        |
| Median (95% CI)                                      | 17.1 (16.8, 17.3) | 17.2 (17.0, 17.6) |                        |
| 75th percentile (95% Cl)                             | 18.7 (17.8, 18.9) | 18.7 (18.3, 19.1) |                        |
| Min, Max (+ for censored)                            | 0+,22             | 0,24              |                        |

Kd = carfilzomib and dexamethasone; KdD = carfilzomib, dexamethasone, and daratumumab; NE = not estimable.

a Stratification factors (as assessed at randomization): International Staging System stage at screening (Stage 1 or 2 vs Stage 3); prior proteasome inhibitor exposure (yes vs no); number of prior lines of therapy (1 vs ≥ 2).

b Medians, percentiles and event-free rates were estimated using the Kaplan-Meier method. 95% Cls for medians and percentiles were estimated using the method by Klein and Moeschberger (1997) with log-log transformation. 95% Cls for event-free rates were estimated using the c Medians and percentiles of follow-up time were estimated using the reverse Kaplan-Meier method (Schemper and Smith, 1996). Corresponding 95% Cls were estimated using the

Source:Table 14-4.6.1

<div style=\"page-break-after: always\"></div>

Figure 10-5. Kaplan-Meier Plot - Overall Survival (Intent-to-Treat Population)

<!-- image -->

Kd = carfilzomib and dexamethasone; KdD = carfilzomib, dexamethasone, and daratumumab; NE = not estimable.

The survival curves in this plot and the median OS in this table are derived by unstratified KaplanMeier method, while other statistics reported in the table from Cox proportional hazards model d :    t  s  s    o proteasome inhibitor exposure (yes vs no); number of prior lines of therapy (1 vs ≥ 2) Source:Figure 14-4.4.1

## Additional Secondary Endpoints

## Duration of Response

As of the data cutoff, for subjects who achieved overall response the median (95% CI) duration of overall response as assessed by IRC was not estimable for the KdD group and was 16.6 (13.9, NE) months for the Kd group

## Time to Next Treatment

As of the data cutoff, the median (95% CI) time to next treatment was not estimable for the KdD group and was 17.3 months (13.5, NE) for the Kd group.

<div style=\"page-break-after: always\"></div>

Time to Next Treatment (IIT population)

|                                      | Kd (N=154)        | KdD (N=312)       |
|--------------------------------------|-------------------|-------------------|
| TTNT event-free rate (95% CI) - %[b] |                   |                   |
| 6 months                             | 82.1 (74.9, 87.5) | 92.6 (88.8, 95.1) |
| 12 months                            | 61.6 (53.0, 69.1) | 83.2 (78.2,87.2)  |
| 18 months                            | 47.7 (38.1, 56.7) | 72.4 (66.3, 77.5) |
| 24months                             | NE (NE, NE)       | NE (NE, NE)       |

## Time to Progression

The HR (95% CI) for time to progression as assessed by IRC was 0.506 (0.363, 0.707). The median (95% CI) time to progression was not estimable for the KdD group and was 17.5 (13.2, NE) months for the Kd group.

## Time to Progression as Assessed by the Independent Review Committee (ITT Population)

|                                     | Kd (N =154)      | KdD (N =312)      | Treatment Difference   |
|-------------------------------------|------------------|-------------------|------------------------|
| TTP event-free rate (95% Cl) - %lc) |                  |                   |                        |
| 3months                             | 90.0 (83.7,93.9) | 95.3 (92.1,97.2)  |                        |
| 6months                             | 79.4(71.6,85.3)  | 86.4(81.8,89.9)   |                        |
| 12months                            | 62.7 (53.6,70.5) | 77.5 (72.1, 82.0) |                        |
| 18months                            | 45.1(34.2,55.4)  | 68.5 (62.2,74.0)  |                        |
| 24 months                           | NE (NE, NE)      | NE (NE, NE)       |                        |

## Time to Response

The median (min, max) time to overall response was 1.0 (1, 14) months for the KdD group and 1.0 (1, 10) for the Kd group.

## Persistence of MRD[-]CR

The sustained MRD[-]CR rate data were not mature as of the data cutoff. The sustained MRD[-]CR rate (95% CI) as assessed by IRC was 0.0 (0.0, 2.4) for the KdD group and 0.0 (0.0, 1.2) for the Kd group.

## Complete Response Rate

The complete response rate (95% CI) as assessed by IRC was 28.5% (23.6, 33.9) for the KdD group and 10.4% (6.1, 16.3) for the Kd group (odds ratio: 3.507 [95% CI:1.971, 6.238). For subjects who achieved CR, median (min, max) time to CR was 8.4 (2, 16) months for the KdD group and 7.0 (3, 14) months for the Kd group.

## MRD[-] Rate

The MRD[-] rate at 12 months (at a 10-5 level) was 17.6% (95% CI: 13.6, 22.3) in the KdD group and 3.9% (95% CI: 1.4, 8.3) in the Kd group (odds ratio: 5.762 [95% CI: 2.375, 13.979]).

## Quality of Life

Completion rates for all expected subjects (ie, randomized subjects who were still on study treatment at that visit) were &gt; 81% for both treatment groups from baseline through cycle 26, with median 5.26% and 12.13% for extent of missingness across all visits for QLQ-C30 GHS/QoL data for the KdD and Kd groups, respectively. The primary analysis using a restricted maximum likelihood-based mixed effects model for repeated measures analysis under the assumption of missing at random, showed no

<div style=\"page-break-after: always\"></div>

statistically significant KdD treatment improvement in overall or by visit. The overall treatment difference (KdD - Kd) (SE; 95% CI) over time in change from baseline QLQ-C30 GHS/QOL values was 0.06 (1.24; 2.39, 2.50). The sensitivity analysis based on a pattern mixture model using a grouping variable to account for the missingness pattern provided similar results to the primary analysis. The overall treatment difference (KdD - Kd) (SE; 95% CI) in change from baseline QLQ-C30 GHS/QOL values for early dropout, middle dropout, and late dropout were -2.78 (2.27; -7.24, 1.69), 0.23 (1.97; -3.65, 4.10), and 1.12 (2.28; -3.36, 5.61), respectively. Results were generally consistent across subgroups. Cumulative distribution frequency graphs of changes from baseline by study group at each visit were plotted showing a positive benefit in the KdD arm compared to the Kd arm at selected visits. Similar findings were observed in the responder analysis and ANCOVA analysis.

## Ancillary analyses

## Subgroup Analyses

Figure 10-2. Subgroup Analyses of Progression-free Survival as Assessed by the Independent Review Committee (Intent-to-Treat Population)

<div style=\"page-break-after: always\"></div>

Kd

(N=154)

KdD

(N=312)

<!-- image -->

| Subgroup                               | No.of subjects    | No.of subjects    |                   | Hazard Ratio(KdD/Kd)(95%Cl)   |
|----------------------------------------|-------------------|-------------------|-------------------|-------------------------------|
| All randomized subjects                | 154               | 312               |                   | 0.630 (0.464, 0.854)          |
| 1or2                                   | 127               | 252               |                   | 0.610 (0.431,0.862)           |
| 3                                      | 27                | 60                | T                 | 0.710(0.371,1.359)            |
| Prior proteasone inhibitor exposure    |                   |                   |                   |                               |
| Yes                                    | 139               | 279               |                   | 0.644 (0.470,0.881)           |
| No                                     | 15                | 33                |                   | 0.928 (0.286,3.015)           |
| Number of priorlines of therapy        |                   |                   |                   |                               |
| 1                                      | 67                | 133               |                   | 0.701(0.418,1.174)            |
| >=2                                    | 87                | 179               |                   | 0.633(0.435,0.920)            |
| Age-at baseline (years)                |                   |                   |                   |                               |
| <=75                                   | 136               | 287               | e                 | 0.606 (0.442,0.832)           |
| >75                                    | 18                | 25                |                   | 1.459 (0.504,4.223)           |
| Sex                                    |                   |                   |                   |                               |
| Male                                   | 91                | 177               | Fe                | 0.636 (0.423,0.956)           |
| Female                                 | 63                | 135               |                   | 0.686 (0.436,1.079)           |
| Race                                   |                   |                   |                   |                               |
| White                                  | 123               | 243               |                   | 0.685(0.494,0.952)            |
| Asian                                  | 20                | 46                |                   | 0.686(0.253,1.857)            |
| Other or Unknown                       | 11                | 23                |                   | 0.482 (0.129,1.802)           |
| Region                                 |                   |                   |                   |                               |
| North America                          | 12                | 21                |                   | 0.041 (0.005,0.339)           |
| Europe                                 | 103               | 207               |                   | 0.857(0.596,1.231)            |
| Asia Pacific                           | 39                | 84                |                   | 0.486(0.253,0.934)            |
| Baseline ECOG PS                       |                   |                   |                   |                               |
| 0-1                                    | 147               | 295               |                   | 0.689(0.505,0.941)            |
| 2                                      | 7                 | 15                |                   | 0.311(0.081,1.190)            |
| Baseline creatinine dlearance (mL/min） |                   |                   |                   |                               |
| >=15-<50                               | 27                | 38                |                   | 0.461(0.209,1.016)            |
| >=50-<80                               | 50                | 97                |                   | 0.778(0.454,1.332)            |
| >=80                                   | 77                | 176               |                   | 0.670 (0.442,1.017)           |
| Prior Lenalidomide exposure            |                   |                   |                   |                               |
| sa人                                    | 74                | 123               | Te                | 0.521(0.339,0.802)            |
| No                                     | 80                | 189               | He                | 0.868(0.558,1.351)            |
| Refractoryto Lenalidomide              |                   |                   |                   |                               |
| Yes                                    | 55                | 99                | Te                | 0.453 (0.279, 0.737)          |
| No                                     | 99                | 213               | HeH               | 0.852 (0.573,1.267)           |
| 0.01 0.1 1 10 100                      | 0.01 0.1 1 10 100 | 0.01 0.1 1 10 100 | 0.01 0.1 1 10 100 | 0.01 0.1 1 10 100             |

<div style=\"page-break-after: always\"></div>

|                                              | Kd (N=154)     | KdD (N=312)       |    |                            |
|----------------------------------------------|----------------|-------------------|----|----------------------------|
| Subgroup                                     | No.of subjects | No.of subjects    |    | HazardRatio(KdD/Kd)(95%Cl) |
| Prior Bortezomib or lxazomib exposure        |                |                   |    |                            |
| Yes                                          | 137            | 289               |    | 0.643(0.470,0.879)         |
| No                                           | 17             | 23                |    | 0.622(0.180,2.156)         |
| RefractorytoBortezomiborlazomib              |                |                   |    |                            |
| Yes                                          | 55             | 100               |    | 0.871(0.540,1.405)         |
| No                                           | 99             | 212               |    | 0.561(0.379,0.831)         |
| PriorIMiDeposure                             |                |                   |    |                            |
| se人                                          | 110            | 206               |    | 0.622(0.439,0.883)         |
| No                                           | 44             | 106               |    | 0.849(0.455,1.584)         |
| Refractoryto IMiD                            |                |                   |    |                            |
| Yes                                          | 65             | 130               |    | 0.448(0.290,0.694)         |
| No                                           | 89             | 182               |    | 0.941(0.611,1.449)         |
| Reised ISS stage at baseline                 |                |                   |    |                            |
| Stage1or2                                    | 62             | 115               |    | 0.530(0.322,0.873)         |
| Stage3                                       | 14             | 25                |    | 1.348(0.538,3.381)         |
| Multiplemyeloma subtype                      |                |                   |    |                            |
| lgG                                          | 88             | 178               |    | 0.608(0.405,0.913)         |
| Non-lgG                                      | 66             | 134               |    | 0.749 (0.475, 1.182)       |
| Determinationofmeasureabledisease atbaseline |                |                   |    |                            |
| SPEPonly                                     | 84             | 171               |    | 0.579(0.378,0.886)         |
| UPEPonly.SPEPandUPEP                         | 44             | 90                |    | 0.871(0.501,1.516)         |
| SFLC only                                    | 25             | 43                |    | 0.640(0.311,1.319)         |
| Beta2-microglobulinlevel（mg/L)               |                |                   |    |                            |
| <3.5                                         | 83             | 158               |    | 0.586 (0.368,0.934)        |
| >=3.5-<5.5                                   | 44             | 92                | He | 0.546(0.322,0.925)         |
| >=5.5                                        | 27             | 61                |    | 0.760 (0.399,1.444)        |
| Risk group determined byFISH                 |                |                   |    |                            |
|                                              | 26             | 48                |    | 0.579(0.300,1.118)         |
| Standardrisk                                 | 52             | 104               |    | 0.551(0.312,0.973)         |
| Unknown                                      | 76             | 160               | Fe | 0.724 (0.472, 1.113)       |
| Presenceofsoft tissueplasmacytoma atbaseline |                |                   |    |                            |
| Yes                                          | 9              | 14                |    | 1.560(0.531,4.580)         |
| No                                           | 145            | 298               |    | 0.631 (0.460,0.866)        |
|                                              |                | 0.01 0.1 1 10 100 |    |                            |

&lt;-KdDbetter Kdbetter-&gt;

IMiD = immunomodulatory drug; ISS = International Staging System; IXRS = interactive voice/web response system; Kd = carfilzomib and dexamethasone; KdD = carfilzomib, dexamethasone, and daratumumab; SPEP = serum protein electrophoresis; UPEP = urine protein electrophoresis

Source: Figure 14-4.1.6

Figure 10-3. Subgroup Analyses of Overall Response Rate as Assessed by the Independent Review Committee (Intent-to-treat Population)

<div style=\"page-break-after: always\"></div>

<!-- image -->

| dnoibqns                               | Kd (N=154)        | KdD (N=312)       |                   | OddsRatio(KdD/Kd)(95%CI)   |
|----------------------------------------|-------------------|-------------------|-------------------|----------------------------|
|                                        | No.of subjects    | No.of subjects    |                   |                            |
| All randomized subjects                | 154               | 312               |                   | 1.925 (1.184.3.129)        |
| ISS stage perIXRS at screeing          |                   |                   |                   |                            |
| 1or2                                   | 127               | 252               |                   | 1.708 (0.971.3.007)        |
| 3                                      | 27                | 60                |                   | 2.554(0.990.6.585)         |
| Priorproteasome inhibitor exposure     |                   |                   |                   |                            |
|                                        | 139               | 279               | Te                | 1.837(1.124.3.003)         |
| No                                     | 15                | 33                |                   | 1.538(0.229.10.326)        |
| Numberof prior lines of therapy        |                   |                   |                   |                            |
| 1                                      | 67                | 133               | T⊥                | 2.896 (1.299.6.457)        |
| >=2                                    | 87                | 179               |                   | 1.428(0.783.2.602)         |
| Age-at baseline (years)                |                   |                   |                   |                            |
| <=75                                   | 136               | 287               | e                 | 1.864(1.131.3.070)         |
| >75                                    | 18                | 25                |                   | 1.500 (0.321.7.012)        |
| Sex                                    |                   |                   |                   |                            |
| Male                                   | 91                | 177               | T                 | 1.742(0.918.3.308)         |
| Female                                 | 63                | 135               |                   | 1.948 (0.960.3.951)        |
| Race                                   |                   |                   |                   |                            |
| White                                  | 123               | 243               | He                | 1.483(0.881.2.494)         |
| Asian                                  | 20                | 46                |                   | 4.778(1.017.22.450)        |
| Other or Unknown                       | 11                | 23                |                   | 8.250(0.746.91.259)        |
| Region                                 |                   |                   |                   |                            |
| North America                          | 12                | 21                |                   | 6.786(1.062.43.360)        |
| e                                      | 103               | 207               | He                | 1.396(0.782.2.490)         |
| Asia Pacific                           | 39                | 84                |                   | 2.552(0.961.6.772)         |
| Baseline ECOG PS                       |                   |                   |                   |                            |
| 0-1                                    | 147               | 295               |                   | 1.845(1.107.3.076)         |
| 2                                      | 7                 | 15                |                   | 5.250(0.502.54.911)        |
| Baseline creatinine clearance (mL/min) |                   |                   |                   |                            |
| >=15-<50                               | 27                | 38                |                   | 6.667 (2.098.21.183)       |
| >=50-<80                               | 50                | 97                |                   | 1.771(0.706.4.441)         |
| >=80                                   | 77                | 176               |                   | 1.039 (0.518.2.087)        |
| Prior Lenalidomide exposure            |                   |                   |                   |                            |
|                                        | 74                | 123               |                   | 1.289(0.654.2.538)         |
| No                                     | 80                | 189               |                   | 2.406(1.233.4.692)         |
| Refr actoryto Lenalidomide             |                   |                   |                   |                            |
|                                        | 55                | 66                |                   | 1.481(0.686.3.199)         |
| No                                     | 66                | 213               |                   | 2.030(1.110.3.714)         |
| 0.01 0.1 1 10 100                      | 0.01 0.1 1 10 100 | 0.01 0.1 1 10 100 | 0.01 0.1 1 10 100 | 0.01 0.1 1 10 100          |

<div style=\"page-break-after: always\"></div>

Kd

(N=154)

KdD

(N=312)

| dnoibqns                                         | No.of subjects    | No.of subjects    | OddsRatio(KdD/Kd)(95%Cl)   | OddsRatio(KdD/Kd)(95%Cl)   |
|--------------------------------------------------|-------------------|-------------------|----------------------------|----------------------------|
| PriorBortezomibor lxazomibesposure               |                   |                   |                            |                            |
|                                                  | 137               | 289               |                            | 1.790(1.096.2.923)         |
| No                                               | 17                | 23                |                            | 4.714 (0.445.49.943)       |
| Refr actoryto Bortezomib or lazomib              |                   |                   |                            |                            |
|                                                  | 55                | 100               |                            | 1.683 (0.797.3.554)        |
| No                                               | 99                | 212               |                            | 1.878(1.012.3.485)         |
| Prior IMiDeposure                                |                   |                   |                            |                            |
| Yes                                              | 110               | 206               |                            | 1.877 (1.067.3.300)        |
| No                                               | 44                | 106               |                            | 1.654 (0.684.4.001)        |
| Refractoryto IMiD                                |                   |                   |                            |                            |
| Yes                                              | 65                | 130               |                            | 1.691(0.839.3.410)         |
| No                                               | 89                | 182               | H                          | 1.939 (1.016.3.701)        |
| Revised ISS stage at baseline                    |                   |                   |                            |                            |
| Stage1or2                                        | 62                | 115               |                            | 1.572(0.721.3.427)         |
| Stage3                                           | 14                | 25                |                            | 2.370(0.623.9.025)         |
| Multiplemyeloma subtype                          |                   |                   |                            |                            |
| IgG                                              | 88                | 178               |                            | 1.451 (0.769.2.737)        |
| Non-lgG                                          | 66                | 134               |                            | 2.447(1.190.5.031)         |
| Determination of measureable disease at baseline |                   |                   |                            |                            |
| SPEPonly                                         | 84                | 171               |                            | 1.465(0.685.3.131)         |
| UPEPonly.SPEPandUPEP                             | 44                | 90                |                            | 2.204(1.006.4.828)         |
| SFLConly                                         | 25                | 43                |                            | 4.588(1.215.17.323)        |
| Beta2-microg lobulin level(mg/L)                 |                   |                   |                            |                            |
| <3.5                                             | 83                | 158               |                            | 1.801(0.831.3.900)         |
| >=3.5-<5.5                                       | 44                | 92                |                            | 1.781(0.758.4.188)         |
| >=5.5                                            | 27                | 61                |                            | 2.403(0.939.6.151)         |
| Riskgroup determined byFISH                      |                   |                   |                            |                            |
| High risk                                        | 26                | 48                |                            | 5.133(1.615.16.314)        |
| Standard risk                                    | 52                | 104               |                            | 1.071(0.441.2.600)         |
| Unknown                                          | 76                | 160               |                            | 1.718(0.881.3.350)         |
| Presence of soft tissue plasmacytoma at baseline |                   |                   |                            |                            |
| Yes                                              | 9                 | 14                |                            | 1.400 (0.199.9.869)        |
| No                                               | 145               | 298               |                            | 1.881(1.121,3.154)         |
| 0.01 0.1 1 10 100                                | 0.01 0.1 1 10 100 | 0.01 0.1 1 10 100 | 0.01 0.1 1 10 100          | 0.01 0.1 1 10 100          |

IMiD = immunomodulator drug; ISS = International Staging System; IXRS = interactive voice/web response system; Kd = carfilzomib and dexamethasone; KdD = carfilzomib, dexamethasone, and daratumumab;

SPEP = serum protein electrophoresis; UPEP = urine protein electrophoresis

Source: Figure 14-4.2.1

<div style=\"page-break-after: always\"></div>

Figure 10-4. Subgroup Analyses of Minimal Residual Disease Negative Complete Response Rate as Assessed by the Independent Review Committee (Intent-to-Treat Population)

<!-- image -->

<div style=\"page-break-after: always\"></div>

<!-- image -->

|                                                  | Kd (N=154)        | KdD (N=312)       |                           |                           |                           |                           |
|--------------------------------------------------|-------------------|-------------------|---------------------------|---------------------------|---------------------------|---------------------------|
| Subgroup                                         | No.of subjects    | No.of subjects    | OddsRatio (KdD/Kd)(95%Cl) | OddsRatio (KdD/Kd)(95%Cl) | OddsRatio (KdD/Kd)(95%Cl) | OddsRatio (KdD/Kd)(95%Cl) |
| Prior Bortezomiborlxazomib exposure              |                   |                   |                           |                           |                           |                           |
| Yes                                              | 137               | 289               |                           | 9.000(2.130.38.034)       |                           |                           |
| No                                               | 17                | 23                |                           | NE (NE NE)                |                           |                           |
| Refractoryto Bontezomib orlbazomib               |                   |                   |                           |                           |                           |                           |
| Yes                                              | 55                | 100               |                           | 4.065(0.487.33.928)       |                           |                           |
| No                                               | 99                | 212               |                           | 17.422(2.345.129.444)     |                           |                           |
| Prior IMiD eposure                               |                   |                   |                           |                           |                           |                           |
| Yes                                              | 110               | 206               |                           | NE(NENE)                  |                           |                           |
| No                                               | 44                | 106               |                           | 3.462 (0.757.15.827)      |                           |                           |
| Refractoryto IMiD                                |                   |                   |                           |                           |                           |                           |
| Yes                                              | 65                | 130               |                           | NE (NE NE)                |                           |                           |
| No                                               | 89                | 182               |                           | 6.292(1.449.27.322)       |                           |                           |
| Reised ISS stage at baseline                     |                   |                   |                           |                           |                           |                           |
| Stage1or2                                        | 62                | 115               |                           | 9.859 (1.275.76.223)      |                           |                           |
| Stage3                                           | 14                | 25                |                           | NE(NENE)                  |                           |                           |
| Multiplemyeloma subype                           |                   |                   |                           |                           |                           |                           |
| IgG                                              | 88                | 178               |                           | 7.026(1.625.30.385)       |                           |                           |
| Non-lgG                                          | 66                | 134               |                           | NE (NE NE)                |                           |                           |
| Detemmination of measureable disease at baseline |                   |                   |                           |                           |                           |                           |
| SPEPonly                                         | 84                | 171               |                           | 7.352(1.701.31.767)       |                           |                           |
| UPEPonly.SPEPandUPEP                             | 44                | 90                |                           | NE(NENE)                  |                           |                           |
| SFLConly                                         | 25                | 43                |                           | NE (NE NE)                |                           |                           |
| Beta2-microg lobulin level(mg/L)                 |                   |                   |                           |                           |                           |                           |
| <3.5                                             | 83                | 158               |                           | 8.347(1.933.36.044)       |                           |                           |
| >=3.5-<5.5                                       | 44                | 92                |                           | NE(NENE)                  |                           |                           |
| >=5.5                                            | 27                | 61                |                           | NE(NENE)                  |                           |                           |
| Riskgroupdetermined byFISH                       |                   |                   |                           |                           |                           |                           |
| High risk                                        | 26                | 48                |                           | NE(NENE)                  |                           |                           |
| Standardrisk                                     | 52                | 104               |                           | 4.545(1.004.20.584)       |                           |                           |
| Uniknown                                         | 76                | 160               |                           | NE(NE NE)                 |                           |                           |
| Presence of softissue plasmacytoma at baseline   |                   |                   |                           |                           |                           |                           |
|                                                  | 9                 | 14                |                           | NE(NENE)                  |                           |                           |
| No                                               | 145               | 298               | 10.450(2.485.43.951)      |                           |                           |                           |
| 0.01 0.1 1 10 100                                | 0.01 0.1 1 10 100 | 0.01 0.1 1 10 100 | 0.01 0.1 1 10 100         | 0.01 0.1 1 10 100         | 0.01 0.1 1 10 100         | 0.01 0.1 1 10 100         |

ECOG = Eastern Cooperative Oncology Group; FISH = fluorescence in situ hybridization; IMiD = immunomodulator drug;ISS=International Staging System;IXRS=interactive voice/webresponse system; Kd = carfilzomib and dexamethasone; KdD = carfilzomib, dexamethasone, and daratumumab; NE = not estimable; SPEP = serum protein electrophoresis; UPEP = urine protein electrophoresis Source:Figure 14-4.3.1

## Sensitivity Analyses

Results of the sensitivity analyses, including investigator-assessed PFS (HR = 0.578 [95% CI: 0.430, 0.778]) and ORCA-assessed PFS (HR = 0.572 [95% CI: 0.425, 0.770]) are presented below.

Table 10-2. Sensitivity Analyses of Progression Free Survival (Intent-to-Treat Population)

<div style=\"page-break-after: always\"></div>

|                                                                                            | Kd (N = 154)         | Kd (N = 154)              | KdD (N = 312)        | KdD (N = 312)             | Hazard Ratio         |                    |
|--------------------------------------------------------------------------------------------|----------------------|---------------------------|----------------------|---------------------------|----------------------|--------------------|
| Analysis                                                                                   | Events/ Subjects (%) | Median (95% CI) (months)a | Events/ Subjects (%) | Median (95% Cl) (months)a | (KdD/Kd) (95% CI)b   | p-valuec (1-sided) |
| Primary Analysis                                                                           | 68/154 (44.2)        | 15.8 (12.1, NE)           | 110/312 (35.3)       | NE (NE, NE)               | 0.630 (0.464,0.854)  | 0.0014             |
| PFSasassessedbytheinvestigator                                                             | 74/154 (48.1)        | 15.3 (11.1, 17.6)         | 113/312 (36.2)       | NE (NE, NE)               | 0.578 (0.430, 0.778) | 0.0001             |
| PFS as assessed by the sponsor using ORCA                                                  | 74/154 (48.1)        | 15.3 (11.1, NE)           | 112/312 (35.9)       | NE (NE, NE)               | 0.572 (0.425, 0.770) | <00001             |
| Unstratified analysisd                                                                     | 68/154 (44.2)        | 15.8 (12.1, NE)           | 110/312 (35.3)       | NE (NE, NE)               | 0.661 (0.488, 0.894) | 0.0035             |
| Initiation of new anti-myeloma therapy treated as PFS Event                                | 91/154 (59.1)        | 11.7 (9.3, 15.3)          | 123/312 (39.4)       | NE (18.5, NE)             | 0.527 (0.401, 0.693) | <0.0001            |
| Initiation of new anti-myeloma therapy treated as neitheraPFSeventnoracensoringevent       | 72/154 (46.8)        | 15.3 (12.0, NE)           | 112/312 (35.9)       | NE (NE, NE)               | 0.607 (0.450,0.818)  | 0.0005             |
| LTFU/Consent withdrew treated as PFS Event                                                 | 73/154 (47.4)        | 15.3 (11.1, 17.6)         | 121/312 (38.8)       | NE (18.5, NE)             | 0.640 (0.477, 0.858) | 0.0013             |
| Missing assessments treated as censoring events in Kd group and as PFS events in KdD group | 68/154 (44.2)        | 15.8 (12.1, NE)           | 122/312 (39.1)       | NE (NE, NE)               | 0.696 (0.516, 0.939) | 0.0086             |
| Per-Protocol Population                                                                    | 61/139 (43.9)        | 15.8 (12.1, NE)           | 98/280 (35.0)        | NE (NE, NE)               | 0.621 (0.450,0.858)  | 0.0018             |
| Analysisbasedonscheduledassessmentdates insteadofactualassessmentdates                     | 68/154 (44.2)        | 15.7 (12.0, NE)           | 111/312 (35.6)       | NE (NE, NE)               | 0.640 (0.472, 0.867) | 0.0020             |

Unless specified otherwise, stratified analyses were conducted. Stratification factors (as assessed at randomization): International Staging System stage (Stage 1 or 2

Kd = carfilzomib and dexamethasone; KdD = carfilzomib, dexamethasone, and daratumumab; NE = not evaluable; ORCA = Onyx Response Computational Assessment.

a Medians were estimated using the Kaplan-Meier method. Corresponding 95% Cls were estimated using the method by Klein and Moeschberger (1997) with log-log transformation.

c P-values were calculated using the stratified (or unstratified) log-rank test as specified.

b Hazard ratios and corresponding 95% Cls were estimated using a stratified (or unstratified) Cox proportional hazards model as specified.

d Unstratified analysis were conducted on PFS assessed by the Independent Review Committee.

Source:Table14-4.2.6

Results of the analyses of investigator-assessed ORR (odds ratio = 2.234 [95% CI: 1.362, 3.664]) and ORCA-assessed ORR (odds ratio = 2.218 [95% CI: 1.365, 3.605]) were consistent with the IRC-assessed ORR. Results for ORR were consistent in the per protocol population.

Results of the analyses of investigator-assessed MRD[-]CR at 12 months (at a 10-5 level) (odds ratio = 9.848 [95% CI: 2.354, 41.196]) and ORCA-assessed MRD[-]CR at 12 months (at a 10-5 level) (odds ratio = 10.693 [95% CI: 2.551, 44.825]) were consistent with the IRC-assessed MRD[-]CR at 12 months (at a 10-5 level).

## Summary of main study(ies)

The following tables summarise the efficacy results from the main studies supporting the present application. These summaries should be read in conjunction with the discussion on clinical efficacy as well as the benefit risk assessment (see later sections).

Table 1. Summary of Efficacy for trial 20160275 (CANDOR)

| Title : A Randomized, Open-label, Phase 3 Study Comparing Carfilzomib, Dexamethasone, and Daratumumab to Carfilzomib and Dexamethasone for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma   | Title : A Randomized, Open-label, Phase 3 Study Comparing Carfilzomib, Dexamethasone, and Daratumumab to Carfilzomib and Dexamethasone for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma   | Title : A Randomized, Open-label, Phase 3 Study Comparing Carfilzomib, Dexamethasone, and Daratumumab to Carfilzomib and Dexamethasone for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma   |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Study identifier                                                                                                                                                                                                    | 20160275 EudraCT Number: 2016-003554-33                                                                                                                                                                             | 20160275 EudraCT Number: 2016-003554-33                                                                                                                                                                             |
| Design                                                                                                                                                                                                              | Phase 3, multicenter, open-label, randomized study in subjects with relapsed or refractory multiple myeloma who had received 1 to 3 prior lines of therapy                                                          | Phase 3, multicenter, open-label, randomized study in subjects with relapsed or refractory multiple myeloma who had received 1 to 3 prior lines of therapy                                                          |
|                                                                                                                                                                                                                     | Duration of main phase: Duration of Run-in phase: Duration of Extension phase:                                                                                                                                      | 2 years and 1 month (study ongoing) not applicable not applicable                                                                                                                                                   |
| Hypothesis                                                                                                                                                                                                          | Superiority                                                                                                                                                                                                         | Superiority                                                                                                                                                                                                         |

<div style=\"page-break-after: always\"></div>

| Treatments groups                  | Carfilzomib + Daratumumab + Dexamethasone (KdD)      | Carfilzomib + Daratumumab + Dexamethasone (KdD)      | Carfilzomib 20 mg/m2 IV on Days 1 and 2 of Cycle 1, escalating to 56 mg/m2 IV beginning on Cycle 1 Day 8 and thereafter. Daratumumab 8 mg/kg IV on Days 1 and 2 of Cycle 1, then 16 mg/kg IV once weekly on Days 8, 15 and 22 of Cycle 1 and Days 1, 8, 15 and 22 of Cycle 2, then every 2 weeks on Cycles 3 to 6, and then every 4 weeks for the remaining cycles or until disease progression. Dexamethasone 40 mg weekly PO or by IV injection. Dexamethasone will be taken at 20 mg each treatment day on weeks with carfilzomib and/or daratumumab infusions and at 40 mg in weeks without carfilzomib and/or Daratumumab                                                                                         | Carfilzomib 20 mg/m2 IV on Days 1 and 2 of Cycle 1, escalating to 56 mg/m2 IV beginning on Cycle 1 Day 8 and thereafter. Daratumumab 8 mg/kg IV on Days 1 and 2 of Cycle 1, then 16 mg/kg IV once weekly on Days 8, 15 and 22 of Cycle 1 and Days 1, 8, 15 and 22 of Cycle 2, then every 2 weeks on Cycles 3 to 6, and then every 4 weeks for the remaining cycles or until disease progression. Dexamethasone 40 mg weekly PO or by IV injection. Dexamethasone will be taken at 20 mg each treatment day on weeks with carfilzomib and/or daratumumab infusions and at 40 mg in weeks without carfilzomib and/or Daratumumab                                                                                         |
|------------------------------------|------------------------------------------------------|------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Treatments groups                  | Carfilzomib + Dexamethasone (Kd)                     | Carfilzomib + Dexamethasone (Kd)                     | Carfilzomib 20 mg/m2 IV on Days 1 and 2 of Cycle 1, escalating to 56 mg/m2 IV beginning on Cycle 1 Day 8 and thereafter. Dexamethasone 40 mg weekly PO or by IV injection. Dexamethasone will be taken at 20 mg each treatment day on weeks with carfilzomib and/or daratumumab infusions and at 40 mg in weeks without carfilzomib and/or Daratumumab infusion. For patients > 75 years of age, Dexamethasone 20mg weekly PO or by IV injection. Dexamethasone will be taken at 20 mg weekly and can be split across treatment days in cycles ≥ 3 except on day 1 of a cycle. Dexamethasone will be administered at least 30 minutes (but no more than 4 hours) prior to carfilzomib and within 1 to 3 hours from the | Carfilzomib 20 mg/m2 IV on Days 1 and 2 of Cycle 1, escalating to 56 mg/m2 IV beginning on Cycle 1 Day 8 and thereafter. Dexamethasone 40 mg weekly PO or by IV injection. Dexamethasone will be taken at 20 mg each treatment day on weeks with carfilzomib and/or daratumumab infusions and at 40 mg in weeks without carfilzomib and/or Daratumumab infusion. For patients > 75 years of age, Dexamethasone 20mg weekly PO or by IV injection. Dexamethasone will be taken at 20 mg weekly and can be split across treatment days in cycles ≥ 3 except on day 1 of a cycle. Dexamethasone will be administered at least 30 minutes (but no more than 4 hours) prior to carfilzomib and within 1 to 3 hours from the |
| Endpoints and definitions          | Primary endpoint                                     | Primary endpoint                                     | N=154 Progressive Free Survival (PFS)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | Time from randomization until disease progression or death from any cause. Response and disease progression determined by a blinded Independent Review Committee (IRC).                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| Endpoints and definitions          | Secondary endpoint                                   | Secondary endpoint                                   | Overall Response Rate (ORR)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | Proportion of best overall response of stringent complete response (sCR), complete response (CR), very good partial response (VGPR), and partial response (PR) by IRC                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| Endpoints and definitions          | Secondary endpoint                                   | Secondary endpoint                                   | MRD[-]CR rate                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | Achievement of CR by IRC per International Myeloma Working Group-Uniform Response Criteria (IMWG-URC) and MRD[-] status as assessed by NGS (at a 10 -5 level) at 12 months                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| Endpoints and definitions          | Secondary endpoint                                   | Secondary endpoint                                   | Overall Survival (OS)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | Time from randomization until death from any cause.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| Database lock                      | 14 July 2019 (data cut off for the primary analysis) | 14 July 2019 (data cut off for the primary analysis) | 14 July 2019 (data cut off for the primary analysis)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | 14 July 2019 (data cut off for the primary analysis)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| Results and Analysis               | Results and Analysis                                 | Results and Analysis                                 | Results and Analysis                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | Results and Analysis                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| Analysis                           | Analysis                                             | Primary Analysis                                     | Primary Analysis                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | Primary Analysis                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| Analysis population and time point | Analysis population and time point                   | Intent to treat                                      | Intent to treat                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | Intent to treat                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |

<div style=\"page-break-after: always\"></div>

| Descriptive statistics   | Descriptive statistics                                                                   | Treatment group                                                                          | Kd                                                                                       | KdD                                                                                      |
|--------------------------|------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------|
| and estimate             | and estimate                                                                             | Number of subject                                                                        | 154                                                                                      | 312                                                                                      |
| variability              | variability                                                                              | Median PFS (months)                                                                      | 15.8                                                                                     | NE                                                                                       |
|                          |                                                                                          | 95% CI                                                                                   | 12.1, NE                                                                                 | NE, NE                                                                                   |
|                          |                                                                                          | ORR (%)                                                                                  | 74.7                                                                                     | 84.3                                                                                     |
|                          |                                                                                          | 95% CI                                                                                   | 67.0, 81.3                                                                               | 79.8, 88.1                                                                               |
|                          |                                                                                          | MRD[-]CR rate 95% CI                                                                     | 1.3 0.2, 4.6                                                                             | 12.5 9.0, 16.7                                                                           |
|                          |                                                                                          | Median OS (months)                                                                       | NE                                                                                       | NE                                                                                       |
|                          |                                                                                          | 95% CI                                                                                   | NE, NE                                                                                   | NE, NE                                                                                   |
| Effect estimate per      | Effect estimate per                                                                      | Primary endpoint PFS                                                                     | Comparison groups                                                                        | KdD vs Kd                                                                                |
| comparison               | comparison                                                                               | Primary endpoint PFS                                                                     | HR                                                                                       | 0.630                                                                                    |
|                          |                                                                                          | Primary endpoint PFS                                                                     | 95% CI                                                                                   | 0.454, 0.854                                                                             |
|                          |                                                                                          | Primary endpoint PFS                                                                     | P-value (1-sided)                                                                        | 0.0014                                                                                   |
|                          |                                                                                          | Secondary endpoint ORR                                                                   | Comparison groups                                                                        | KdD vs Kd                                                                                |
|                          |                                                                                          | Secondary endpoint ORR                                                                   | Odds ratio                                                                               | 1.925                                                                                    |
|                          |                                                                                          | Secondary endpoint ORR                                                                   | 95% CI                                                                                   | 1.184, 3.129                                                                             |
|                          |                                                                                          | Secondary endpoint ORR                                                                   | P-value (1-sided)                                                                        | 0.0040                                                                                   |
|                          |                                                                                          | Secondary endpoint MRD[-]CR rate                                                         | Comparison groups                                                                        | KdD vs Kd                                                                                |
|                          |                                                                                          | Secondary endpoint MRD[-]CR rate                                                         | Odds ratio                                                                               | 11.329                                                                                   |
|                          |                                                                                          | Secondary endpoint MRD[-]CR rate                                                         | 95% CI                                                                                   | 2.703, 47.476                                                                            |
|                          |                                                                                          | Secondary endpoint MRD[-]CR rate                                                         | P-value (1-sided)                                                                        | <0.0001                                                                                  |
|                          |                                                                                          | Secondary endpoint OS                                                                    | Comparison groups                                                                        | KdD vs Kd                                                                                |
|                          |                                                                                          | Secondary endpoint OS                                                                    | HR                                                                                       | 0.745                                                                                    |
|                          |                                                                                          | Secondary endpoint OS                                                                    | 95% CI                                                                                   | 0.491, 1.131                                                                             |
|                          |                                                                                          | Secondary endpoint OS                                                                    | P-value (1-sided)                                                                        | 0.0836                                                                                   |
| Notes                    | Randomization was stratified by the original International Staging System stage at study | Randomization was stratified by the original International Staging System stage at study | Randomization was stratified by the original International Staging System stage at study | Randomization was stratified by the original International Staging System stage at study |

## 2.4.2. Discussion on clinical efficacy

## Design and conduct of clinical studies

The CANDOR study was designed to allow the recruitment of patients with MM previously treated with at least one prior line (transplant is considered as 1 line of therapy) but not more than three. Patients were 2:1 randomized to KdD and Kd arms, using as stratification factors: original ISS stage, lines of therapy, prior PI exposure and prior CD38 Ab exposure. Prior therapy with carfilzomib and anti-CD38 antibodies were allowed as previous treatment, provided at least PR was obtained and there was a treatment-free interval of 6 months. Patients refractory to any prior lenalidomide treatment and any prior PI-including regimen were allowed.

Subjects in both arms received dexamethasone (40 mg/weekly) plus carfilzomib 20 mg/m2 IV over 30 minutes on days 1 and 2 of cycle 1, followed by escalation to 56 mg/m2 over 30 minutes on days 8, 9, 15, and 16 of cycle 1. Subjects who tolerated 56 mg/m2 in cycle 1 were kept at this dose for each subsequent 28 day cycle until disease progression, intolerable side effects, withdrawal of consent or death. The same posology authorized in combination with dexamethasone based on ENDEAVOR study. In the KdD arm, daratumumab was added as 16 mg/Kg IV infusion (weekly for 8 weeks, then every 2 weeks for 16 weeks and then every 4 weeks for the remaining cycles or until disease progression) as per the SmPC.

According to the MAH, the rational for the selected dose of 56 mg/m 2  twice-weekly was related to the available mature safety long-term data for Kd from the ENDEAVOR study. This, combined with the fact

<div style=\"page-break-after: always\"></div>

that at the time of the study design daratumumab had been safely added to a series of established standard of care myeloma back bone therapies, including triplets containing a proteasome inhibitor (DVMP, DVd), resulted in the use of this dose regimen for carfilzomib in this study.

PFS was the primary endpoint, with ORR, MRD(-)CR and OS as key secondary endpoints. PFS is defined as time from randomization until disease progression or death from any cause. Disease progression was determined by a blinded Independent Review Committee (IRC), based on IMWG-URC (Kumar, 2016) criteria. The use of PFS as main outcome variable is acceptable, given that there are different efficacious treatment alternatives that patients could receive, which will likely modify the expected survival. Although the design of the study is unblinded, the use of an IRC to assess response (as defined by IMWG-URC) is endorsed. In addition, the different sensitivity analyses planned increase the level of robustness of the results.

Regarding the amendment 1 - updated and clarified the IMWG-URC, during the time this modification was in effect, 101 subjected were enrolled, but, according to the MAH, none of the patients were assessed with the previous IMWG-URC version, as the analyses took place after the date of this amendment 1.

Amendment 4 - added 2 interim readouts of OS at 36 and 48 months after the first subject enrolled, as well as, methods for the analyses and clarification of the timing of the OS final analysis. This amendment seems to be conducted before database snapshot for the primary analysis. Thus, this issue is not further pursued.

The applicant was requested to provide further details on important protocol deviation 'Entered study even though entry criteria were not satisfied' and 'Missing data (other than TA or TC)'. Patients with missing data (other than TA or TC) were classified as important protocol deviations following strictly the protocol deviation handling plan (50 patients). Overall, the efficacy results on the ITT population were consistent with the per protocol population analysis so these deviations seemed to have had no impact on the study results. The 'entered study even though entry criteria were not satisfied' category was applied for failure to adhere to the CANDOR study inclusion/exclusion criteria detected in the 21-day window between enrolment and randomization. This happened in 39 patients and details were provided showing no effect on the efficacy analyses.

## Efficacy data and additional analyses

A total of 466 subjects were randomized (312 subjects in the KdD group and 154 subjects in the Kd group). As of the data cutoff of 14 July 2019, 129 subjects (41.3%) in the KdD group and 46 subjects (29.9%) in the Kd group were continuing carfilzomib. One hundred and three patients were screened but not randomized as per study inclusion/exclusion criteria. Additionally, 3 patients were randomized but not dosed due to worsening of their condition before starting treatment, which was recorded as 'sponsor reasons'.

The population recruited in the study is the one expected at relapse. The median age of 64 is similar to that in other phase 3 studies in relapsed MM patients. The study enrolled 43 subjects (9.2%) above 75 years and no one ≥ 85 years. Pointing out that the percentage of subjects aged 75 to 84 years was lower in the KdD group (9.0%) than in the Kd group (14.3%). The majority geographic region is Europe (66.5%).

Around half of patients received previous transplant (48.7% in Kd vs 62.5% in KdD), most of them autologous. Patients with at least 2 previous regimens were 77%. Most patients received PI-including regimen (92.1%; 90.3% in Kd and 92.9% in KdD). However, only 1 patient in KdD arm received previous CD38 therapy. This information is reflected in section 5.1 of the SmPC. Lenalidomide was administered to 42.3%, with slightly differences between arms (48.1% in Kd and 39.4% in KdD). IMiD was administered

<div style=\"page-break-after: always\"></div>

to 67.8%, with slightly differences between arms (71.4% in Kd and 66.0% in KdD). The potential impact on the results of this study of these unbalances on lenalidomide and IMiD prior treatment was discussed and efficacy endpoints were adjusted for this covariate, showing no differences between both treatment arms. Approximately 34% of patients were refractory to any prior PI-including regimen (35.7% in Kd vs 32.7% in KdD), 33% to any prior lenalidomide-including regimen (35.7% in Kd vs 31.7%in KdD) and 41.8 % to any prior IMiD-including regimen (42.2% in Kd vs 41.7%in KdD).

It should be noted that, according to Multiple Myeloma ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up, association of Carfilzomib and Dexamethasone (Kd) is one of the standards of care at relapse after an IMiD-based induction. However, an IMiD based induction treatment was not part of the inclusion criteria. The MAH noted that the inclusion criteria for the CANDOR study were defined before the publication of the current version of the ESMO Guidelines and were based on those used in the ENDEAVOR study (which led to the marketing authorization of Kd 20/56 mg/m 2  twice-weekly), to ensure that the control group enrolled in CANDOR was similar to the indicated population in the different regions. The majority of patients had prior IMiD exposure before entering the CANDOR study. The benefit of KdD in patients exposed to prior IMiDs is acknowledged.

Regarding medical history pointing out the following slightly unbalances between arms (Kd, KdD): vascular disorders (59.7%, 49.7%), an abnormal baseline electrocardiogram interpretation (34.4%, 26.2%), baseline history of hypertension (54.5%, 43.3%). These unbalances could have impact on safety finding.

Regarding the best overall response to last prior systemic therapy and refractory to the last prior line of therapy, an unbalance in favour of KdD arm is observed (sCR+CR+VGPR: 40.9% in Kd, 51.3% in KdD; refractory to last prior line therapy: 61.7% in Kd, 52.9% in KdD), which could suggest that patients included in the KdD could have better prognostic factors. The MAH provided additional results for PFS HR adjusting for these 2 baseline covariates (best overall response [BOR] of very good partial response [VGPR] or better to the last prior therapy, or refractoriness to the last prior therapy) which were consistent with the PFS results from the main analysis in the ITT population. Although these results, as obtained from post-hoc analysis, should be taken with caution, it seems that these unbalances maynot have had an impact on the study results.

Overall, 74 subjects (23.7%) in the KdD group and 70 subjects (45.5%) in the Kd group had at least 1 antimyeloma therapy after discontinuation of study treatment. As expected, most of new antimyeloma therapies were administered more frequently in the Kd arm, being daratumumab (1.3%, 15.6%) and dexamethasone (14.1%, 25.3%) the most frequent ones. Only the following new antimyeloma therapy were administered with slightly higher frequency in the KdD arm (Kd, KdD): cyclophosphamide (5.2%, 6.1%), ixazomib (1.3%, 1.9%), dexamethasone with lenalidomide (0.6%, 1.9%), elotuzumab (1.3%, 1.6%).

A statistically significant difference was observed for PFS (as assessed by the IRC) between the KdD and Kd groups (HR = 0.630; 95% CI: 0.464, 0.854; p = 0.0014) in the final PFS analysis. The median PFS was 15.8 months (95% CI: 12.1, not estimable [NE]) in the Kd arm, while median PFS was not reached in the KdD arm. Highlighted that the median PFS is slightly lower than that observed for Kd in the ENDEAVOR study (18.7 months) and slightly lower than it was expected in the calculation of sample size. This could be in relation with data on the best response to last prior systemic regimen (sCR+CR+VGPR; 47% in ENDEAVOR study for Kd) and refractory to last prior systemic therapy (39.7% in ENDEAVOR study for Kd) (see data of this study above). This result seems robust as the different sensitive analyses (investigator and ORCA among others) offer similar results. Results for PFS were consistent in the PP population. As median PFS was not reached for KdD arm. No formal PFS additional analyses were planned. Updated data for PFS, based on ORCA, using a data cutoff date of 15 June 2020 were provided.

<div style=\"page-break-after: always\"></div>

Results showed that improvement of PFS was maintained, HR = 0.590; 95% CI: 0.449, 0.776; p &lt; 0.0001.  Median PFS was 28.6 months in the KdD arm and 15.2 months in the Kd arm. It is not proven that this delay in the progression of MM can be translated into a longer survival, since OS data are not mature. In this regard the first OS interim analysis (IA) offered a positive trend for KdD vs Kd (0.745 (95% CI: 0.491, 1.131; p = 0.0836). The OS event-free rate was 84.5% in the KdD group and 85.2% in the Kd group at 12 months and 79.9% in the KdD group and 74.4% in the Kd group at 18 months. The MAH provided results of the second OS IA using a data cutoff date of 15 june 2020. OS data were still not mature (28.5 events in the KdD group and 33.1 events in the Kd group) and statistical significance was not reached since the p value did not cross the prespecified 0.004 boundary, but a positive trend was noted: HR = 0.758; 95% CI: 0.536, 1.073; p = 0.0590 (data still not mature). Another IA for OS and final analysis for OS are planned. Results of this 3rd IA and the final analysis are expected by 2nd quarter 2021 and 2nd quarter 2022, respectively. Results of these additional OS analyses will be provided once available. The other secondary key variables ORR and MRD(-)CR at 12 months (at a 10-5 level) according to IRC support the PFS results. The ORR as assessed by IRC was 84.3% (95% CI: 79.8, 88.1) in the KdD group and 74.7% (95% CI: 67.0, 81.3) in the Kd group (odds ratio: 1.925 [95% CI: 1.184, 3.129]; p = 0.0040). The MRD[-]CR rate at 12 months (at a 10-5 level) based on IRC assessment was 12.5% (95% CI: 9.0, 16.7) in the KdD group and 1.3% (95% CI: 0.2, 4.6) in the Kd group (odds ratio: 11.329 [95% CI: 2.703, 47.476]; p &lt; 0.0001). The sensitive analyses (investigator and ORCA among others) for ORR and MRD(-)CR offer similar results. Additional secondary endpoints (DoR, time to next treatment) are overall in line with PFS. The updated data (cutoff data of 15 June 2020) for secondary endpoints confirm results observed in the primary analysis. PFS results are highly contrasted between subgroups of particular interest. Indeed, only a nonstatistically significant positive trend was observed for the European population subgroup (HR= 0.857 [95% CI: 0.596 - 1.231], 66% of the subjects) whereas results are highly statistically significant for the North-America region (HR= 0.041 [95% CI=0.005; 0.339], 7% of the subjects). Baseline disease characteristics were further analyzed in both subgroups (Europe and North-America regions) to explore if a worse disease stage or refractoriness to previous treatments could have impacted PFS results but no particular trend was observed to clearly explain this difference. Of note, even if these results per region are somehow unexpected, the small size of the subgroup precludes any conclusion. Further, region was not a stratification factor in the study and there is no obvious justification, either from a biological plausibility perspective (based on clinical, pharmacological, and mechanistic considerations) or after consideration of data from other trials with carflizomib (e.g. ASPIRE, ENDEAVOR), to support that the treatment effect should not be consistent among European and North American patients. Overall, the PFS benefit of KdD was consistently observed in most subgroups, although there are several subgroups with categories crossing 1, most cases due to limited number of patients included in those categories. Pointing out among those cases , those with HR &gt;1: patients ≥ 75 years of age (n = 43; PFS HR 1.459 95% CI [0.504, 4.223]), revised ISS stage at baseline- stage 3 (n=39; PFS HR 1.348 95%CI [0.538, 3.381]) and presence of soft tissue plasmacytoma at baseline (n=23; PFS HR 1.560 95%CI [0.531, 4.580]). It should be also highlighting that among stratification factors, for subgroup of 1 prior line of therapy the benefit is less clear (PFS HR 0.701 95%CI [0.418, 1.174]). Subgroups of interest that showed the superiority of the new combination (KdD) for PFS: prior bortezomib or ixazomib treatment (PFS HR 0.643 95%CI [0.470, 0.879]), prior lenalidomide (PFS HR 0.521 95%CI [0.339, 0.802]), refractory to lenalidomide (PFS HR 0.453 95%CI [0.279, 0.737]), prior IMiD (PFS HR 0.622 95%CI [0.439, 0.883]) and refractory to IMiD (PFS HR 0.448 95%CI [0.290, 0.694]). However, in one potential population for this combination, patients refractory to bortezomib or ixazomib, the benefit is less clear (PFS HR 0.871 95%CI [0.540, 1.405]).

<div style=\"page-break-after: always\"></div>

The number of subjects with any subsequent anti-myeloma therapy use was respectively 70 (45.5%) and 74 (23.7%) in Kd and KdD arms, twice less frequent in KdD arm. Thus, the MAH was asked to provide Progression Free Survival to the subsequent anti-myeloma therapy (PFS2) data. The median (95% CI) PFS2 was not estimable for the KdD group and of 33.2 months (33.2, not estimable) for the Kd group. The PFS2 event-free rate at 24 months was 72.5% in the KdD group and 65.1% for the Kd group. As the design of the study did not include the PFS2 assessment and these were provided upon request during the assessment, these data should be interpreted with caution.

In the ORR subgroups analysis, there are several subgroups containing 1 in their 95% CI, although all of them showed odds ratio &gt; 1. Regarding stratification factors, all subgroups contain 1 in their 95% CI, except prior proteasome i nhibition (yes) and ≥ 2 prior lines of therapy. Pointing out that results observed on subgroups of interest that showed the superiority of the new combination (KdD) for PFS are not fully consistent with results for ORR in the following cases: prior lenalidomide (ORR Odds ratio= 1.289 [95%CI: 0.654, 2.538]), refractory to lenalidomide (ORR Odds ratio= 1.481[95%CI: 0.686, 3.199]) and refractory to IMiD (ORR Odds ratio=1.691 [95%CI: 0.839, 3.410]).

In MRD(-)CR subgroups analysis, the benefit for KdD was consistently seen in most subgroups. All showed odds ratio &gt; 1, with 95% CI excluding 1, with exception of patients &gt; 75 years, Asian, Asian Pacific region, refractory to bortezomib or ixazomib and no prior IMiD exposure.

Subgroups analyses in the three endpoints suggest that benefit in patients &gt; 75 and refractory to bortezomib and ixazomib is less clear. A total of 43 patients above 75 years of age were enrolled and it should be kept in mind that the percentage of subjects aged 75 to 84 years was lower in the KdD group (9.0%) than in the Kd group (14.3%) and no patients ≥ 85 years have been included in this study. It is considered that the small size of the subgroup of patients over 75 years of age precludes any firm conclusion. . KdD should be used with caution in patients ≥75 years after ca reful consideration of the potential benefit/risk on an individual basis (see section 5.1 and 4.8 of the SmPC).

A pre-planned interim OS analysis was performed approximately 36 months after first subject enrolled. The median follow-up was approximately 28 months. Current OS data are not mature. The first OS interim analysis offered a positive trend for KdD vs Kd (HR 0.745 (95% CI: 0.491, 1.131; p = 0.0836). The OS event-free rate was 84.5% in the KdD group and 85.2% in the Kd group at 12 months and 79.9% in the KdD group and 74.4% in the Kd group at 18 months. Results from a second IA were overall consistent with the first IA. A trend in favour of KdD was observed although statistical significance was not reached (HR 0.758; 95% CI: 0.536, 1.073; p = 0.0590). Data from a third IA for OS and the final analysis will not be available before the MA is granted. Thus, the MAH will provide them as a postauthorisation measure.

Overall survival data were not mature at the time of the analysis, and while, a trend toward longer OS in the KdD arm compared with Kd armin the overall population and even in elderly patients for OS could be observed, according to the KM curves there was a higher rate of deaths in elderly patients treated with KdD compared with those receiving Kd during (approximately) the first year of treatment. This could be related to the higher rate of fatal adverse events reported in subjects ≥ 65 years of age (see clinical safety discussion and SmPC section 4.8).  All available efficacy results have been adequately reflected in the updated SmPC section 5.1.

<div style=\"page-break-after: always\"></div>

## 2.4.3. Conclusions on the clinical efficacy

The superiority of the new combination of carfilzomib plus dexamethasone plus daratumumab (KdD) vs. carfilzomib plus dexamethasone (Kd) has been shown in terms of improved PFS and improved depth of response. OS results showed an apparently significant benefit for those patients treated with KdD.

## 2.5. Clinical safety

## Introduction

Safety data submitted is based on the results from the phase 3, randomized Study 20160275 (hereafter referred to as CANDOR) of carfilzomib in combination with daratumumab and dexamethasone (KdD) versus carfilzomib in combination with dexamethasone (Kd) in subjects with relapsed or refractory multiple myeloma who had received 1 to 3 prior lines of therapy.

The primary analysis of safety is a within-study comparison of the safety profile for subjects receiving KdD versus Kd intended to identify any meaningful imbalances between treatment groups in CANDOR, with 14 July 2019 as cutoff date for this analysis.

Carfilzomib has been authorized in the EU, at 20/27 mg/m 2  twice-weekly dosing, in combination with lenalidomide and dexamethasone and, at 20/56 mg/m 2  twice-weekly, in combination with dexamethasone for the treatment of patients with relapsed or refractory multiple myeloma.

As of 17 October 2019, an estimated 4202 subjects had been treated with carfilzomib for 3752.0 subjectyears of exposure as participants in 26 company-sponsored clinical studies (20 completed and 6 ongoing) and an estimated 139 006 patients had received carfilzomib for 53 878 patient-years of exposure in the postmarketing setting. Updated data submitted showed that, as of 19 January 2020, an estimated 4297 subjects had been treated with carfilzomib for 3823.5 subject-years of exposure as participants in 27 company-sponsored clinical studies (20 completed and 7 ongoing) and an estimated 149785 patients had received carfilzomib for 58 056 patient-years of exposure in the marketed setting.

Based on 1 676 445 500 milligrams distributed from launch to 31 October 2019, the estimated exposure to daratumumab is 63 675 person-years in the postmarketing setting.

## Patient exposure

In the CANDOR study, 461 subjects were treated with at least 1 dose of investigational product (308 subjects in the KdD group and 153 subjects in the Kd group) and comprise the safety population. The median treatment duration for any investigational product (carfilzomib, daratumumab, or dexamethasone) was longer for the KdD group (70.1 weeks) than the Kd group (40.3 weeks). As for the new safety data cutoff (Jan 2020), when compared with the CANDOR primary analysis, the median treatment duration for any investigational product was 9.2 weeks longer for the KdD group, but remained unchanged for the Kd group

Given the difference in the treatment exposure in each group, exposure-adjusted risk estimates are presented along the data provided to identify if the observed imbalance in incidence may be related to duration of treatment.  The risk estimate presented is the number of events per 100 subject-years.

Exposure to Carfilzomib

<div style=\"page-break-after: always\"></div>

As of the data cutoff (14 July 2019), subjects received a median of 58.36 weeks of treatment with carfilzomib in the KdD group and 40.29 weeks in the Kd group (Table 1). As for number of cycles, patients in KdD arm received a median of 15 cycles (Min, Max: 1, 26) and subjects from Kd arm received a median of 11 cycles (1, 25). The median relative dose intensity of carfilzomib was 90.80 % in the KdD group and 93.29 % in the Kd group. Upon the updated safety data, subjects received a median of 61.1 weeks of treatment with carfilzomib in the KdD group and 40.3 weeks in the Kd group (Table 1). When compared with the CANDOR primary analysis, the median treatment duration for carfilzomib was 2.7 weeks longer for the KdDgroup but unchanged for the Kd group.

Table 1.  Summary of Exposure to Carfilzomib or Daratumumab (Safety Population)

|                                                            | Carfilzomib                                                | Carfilzomib                                                | Daratumumab                                                |
|------------------------------------------------------------|------------------------------------------------------------|------------------------------------------------------------|------------------------------------------------------------|
|                                                            | Kd 20/56 mg/m 2 BIW (N = 153)                              | KdD 20/56 mg/m 2 BIW (N = 308)                             | KdD 20/56 mg/m 2 BIW (N = 308)                             |
| Duration of carfilzomib/daratumumab administration (weeks) | Duration of carfilzomib/daratumumab administration (weeks) | Duration of carfilzomib/daratumumab administration (weeks) | Duration of carfilzomib/daratumumab administration (weeks) |
| Mean                                                       | 43.45                                                      | 51.89                                                      | 54.38                                                      |
| SD                                                         | 28.57                                                      | 27.73                                                      | 27.87                                                      |
| Median                                                     | 40.29                                                      | 58.36                                                      | 68.14                                                      |
| Min, max                                                   | 0.3, 97.3                                                  | 0.3, 102.3                                                 | 0.1, 100.3                                                 |
| Average carfilzomib dose per administration (mg/m 2 )      | Average carfilzomib dose per administration (mg/m 2 )      | Average carfilzomib dose per administration (mg/m 2 )      | Average carfilzomib dose per administration (mg/m 2 )      |
| Mean                                                       | 50.37                                                      | 50.39                                                      | -                                                          |
| SD                                                         | 6.16                                                       | 7.52                                                       | -                                                          |
| Median                                                     | 52.82                                                      | 53.89                                                      | -                                                          |
| Min, max                                                   | 20.2, 57.6                                                 | 19.9, 60.0                                                 | -                                                          |
| Relative dose intensity ( % ) a                            | Relative dose intensity ( % ) a                            | Relative dose intensity ( % ) a                            | Relative dose intensity ( % ) a                            |
| Mean                                                       | 87.19                                                      | 85.81                                                      | 92.78                                                      |
| SD                                                         | 15.11                                                      | 15.47                                                      | 9.12                                                       |
| Median                                                     | 93.29                                                      | 90.80                                                      | 95.61                                                      |
| Min, max                                                   | 40.1, 105.9                                                | 21.6, 106.0                                                | 24.0, 102.4                                                |

BIW = twice-weekly; Kd = carfilzomib plus dexamethasone; KdD = carfilzomib, dexamethasone, plus daratumumab; -= not applicable

a  Relative dose intensity ( % ) = actual dose intensity/planned dose intensity x 100, where actual (planned) dose intensity is the actual (planned) cumulative dose (mg/m 2 ) divided by the actual (planned) duration of carfilzomib/daratumumab administration (weeks).

Source:  Table 14-5.1.2 and Table 14-5.1.3 of Study 20160275

## Exposure to Daratumumab

In the KdD group, subjects received a median of 68.14 weeks of treatment with daratumumab (Table 1), which was translated into a median of 17 cycles (Min, Max: 1, 26).  The median relative dose intensity of daratumumab was 95.61%. For the updated safety data analyses, compared with the CANDOR primary

<div style=\"page-break-after: always\"></div>

analysis, in the KdD group, subjects received a median of 79.2 weeks of treatment with daratumumab, an increase of 11.1 weeks from the primary analysis.

## Adverse events

In CANDOR, 306 subjects (99.4 % ) in the KdD group and 147 subjects (96.1 % ) in the Kd group had at least 1 adverse event. A higher subject incidence in the KdD group compared with the Kd group was reported (KdD, Kd) for grade ≥ 3 adverse events (82.1 % , 73.9 % ), serious adverse events (56.2 % , 45.8 % ), and fatal adverse events (9.7 % , 5.2 % ).  A similar subject incidence in the KdD group and the Kd group was reported for adverse events that led to the discontinuation of carfilzomib (KdD:  21.1 % , Kd:  21.6 % ). An overview of the adverse events is provided below.

Table 6 .  Overview of Adverse Events (Safety Population)

|                                                      | Kd (N = 153) n (%)   | KdD (N = 308) n (%)   |
|------------------------------------------------------|----------------------|-----------------------|
| All treatment-emergent adverse events                | 147 (96.1)           | 306 (99.4)            |
| Grade ≥ 3                                            | 113 (73.9)           | 253 (82.1)            |
| Serious adverseevents                                | 70 (45.8)            | 173 (56.2)            |
| Leading to discontinuation of carfilzomib            | 33 (21.6)            | 65 (21.1)             |
| Leading to discontinuation of daratumumab            |                      | 28 (9.1)              |
| Leading to discontinuation of dexamethasone          | 37 (24.2)            | 33 (10.7)             |
| Fatal adverse events                                 | 8 (5.2)              | 30 (9.7)              |
| Treatment-related treatment-emergent adverse eventsa | 129 (84.3)           | 260 (84.4)            |
| Grade ≥3                                             | 74 (48.4)            | 187 (60.7)            |
| Seriousadverseevents                                 | 32 (20.9)            | 84 (27.3)             |
| Leading to discontinuation of carfilzomib            | 21 (13.7)            | 50 (16.2)             |
| Leading to discontinuation ofdaratumumab             |                      | 15 (4.9)              |
| Leading to discontinuation of dexamethasone          | 24 (15.7)            | 19 (6.2)              |
| Fatal adverse events                                 | 0 (0.0)              | 5 (1.6)               |

Kd=carfilzomibanddexamethasone;KdD=carfilzomib,dexamethasone,anddaratumumab;;MedDRA= Medical Dictionary for Regulatory Activities; NCl-CTCAE = National Cancer Institute-Common Terminology Criteria for Adverse Events; - = not applicable

Treatment-emergent adverse events were defined as any adverse event with an onset after the administration of the first dose of any study treatment and within the end of study or 30 days of the last dose of any study treatment, whichever occurs earlier. Adverse events were coded using MedDRA (version 22.0) and graded using NCI-CTCAE (version 4.03).

a Treatment-related adverse events are adverse events considered related to at least one investigational product by the investigator, including those with unknown relationship.

Source:Table 14-6.1.1 of Study 20160275

After adjusting for exposure, the risk estimate (95 % CI) of adverse events was higher in the KdD group compared with the Kd group (1308.74 [1170.02, 1463.91] versus 831.53 [707.41, 977.42]; per 100 subject-years, respectively).  Exposure-adjusted risk estimates for serious adverse events were similar at 75.89 and 73.35 in the KdD group and the Kd group, respectively. This suggests that the higher crude incidence of serious adverse events in the KdD group may be because of longer treatment.

<div style=\"page-break-after: always\"></div>

Table 7 . Overview of Exposure-adjusted Rate of Adverse Events (Safety Population)

|                                           | Total Number of Subjects with Events (%)   |   Kd (N = 153) n (%) Total Person Time (years)a | Exposure Adjusted Risk Estimate (95% CI)b   | Total Number of Subjects with Events (%)   |   KdD (N = 308) n (%) Total Person Time (years)a | Exposure Adjusted Risk Estimate (95% CI)b   |
|-------------------------------------------|--------------------------------------------|-------------------------------------------------|---------------------------------------------|--------------------------------------------|--------------------------------------------------|---------------------------------------------|
| All treatment-emergentadverse events      | 147 (96.1)                                 |                                            17.7 | 831.53 (707.41, 977.42)                     | 306 (99.4)                                 |                                             23.4 | 1308.74 (1170.02, 1463.91)                  |
| Grade≥3 adverse events                    | 113 (73.9)                                 |                                            65.5 | 172.47 (143.43, 207.39)                     | 253 (82.1)                                 |                                            129.2 | 195.83 (173.12, 221.51)                     |
| Seriousadverseevents                      | 70 (45.8)                                  |                                            95.4 | 73.35 (58.03, 92.72)                        | 173 (56.2)                                 |                                            228   | 75.89 (65.38, 88.08)                        |
| Leading to discontinuation of carfilzomib | 33 (21.6)                                  |                                           127.3 | 25.93 (18.43, 36.47)                        | 65 (21.1)                                  |                                            306.6 | 21.20 (16.63, 27.04)                        |
| Leadingtodiscontinuationof daratumumab    | 0 (0.0)                                    |                                             0   | 0.00 (NA, NA)                               | 28 (9.1)                                   |                                            321.9 | 8.70 (6.01, 12.60)                          |
| Leadingtodiscontinuationof dexamethasone  | 37 (24.2)                                  |                                           125.5 | 29.47 (21.35, 40.68)                        | 33 (10.7)                                  |                                            323.4 | 10.20 (7.25, 14.35)                         |
| Fatal adverse events                      | 8 (5.2)                                    |                                           128.6 | 6.22 (3.11, 12.44)                          | 30 (9.7)                                   |                                            330.3 | 9.08 (6.35, 12.99)                          |

Treatment-emergent adverse eventswere defined as any adverse eventswith an onset after the administration of thefirst dose of any studytreatment and within the end of study or 30 days of the last dose of any study treatment, whichever occurs earlier. Adverse events were coded using MedDRA (version 22.0) and graded using NCI-CTCAE (version 4.03).

Kd=carfilzomib and dexamethasone;KdD=carfilzomib,dexamethasone,and daratumumab;MedDRA=Medical Dictionary for RegulatoryActivities;NCI-CTCAE= National Cancer Institute-Common Terminology Criteria for Adverse Events a Total person time is the sum of the time to first treatment emergent adverse event for all subjects in each treatment group. If a subject has no event, then the entire exposure time to study treatment is considered in the sum.

Source:Table14-6.10.403ofStudy20160275

b Per 100 subject years.

Consistent with the CANDOR primary analysis, along the updated safety data, a higher incidence in the KdD group compared with the Kd group was reported (KdD, Kd) for grade ≥ 3 adverse events (84.7%, 74.5%), serious adverse events (61.0%, 47.1%), and fatal adverse events (9.7%, 5.2%) (Table 3). No new fatal adverse events were reported since the CANDOR primary analysis.

Compared with the CANDOR primary analysis, a higher incidence in the KdD group (23.4%) compared with the Kd group (21.6%) was also reported for adverse events that led to the discontinuation of carfilzomib.

## Common Adverse Events

Adverse events by system organ class (SOC) that occur red with a ≥ 10% higher subject incidence in the KdD group compared with the Kd group were gastrointestinal disorders, infections and infestations, general disorders and administration site conditions, and nervous system disorders (Table 4). No adverse eve nts by SOC occurred more frequently (≥ 10% difference) in the Kd group compared with the KdD group.

Adverse events by preferred term that occurred wit h a ≥ 5% higher subject incidence in the KdD group compared with the Kd group (KdD, Kd) were thrombocytopenia (37.3%, 29.4%), diarrhea (31.5%, 14.4%), upper respiratory tract infection (29.2%, 22.9%), fatigue (24.4%, 18.3%), nausea (18.2%, 13.1%), pneumonia (17.9%, 12.4%), insomnia (17.9%, 11.1%), bronchitis (16.9%, 11.8%), back pain (16.2%, 9.8%), infusion-related reaction (7.8%, 2.0%), and peripheral sensory neuropathy (6.5%, 1.3%). No adverse events occurred with a ≥ 5% higher subject incidence in the Kd group than in the KdD group.

<div style=\"page-break-after: always\"></div>

Table 8 . Adverse Events Occurring in ≥ 5 % of Subjects in Any Group by System Organ Class and Preferred Term (Safety Population)

| System Organ Class Preferred Term                              | Kd (N = 153) n ( % )   | KdD (N = 308) n ( % )   |
|----------------------------------------------------------------|------------------------|-------------------------|
| Number of subjects reporting treatment-emergent adverse events | 147 (96.1)             | 306 (99.4)              |
| Infections and infestations                                    | 102 (66.7)             | 250 (81.2)              |
| Upper respiratory tract infection                              | 35 (22.9)              | 90 (29.2)               |
| Pneumonia                                                      | 19 (12.4)              | 55 (17.9)               |
| Bronchitis                                                     | 18 (11.8)              | 52 (16.9)               |
| Influenza                                                      | 10 (6.5)               | 34 (11.0)               |
| Respiratory tract infection                                    | 8 (5.2)                | 31 (10.1)               |
| Nasopharyngitis                                                | 13 (8.5)               | 27 (8.8)                |
| Urinary tract infection                                        | 4 (2.6)                | 18 (5.8)                |
| Lower respiratory tract infection                              | 4 (2.6)                | 17 (5.5)                |
| Conjunctivitis                                                 | 3 (2.0)                | 16 (5.2)                |
| General disorders and administration site conditions           | 74 (48.4)              | 182 (59.1)              |
| Fatigue                                                        | 28 (18.3)              | 75 (24.4)               |
| Pyrexia                                                        | 23 (15.0)              | 60 (19.5)               |
| Oedema peripheral                                              | 14 (9.2)               | 33 (10.7)               |
| Asthenia                                                       | 17 (11.1)              | 30 (9.7)                |
| Chills                                                         | 6 (3.9)                | 17 (5.5)                |
| Oedema                                                         | 8 (5.2)                | 11 (3.6)                |
| Blood and lymphatic system disorders                           | 89 (58.2)              | 168 (54.5)              |
| Thrombocytopenia                                               | 45 (29.4)              | 115 (37.3)              |
| Anaemia                                                        | 48 (31.4)              | 101 (32.8)              |
| Neutropenia                                                    | 15 (9.8)               | 43 (14.0)               |
| Lymphopenia                                                    | 12 (7.8)               | 27 (8.8)                |
| Leukopenia                                                     | 6 (3.9)                | 20 (6.5)                |
| Respiratory, thoracic and mediastinal disorders                | 70 (45.8)              | 150 (48.7)              |
| Dyspnoea                                                       | 34 (22.2)              | 61 (19.8)               |
| Cough                                                          | 30 (19.6)              | 52 (16.9)               |
| Productive cough                                               | 6 (3.9)                | 21 (6.8)                |
| Musculoskeletal and connective tissue disorders                | 57 (37.3)              | 132 (42.9)              |
| Back pain                                                      | 15 (9.8)               | 50 (16.2)               |
| Muscle spasms                                                  | 18 (11.8)              | 36 (11.7)               |
| Arthralgia                                                     | 8 (5.2)                | 26 (8.4)                |
| Pain in extremity                                              | 10 (6.5)               | 19 (6.2)                |
| Vascular disorders                                             | 57 (37.3)              | 124 (40.3)              |

<div style=\"page-break-after: always\"></div>

| System Organ Class Preferred Term              | Kd (N = 153) n ( % )   | KdD (N = 308) n ( % )   |
|------------------------------------------------|------------------------|-------------------------|
| Hypertension                                   | 42 (27.5)              | 94 (30.5)               |
| Gastrointestinal disorders                     | 50 (32.7)              | 171 (55.5)              |
| Diarrhoea                                      | 22 (14.4)              | 97 (31.5)               |
| Nausea                                         | 20 (13.1)              | 56 (18.2)               |
| Vomiting                                       | 13 (8.5)               | 37 (12.0)               |
| Constipation                                   | 6 (3.9)                | 22 (7.1)                |
| Nervous system disorders                       | 45 (29.4)              | 123 (39.9)              |
| Headache                                       | 18 (11.8)              | 41 (13.3)               |
| Neuropathy peripheral                          | 5 (3.3)                | 25 (8.1)                |
| Dizziness                                      | 4 (2.6)                | 23 (7.5)                |
| Peripheral sensory neuropathy                  | 2 (1.3)                | 20 (6.5)                |
| Metabolism and nutrition disorders             | 37 (24.2)              | 105 (34.1)              |
| Hyperglycaemia                                 | 11 (7.2)               | 28 (9.1)                |
| Decreased appetite                             | 9 (5.9)                | 27 (8.8)                |
| Hypokalaemia                                   | 9 (5.9)                | 18 (5.8)                |
| Psychiatric disorders                          | 33 (21.6)              | 77 (25.0)               |
| Insomnia                                       | 17 (11.1)              | 55 (17.9)               |
| Skin and subcutaneous tissue disorders         | 28 (18.3)              | 70 (22.7)               |
| Rash                                           | 10 (6.5)               | 17 (5.5)                |
| Injury, poisoning and procedural complications | 25 (16.3)              | 61 (19.8)               |
| Infusion related reaction                      | 3 (2.0)                | 24 (7.8)                |
| Eye disorders                                  | 16 (10.5)              | 48 (15.6)               |
| Cataract                                       | 5 (3.3)                | 17 (5.5)                |
| Renal and urinary disorders                    | 20 (13.1)              | 37 (12.0)               |
| Acute kidney injury                            | 9 (5.9)                | 12 (3.9)                |

Kd = carfilzomib and dexamethasone; KdD = carfilzomib, dexamethasone, and daratumumab; MedDRA = Medical Dictionary for Regulatory Activities

Treatment-emergent adverse events were defined as any adverse event with an onset after the administration of the first dose and within 30 days of the last dose of any investigational product.  Adverse events were coded using MedDRA (version 22.0).

Source:  Table 14-6.2.2 of Study 20160275

Regarding the updated safety data and, consistent with the CANDOR primary analysis, adverse events by system organ class (SOC) that occurred with a ≥ 10% higher subject incid ence in the KdD group compared with the Kd group included infections and infestations (84.1%, 68.6%), gastrointestinal disorders (57.8%, 35.9%), and nervous system disorders (42.5%, 30.1%) . Compared with the CANDOR primary analysis, general disorders and administration site conditions no longer had a ≥ 10% higher subject incidence in the KdD (60.7%) group compared with the Kd group (51.0%).

## Grade 3 or Higher Adverse Events

<div style=\"page-break-after: always\"></div>

Grade ≥ 3 adverse events were reported for a higher incidence of subjects in the KdD group (82.1%) compared with the Kd group (73.9%). After adjusting for exposure, the risk estimate (95% CI) of grade ≥ 3 adverse events remained higher in the KdD group compared with the Kd group (195.83 and 172.47; per 100 subject-years, respectively).

G rade ≥ 3 adverse events of the SOC of infections and infestations occurred more frequently (≥ 5% difference in subject incidence) in the KdD group (37.3%) compared with the Kd group (29.4%) (exposure-adjusted rates of 43.37 and 40.35; per 100 subject-years , respectively) (Table 5). No grade ≥ 3 adverse events by SOC occurred more freque ntly (≥ 5% difference) in the Kd group compared with the KdD group.

Grade ≥ 3 adverse events that occurred with a ≥ 2% higher subject incidence in the KdD group compared with the Kd group (KdD, Kd) were thrombocytopenia (24.4%, 16.3%), anemia (16.6%, 14.4%), neutropenia (8.4%, 5.9%), pneumonia (13.3%, 8.5%), sepsis (3.9%, 1.3%), influenza (3.6%, 0.7%), hypertension (17.5%, 13.1%), fatigue (7.8%, 4.6%), and diarrhea (3.9%, 0.7 %). Grade ≥ 3 adverse events that occurred with a ≥ 2% higher subject incidence in the Kd group than in the KdD group (KdD, Kd) were cardiac failure (1.6%, 3.3%), pulmonary embolism (1.6%, 3.9%), and acute kidney injury (2.3%, 4.6%).

Table 9 . Grade ≥ 3 Adverse Events Occurring in ≥ 2 % of Subjects in Any Group by System Organ Class and Preferred Term (Safety Population)

| System Organ Class Preferred Term                                                   | Kd (N = 153) n ( % )   | KdD (N = 308) n ( % )   |
|-------------------------------------------------------------------------------------|------------------------|-------------------------|
| Number of subjects reporting treatment-emergent adverse events of grade 3 or higher | 113 (73.9)             | 253 (82.1)              |
| Blood and lymphatic system disorders                                                | 54 (35.3)              | 114 (37.0)              |
| Thrombocytopenia                                                                    | 25 (16.3)              | 75 (24.4)               |
| Anaemia                                                                             | 22 (14.4)              | 51 (16.6)               |
| Neutropenia                                                                         | 9 (5.9)                | 26 (8.4)                |
| Lymphopenia                                                                         | 11 (7.2)               | 21 (6.8)                |
| Leukopenia                                                                          | 2 (1.3)                | 9 (2.9)                 |
| Infections and infestations                                                         | 45 (29.4)              | 115 (37.3)              |
| Pneumonia                                                                           | 13 (8.5)               | 41 (13.3)               |
| Sepsis                                                                              | 2 (1.3)                | 12 (3.9)                |
| Influenza                                                                           | 1 (0.7)                | 11 (3.6)                |
| Bronchitis                                                                          | 2 (1.3)                | 8 (2.6)                 |
| Upper respiratory tract infection                                                   | 2 (1.3)                | 8 (2.6)                 |
| Lower respiratory tract infection                                                   | 1 (0.7)                | 8 (2.6)                 |
| Urinary tract infection                                                             | 3 (2.0)                | 4 (1.3)                 |
| Vascular disorders                                                                  | 25 (16.3)              | 60 (19.5)               |
| Hypertension                                                                        | 20 (13.1)              | 54 (17.5)               |
| Deep vein thrombosis                                                                | 3 (2.0)                | 1 (0.3)                 |
| General disorders and administration site conditions                                | 21 (13.7)              | 47 (15.3)               |

<div style=\"page-break-after: always\"></div>

| System Organ Class Preferred Term                                   | Kd (N = 153) n ( % )   | KdD (N = 308) n ( % )   |
|---------------------------------------------------------------------|------------------------|-------------------------|
| Fatigue                                                             | 7 (4.6)                | 24 (7.8)                |
| Asthenia                                                            | 5 (3.3)                | 9 (2.9)                 |
| Chest pain                                                          | 3 (2.0)                | 1 (0.3)                 |
| Cardiac disorders                                                   | 16 (10.5)              | 28 (9.1)                |
| Atrial fibrillation                                                 | 1 (0.7)                | 7 (2.3)                 |
| Cardiac failure                                                     | 5 (3.3)                | 5 (1.6)                 |
| Respiratory, thoracic and mediastinal disorders                     | 14 (9.2)               | 40 (13.0)               |
| Dyspnoea                                                            | 4 (2.6)                | 12 (3.9)                |
| Pulmonary embolism                                                  | 6 (3.9)                | 5 (1.6)                 |
| Pulmonary oedema                                                    | 3 (2.0)                | 4 (1.3)                 |
| Renal and urinary disorders                                         | 14 (9.2)               | 14 (4.5)                |
| Acute kidney injury                                                 | 7 (4.6)                | 7 (2.3)                 |
| Metabolism and nutrition disorders                                  | 10 (6.5)               | 33 (10.7)               |
| Hyperglycaemia                                                      | 5 (3.3)                | 13 (4.2)                |
| Investigations                                                      | 8 (5.2)                | 22 (7.1)                |
| Aspartate aminotransferase increased                                | 3 (2.0)                | 1 (0.3)                 |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) | 8 (5.2)                | 13 (4.2)                |
| Plasma cell myeloma                                                 | 5 (3.3)                | 7 (2.3)                 |
| Psychiatric disorders                                               | 5 (3.3)                | 20 (6.5)                |
| Insomnia                                                            | 3 (2.0)                | 12 (3.9)                |
| Agitation                                                           | 2 (1.3)                | 7 (2.3)                 |
| Gastrointestinal disorders                                          | 5 (3.3)                | 16 (5.2)                |
| Diarrhoea                                                           | 1 (0.7)                | 12 (3.9)                |
| Eye disorders                                                       | 3 (2.0)                | 8 (2.6)                 |
| Cataract                                                            | 3 (2.0)                | 7 (2.3)                 |

Kd = carfilzomib and dexamethasone; KdD = carfilzomib, dexamethasone, and daratumumab; MedDRA = Medical Dictionary for Regulatory Activities

Treatment-emergent adverse events were defined as any adverse event with an onset after the administration of the first dose and within 30 days of the last dose of any investigational product.  Adverse events were coded using MedDRA (version 22.0).

Source:  Table 14-6.4.2 of Study 20160275

For the updated safety data, consistent with the CANDOR primary analysis, grade ≥ 3 adverse events that occurred with a ≥ 2% higher incidence in the Kd group compared with the KdD group (K dD, Kd) were pulmonary embolism (1.6%, 3.9%) and acute kidney injury (2.6%, 4.6%).

Compared with the CANDOR primary analysis, cardiac failure no longer had a ≥ 2% higher subject incidence in the Kd group (3.3%) compared with the KdD group (1.9%). Grade ≥ 3 adverse events within the SOC of infections and infestations occurred more frequently ( ≥ 5% difference in subject incidence) in the KdD group (40.3%) compared with the Kd group (29.4%).

<div style=\"page-break-after: always\"></div>

## Serious adverse event/deaths/other significant events

## Serious adverse events

Serious adverse events were reported for a higher incidence of subjects in the KdD group (56.2 % ) compared with the Kd group (45.8 % ) . After adjusting for exposure, the risk estimate (95 % CI) of serious adverse events was similar in the KdD group compared with the Kd group (75.89 [65.38, 88.08] versus 73.35 [58.03, 92.72] per 100 subject-years, respectively).

Consistent with the CANDOR primary analysis, serious adverse events occurred at a higher subject incidence in the KdD group (61.0%) compared with the Kd group (47.1%). After adjusting for exposure, the risk estimate of serious adverse events remained higher in the KdD group (70.71 [95% CI: 61.29, 81.57] per 100 subject-years) compared with the Kd group (65.94 [95% CI: 52.34, 83.08] per 100 subject-years).

Serious adverse events of the SOCs with a ≥ 2 % difference in the KdD group compared with the Kd group (KdD, Kd) were infections and infestations (29.5 % , 24.8 % ) and general disorders and administration site conditions (7.5 % , 3.9 % ).

Serious adverse events of the SOCs with a ≥ 2 % difference in the Kd group compared with the KdD group (KdD, Kd) were renal and urinary disorders (2.6 % , 6.5 % ) and vascular disorders (1.6 % , 3.9 % ).

Table 10.  Serious Adverse Events Occurring in ≥ 1 % of Subjects by System Organ Class and Preferred Term (Safety Population)

| System Organ Class Preferred Term     | Kd (N = 153) n ( % )   | KdD (N = 308) n ( % )   |
|---------------------------------------|------------------------|-------------------------|
| Number of subjects reporting          | 70 (45.8)              | 173 (56.2)              |
| Infections and infestations           | 38 (24.8)              | 91 (29.5)               |
| Pneumonia                             | 14 (9.2)               | 38 (12.3)               |
| Influenza                             | 2 (1.3)                | 12 (3.9)                |
| Sepsis                                | 2 (1.3)                | 12 (3.9)                |
| Bronchitis                            | 0 (0.0)                | 6 (1.9)                 |
| Respiratory tract infection           | 2 (1.3)                | 5 (1.6)                 |
| Septic shock                          | 2 (1.3)                | 5 (1.6)                 |
| Lower respiratory tract infection     | 1 (0.7)                | 5 (1.6)                 |
| Urinary tract infection               | 3 (2.0)                | 4 (1.3)                 |
| Upper respiratory tract infection     | 1 (0.7)                | 3 (1.0)                 |
| Respiratory syncytial virus infection | 0 (0.0)                | 3 (1.0)                 |
| Gastroenteritis                       | 2 (1.3)                | 1 (0.3)                 |
| Pneumonia viral                       | 2 (1.3)                | 0 (0.0)                 |

<div style=\"page-break-after: always\"></div>

|                                                                     | Kd               | KdD               |
|---------------------------------------------------------------------|------------------|-------------------|
| System Organ Class                                                  | (N = 153)        | (N = 308) n ( % ) |
| Preferred Term Respiratory, thoracic and mediastinal                | n ( % ) 15 (9.8) | 34 (11.0)         |
| Pulmonary embolism                                                  | 5 (3.3)          | 7 (2.3)           |
| Pulmonary oedema                                                    | 2 (1.3)          | 5 (1.6)           |
| Dyspnoea                                                            | 5 (3.3)          | 4 (1.3)           |
| Pleural effusion                                                    | 1 (0.7)          | 3 (1.0)           |
| Cardiac disorders                                                   | 11 (7.2)         | 28 (9.1)          |
| Atrial fibrillation                                                 | 1 (0.7)          | 5 (1.6)           |
| Cardiac failure                                                     | 4 (2.6)          | 4 (1.3)           |
| Cardiac arrest                                                      | 0 (0.0)          | 3 (1.0)           |
| Cardiac failure acute                                               | 2 (1.3)          | 2 (0.6)           |
| Renal and urinary disorders                                         | 10 (6.5)         | 8 (2.6)           |
| Acute kidney injury                                                 | 7 (4.6)          | 7 (2.3)           |
| Renal failure                                                       | 2 (1.3)          | 0 (0.0)           |
| General disorders and administration site conditions                | 6 (3.9)          | 23 (7.5)          |
| Pyrexia                                                             | 3 (2.0)          | 12 (3.9)          |
| Fatigue                                                             | 0 (0.0)          | 3 (1.0)           |
| Blood and lymphatic system disorders                                | 6 (3.9)          | 16 (5.2)          |
| Anaemia                                                             | 1 (0.7)          | 7 (2.3)           |
| Thrombocytopenia                                                    | 1 (0.7)          | 5 (1.6)           |
| Thrombotic thrombocytopenic purpura                                 | 2 (1.3)          | 2 (0.6)           |
| Injury, poisoning and procedural complications                      | 5 (3.3)          | 13 (4.2)          |
| Infusion related reaction                                           | 0 (0.0)          | 3 (1.0)           |
| Thoracic vertebral fracture                                         | 2 (1.3)          | 0 (0.0)           |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) | 5 (3.3)          | 12 (3.9)          |
| Plasma cell myeloma                                                 | 5 (3.3)          | 7 (2.3)           |
| Gastrointestinal disorders                                          | 4 (2.6)          | 10 (3.2)          |
| Diarrhoea                                                           | 0 (0.0)          | 5 (1.6)           |
| Musculoskeletal and connective tissue disorders                     | 3 (2.0)          | 9 (2.9)           |
| Back pain                                                           | 1 (0.7)          | 3 (1.0)           |
| Vascular disorders                                                  | 6 (3.9)          | 5 (1.6)           |
| Hypertension                                                        | 2 (1.3)          | 2 (0.6)           |
| vein                                                                | 2 (1.3)          | 1                 |
| Deep thrombosis                                                     |                  | (0.3)             |

<div style=\"page-break-after: always\"></div>

|                           | Kd        | KdD       |
|---------------------------|-----------|-----------|
| System Organ Class        | (N = 153) | (N = 308) |
| Preferred Term            | n ( % )   | n ( % )   |
| Eye disorders             | 1 (0.7)   | 3 (1.0)   |
| Cataract                  | 1 (0.7)   | 3 (1.0)   |
| Interstitial lung disease | 0 (0.0)   | 3 (1.0)   |
| Respiratory failure       | 0 (0.0)   | 3 (1.0)   |

Kd = carfilzomib and dexamethasone; KdD = carfilzomib, dexamethasone, and daratumumab; MedDRA = Medical Dictionary for Regulatory Activities

Treatment-emergent adverse events were defined as any adverse event with an onset after the administration of the first dose and within 30 days of the last dose of any investigational product.  Adverse events were coded using MedDRA (version 22.0).

Source:  Table 14-6.5.2 of Study 20160275

## Deaths

Fatal adverse events were reported for a higher incidence of subjects in the KdD group (9.7 % ) compared with the Kd group (5.2 % ) (Table 11). At the new safety data cutoff, no additional subjects in either the KdD group or the Kd group had a fatal adverse event

Fatal adverse events of the SOCs with a ≥ 1 % difference in the KdD group compared with the Kd group (KdD, Kd) were infections and infestations (4.5 % , 2.6 % ) and cardiac disorders (1.3 % , 0.0 % ) (Table 11). No fatal adverse events by SOC occurred more frequently ( ≥ 1 % difference) in the Kd group compared with the KdD group.

The only fatal adverse event that occurred with a ≥ 1 % higher subject incidence in the KdD group compared with the Kd group was pneumonia (KdD:  1.3 % , Kd:  0.0 % ) (Table 7).No fatal adverse events occurred with a ≥ 1 % higher subject incidence in the Kd group than in the KdD group.

For the reported events of death and sudden death, in the KdD group no clear etiology (eg, infections, cardiac disease, or disease progression) was identified.  For the reported events from the SOC cardiac disorders, no other cardiac cause (eg, myocardial infarction or cardiac arrythmia) was identified.

Events from the SOC infections and infestations accounted for most fatal adverse events in the KdD group and included septic shock (5 subjects [1.6 % ]), pneumonia (4 subjects [1.3 % ]), and sepsis (3 subjects [1.0 % ]) (Table 11).

In the Kd group, infections accounted for the largest group of fatal adverse events and included sepsis (2 subjects [1.3 % ]), septic shock (1 subject [0.7 % ]), and influenza (1 subject [0.7 % ]) (Table 11).  For the 2 cases of sepsis, there was no direct evidence of infection in 1 case as no cultures were taken and the etiology of the sepsis in the other case was chronic renal failure.  For the 1 case of septic shock, lung infection appeared to be the primary source of infection (ie, infectious pneumonitis/pneumopathy).  For the 1 case of influenza, the subject developed respiratory tract infection and was later diagnosed with influenza A virus infection.

<div style=\"page-break-after: always\"></div>

Table 11 .  Fatal Adverse Events by System Organ Class and Preferred Term (Safety Population)

| System Organ Class Preferred Term                                    | Kd (N = 153) n ( % )   | KdD (N = 308) n ( % )   |
|----------------------------------------------------------------------|------------------------|-------------------------|
| Number of subjects reporting treatment-emergent fatal adverse events | 8 (5.2)                | 30 (9.7)                |
| Infections and infestations                                          | 4 (2.6)                | 14 (4.5)                |
| Septic shock                                                         | 1 (0.7)                | 5 (1.6)                 |
| Pneumonia                                                            | 0 (0.0)                | 4 (1.3)                 |
| Sepsis                                                               | 2 (1.3)                | 3 (1.0)                 |
| Acinetobacter infection                                              | 0 (0.0)                | 1 (0.3)                 |
| Respiratory tract infection                                          | 0 (0.0)                | 1 (0.3)                 |
| Influenza                                                            | 1 (0.7)                | 0 (0.0)                 |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps)  | 2 (1.3)                | 4 (1.3)                 |
| Plasma cell myeloma                                                  | 2 (1.3)                | 4 (1.3)                 |
| Cardiac disorders                                                    | 0 (0.0)                | 4 (1.3)                 |
| Cardiac arrest                                                       | 0 (0.0)                | 2 (0.6)                 |
| Cardiac failure                                                      | 0 (0.0)                | 1 (0.3)                 |
| Cardio-respiratory arrest                                            | 0 (0.0)                | 1 (0.3)                 |
| General disorders and administration site conditions                 | 1 (0.7)                | 3 (1.0)                 |
| Sudden death                                                         | 0 (0.0)                | 2 (0.6)                 |
| Death                                                                | 1 (0.7)                | 1 (0.3)                 |
| Respiratory, thoracic and mediastinal disorders                      | 1 (0.7)                | 2 (0.6)                 |
| Pulmonary oedema                                                     | 0 (0.0)                | 1 (0.3)                 |
| Respiratory failure                                                  | 0 (0.0)                | 1 (0.3)                 |
| Pulmonary embolism                                                   | 1 (0.7)                | 0 (0.0)                 |
| Injury, poisoning and procedural complications                       | 0 (0.0)                | 1 (0.3)                 |
| Tracheal obstruction                                                 | 0 (0.0)                | 1 (0.3)                 |
| Metabolism and nutrition disorders                                   | 0 (0.0)                | 1 (0.3)                 |
| Tumour lysis syndrome                                                | 0 (0.0)                | 1 (0.3)                 |
| Nervous system disorders                                             | 0 (0.0)                | 1 (0.3)                 |
| Cerebrovascular accident                                             | 0 (0.0)                | 1 (0.3)                 |

Kd = carfilzomib and dexamethasone; KdD = carfilzomib, dexamethasone, and daratumumab; MedDRA = Medical Dictionary for Regulatory Activities

Treatment-emergent adverse events were defined as any adverse event with an onset after the administration of the first dose and within 30 days of the last dose of any investigational product.  Adverse events were coded using MedDRA (version 22.0).

Source:  Table 14-6.6.2 of Study 20160275

Among subjects with fatal adverse events, the median age of subjects with fatal adverse events was higher in the KdD group (68.5 years) compared with the Kd group (61.0 years) (Table 8).  In contrast,

<div style=\"page-break-after: always\"></div>

the median age of subjects was 64.0 years in the KdD group and 64.5 years in the Kd group for the ITT population.

Subgroup analysis of the fatal adverse events by age are provided in Table 8.  In the KdD group, 13.7 % of subjects in the ≥ 65 years subgroup had a fatal adverse event compared with 6.2 % of subjects in the &lt; 65 years group.  By comparison, in the Kd group, 2.6 % of subjects in the ≥ 65 years subgroup had a fatal adverse event compared with 7.8 % of subjects in the &lt; 65 years group.  This data suggests that among subjects ≥ 65 years, the risk of a fatal adverse event was higher in subjects treated with KdD compared with Kd.  Among subjects &lt; 65 years, the risk of a fatal adverse event was similar in the KdD and Kd groups.  Of note, in the ITT population, the proportion of subjects ≥ 65 years was similar in the KdD (47.8 % ) and Kd (50.0 % ) groups, indicating that the observed imbalance in fatal adverse events in subjects ≥ 65 years was not because of an imbalance at time of study entry.

In the KdD group, 14.3 % of subjects in the ≥ 75 years subgroup had a fatal adverse event compared with 9.3 % of subjects in the &lt; 75 years subgroup (Table 12).  By comparison, in the Kd group, 0.0 % of subjects in the ≥ 75 years subgroup had a fatal adverse event compared with 6.1 % of subjects in the &lt; 75 years subgroup.  This data suggests that among subjects ≥ 75 years, the risk of a fatal adverse event was higher in subjects treated with KdD compared with Kd; however, the absolute number of fatal events among subjects ≥ 75 years was 4 and thus there is inherent uncertainty regarding any inferences that can be made based on the small number of events.  Among subjects &lt; 75 years, the risk of a fatal adverse event was higher in the KdD group (9.3 % ) compared with the Kd group (6.1 % ).  Of note, in the ITT population, the proportion of subjects ≥ 75 years was similar in the KdD (11.7 % ) and Kd (8.0 % ) groups, indicating that the observed imbalance in fatal adverse events in subjects ≥ 75 years was not because of an imbalance at time of study entry.

Table 12 . Subgroup Analysis of Fatal Adverse Events by Age (Safety Population)

|                                        | Age<65         | Age<65         | Age ≥65        | Age ≥65         | Age<75          | Age<75         | Age ≥ 75       | Age ≥ 75       |
|----------------------------------------|----------------|----------------|----------------|-----------------|-----------------|----------------|----------------|----------------|
|                                        | Kd             | KdD            | Kd             | KdD             | Kd              | KdD            | Kd             | KdD            |
| SystemOrganClass PreferredTerm         | (N = 77) n (%) | (N =162) n (%) | (N = 76) n (%) | (N = 146) n (%) | (N = 131) n (%) | (N =280) n (%) | (N = 22) n (%) | (N = 28) n (%) |
| Numberofsubjects reportingfataladverse | 6 (7.8)        | 10 (6.2)       | 2 (2.6)        | 20 (13.7)       | 8 (6.1)         | 26 (9.3)       | 0 (0.0)        | 4 (14.3)       |

Kd=carfilzomibplusdexamethasone;KdD=carfilzomib,dexamethasone,anddaratumumab;MedDRA=MedicalDictionaryforRegulatoryActivities Treatment-emergentadverseeventsweredefinedasanyadverseeventwithanonsetaftertheadministrationofthefirstdoseofanystudytreatmentandwithinthe endofstudyor30daysofthelastdoseofanystudytreatment,whicheveroccursearlier.AdverseeventswerecodedusingMedDRA(version22.0). Source:Table14-6.4.405andTable14-6.904.403inAppendix4

Of the subjects with a fatal adverse event, a lower proportion of subjects in the KdD group (46.7 % ) compared with the Kd group (75.0 % ) had a frailty status of fit at baseline.  A higher proportion of subjects in the KdD group (33.3 % ) compared with the Kd group (12.5 % ) had a frailty status of intermediate fitness.  Of note, in the ITT population, a higher proportion of subjects in the KdD group (56.4 % ) compared with the Kd group (44.2 % ) had a frailty status of fit at baseline.  A lower proportion of subjects in the KdD group (17.3 % ) compared with the Kd group (23.4 % ) had a frailty status of intermediate fitness at baseline.

Subgroup analyses by derived frailty status are provided in Table 13  Frailty status was derived as a composite of the age, functional status, and comorbidities.  Among subjects with a frailty status of fit, the proportion of subjects who had a fatal adverse event was similar in the KdD group (7.9 % ) compared with the Kd group (3.8 % ).  Among subjects having a frailty status of intermediate, a higher proportion of subjects in the KdD group (29.4 % ) had a fatal adverse event compared with the Kd group (0.0 % ).

Among subjects with a frailty status of intermediate, the proportion of subjects who had a fatal adverse event was similar in the KdD group (8.0 % ) compared with the Kd group (8.8 % ).  Among subjects having a

<div style=\"page-break-after: always\"></div>

frailty status of intermediate, a higher proportion of subjects in the KdD group (18.9 % ) had a fatal adverse event compared with the Kd group (2.9 % ).

Table 13 . Overview of Adverse Events by Frailty Status Derived (Fit, Intermediate, and Frail) (Safety Population)

|                                                              | Kd n (%)    | Kd n (%)     | Kd n (%)    | Kd n (%)   | KdD n (%)   | KdD n (%)    | KdD n (%)   | KdD n (%)   |
|--------------------------------------------------------------|-------------|--------------|-------------|------------|-------------|--------------|-------------|-------------|
|                                                              | Fit         | Intermediate | Frail       | Total      | Fit         | Intermediate | Frail       | Total       |
| Analysis set: safety                                         | 26          | 23           | 20          | 69         | 76          | 34           | 27          | 137         |
| Any adverse event                                            | 26 (100.0%) | 22 (95.7%)   | 20 (100.0%) | 68 (98.6%) | 76 (100.0%) | 34 (100.0%)  | 26 (96.3%)  | 136 (99.3%) |
| Maximum toxicity grade                                       |             |              |             |            |             |              |             |             |
| Grade 1                                                      | 0 (0.0%)    | 1 (4.3%)     | 0 (0.0%)    | 1 (1.4%)   | 0 (0.0%)    | 0 (0.0%)     | 1 (3.7%)    | 1 (0.7%)    |
| Grade 2                                                      | 6 (23.1%)   | 0 (0.0%)     | 2 (10.0%)   | 8 (11.6%)  | 14 (18.4%)  | 4 (11.8%)    | 4 (14.8%)   | 22 (16.1%)  |
| Grade 3                                                      | 12 (46.2%)  | 18 (78.3%)   | 15 (75.0%)  | 45 (65.2%) | 39 (51.3%)  | 13 (38.2%)   | 14 (51.9%)  | 66 (48.2%)  |
| Grade 4                                                      | 7 (26.9%)   | 3 (13.0%)    | 2 (10.0%)   | 12 (17.4%) | 17 (22.4%)  | 7 (20.6%)    | 5 (18.5%)   | 29 (21.2%)  |
| Grade 5                                                      | 1 (3.8%)    | 0 (0.0%)     | 1 (5.0%)    | 2 (2.9%)   | 6 (7.9%)    | 10 (29.4%)   | 2 (7.4%)    | 18 (13.1%)  |
| Any serious adverse event                                    | 14 (53.8%)  | 8 (34.8%)    | 13 (65.0%)  | 35 (50.7%) | 40 (52.6%)  | 24 (70.6%)   | 16 (59.3%)  | 80 (58.4%)  |
| Adverse event leading to discontinuation of carfilzomib      | 4 (15.4%)   | 7 (30.4%)    | 8 (40.0%)   | 19 (27.5%) | 17 (22.4%)  | 13 (38.2%)   | 7 (25.9%)   | 37 (27.0%)  |
| Adverse event leading to discontinuationof dexamethasone     | 6 (23.1%)   | 7 (30.4%)    | 8 (40.0%)   | 21 (30.4%) | 9 (11.8%)   | 6 (17.6%)    | 4 (14.8%)   | 19 (13.9%)  |
| Adverse event leading to discontinuationof daratumumab       | 0 (0.0%)    | 0 (0.0%)     | 0 (0.0%)    | 0 (0.0%)   | 8 (10.5%)   | 6 (17.6%)    | 2 (7.4%)    | 16 (11.7%)  |
| Adverseeventleadingto discontinuation of all study treatment | 4 (15.4%)   | 6 (26.1%)    | 7 (35.0%)   | 17 (24.6%) | 7 (9.2%)    | 6 (17.6%)    | 2 (7.4%)    | 15 (10.9%)  |

Kd =carfilzomib plus dexamethasone;KdD=carfilzomib,dexamethasone,and daratumumab;MedDRA=Medical Dictionary for Regulatory Activities;NCl-CTCAE = NationalCancerInstitute-CommonTerminologyCriteriaforAdverseEvents

Page 2 of 2

Treatment-emergent adverseeventsweredefined asany adverseeventwith an onset afterthe administrationof thefirstdoseof anystudytreatment andwithin the end of study or 30 days of the last dose of any study treatment, whichever occurs earlier. Adverse events were coded using MedDRA (version 22.0) and graded using NCI-CTCAE (version 4.03).

Source:Table14-6.1.410inAppendix4

Given the comorbidities are included as a component of frailty status, comorbidities among subjects with a fatal adverse event, by treatment group, are provided in Table 10.  Comorbidities were assessed using the Charlson Comorbidity Index (CCI) (adapted from Lonial and Nooka, 2016 and Palumbo et al, 2015). Among subjects with a fatal adverse event, a higher proportion of subjects in the KdD group (17 subjects [56.7 % ]) compared with the Kd group (0 subjects) had baseline comorbidities per the CCI.  Per protocol, the CCI should only have been assessed among subjects ≥ 65 years.  In the KdD group, 20 of 30 subjects with fatal adverse events were ≥ 65 years and would have had the CCI assessed.  In contrast, in the Kd group, 2 of 8 subjects with a fatal adverse event were ≥ 65 years and would have had the CCI assessed. Thus, the higher proportion of comorbidities as assessed by the CCI in the KdD group may reflect the larger proportion of subjects with fatal adverse events who were ≥ 65 years, rather than a true imbalance in baseline comorbidities.

<div style=\"page-break-after: always\"></div>

Table 14 . Fatal Adverse Events by Charlson Comorbidity Index Category (Safety Population: Subjects with Fatal Adverse Events)

| Charlson Comorbidity Index Category                                                                                 | Kd (N = 8) n (%)   | KdD (N = 30) n (%)   |
|---------------------------------------------------------------------------------------------------------------------|--------------------|----------------------|
| Number of subjectswith a treatment-emergent fatal adverseeventreportingacomorbiditypertheCharlson Comorbidity Index | 0 (0.0)            | 17 (56.7)            |
| Tumor without Metastasis                                                                                            | 0 (0.0)            | 5 (16.7)             |
| Diabeteswithout Chronic Complication                                                                                | 0 (0.0)            | 4 (13.3)             |
| Chronic Pulmonary Disease                                                                                           | 0 (0.0)            | 3 (10.0)             |
| Myocardial Infarction                                                                                               | 0 (0.0)            | 3 (10.0)             |
| CerebrovascularDisease                                                                                              | 0 (0.0)            | 2 (6.7)              |
| Congestive Heart Failure                                                                                            | 0 (0.0)            | 2 (6.7)              |
| Peripheral VascularDisease                                                                                          | 0 (0.0)            | 2 (6.7)              |
| Renal Disease                                                                                                       | 0 (0.0)            | 1 (3.3)              |
| Rheumatic Disease                                                                                                   | 0 (0.0)            | 1 (3.3)              |

Kd = carfilzomib plus dexamethasone; KdD = carfilzomib, dexamethasone, and daratumumab

Treatment-emergent adverse eventswere defined as any adverse event with an onset after the administrationofthefirstdoseofanystudytreatmentandwithintheendofstudyor30daysofthelastdose ofanystudytreatment,whicheveroccursearlier. For each individual Charlson Comorbidity category, counted subjects who reported a score of ≥ 1. Source:Table14-6.6.403ofStudy20160275

The median (range) time from initial diagnosis to randomization for subjects with a fatal adverse event was higher in the KdD group (42.15 [0.7 to 146.2] months) compared with the Kd group (24.05 [14.4 to 60.8] months). The median total number of prior regimens was 2.0 for the KdD group and 1.5 for the Kd group. A higher incidence of subjects in the KdD group (76.7 % ) compared with the Kd group (37.5 % ) were refractory to the last prior line of therapy.  However, there was no apparent difference in the International Staging System stage, cytogenetic risk (determined by fluorescent in situ hybridization [FiSH]), or best overall response to prior therapy.

Among subjects with a fatal adverse event, 6 subjects in the KdD group and 3 subjects in the Kd group had evidence of progressive disease as assessed by the investigator. The median time from first progressive disease to fatal adverse events was similar in the KdD group (1.05 months) compared with the Kd group (1.09 months).

## Adverse events leading to discontinuation

Overall, 21.1% of subjects in the KdD group and 21.6% of subjects in the Kd group had at least 1 adverse event leading to discontinuation of carfilzomib. The most frequently reported (occurring in ≥ 2% of subjects in either treatment group [KdD, Kd]) adverse events that led to treatment discontinuation of carfilzomib were cardiac failure (1.9%, 2.0%), hypertension (1.3%, 2.0%), and acute kidney injury (0.3%, 2.0%). Adverse events leading to the discontinuation of carfilzomib which occurred more frequently (≥ 1% difference) in the KdD group compared with the Kd group included fa tigue, pneumonia, and septic shock. Adverse events leading to the discontinuation of carfilzomib which occurred more frequently (≥ 1% difference) in the Kd group compared with the KdD group included acute kidney injury and proteinuria.

The most frequently reported (occurring in ≥ 1% of subjects in either treatment group [KdD, Kd]) grade ≥ 3 adverse events that led to discontinuation of carfilzomib were fatigue (1.9%, 0.7%), hypertension (1.3%, 1.3%), cardiac failure (1.0%, 1.3%), acute kidney injury (0.3%, 2.0%), thrombotic

<div style=\"page-break-after: always\"></div>

thrombocytopenic purpura (0.6%, 1.3%), plasma cell myeloma (0.6%, 1.3%), pulmonary edema (0.6%, 1.3%), pneumonia (1.3%, 0.0%), proteinuria (0.3%, 1.3%), and septic shock (1.0%, 0.0%).

Overall, 9.1% of subjects in the KdD group had at least 1 adverse event leading to the discontinuation of daratumumab. The most frequently reported (occurring in ≥ 1% of subjects) adverse events that led to the discontinuation of daratumumab were cardiac failure (1.0%), pneumonia (1.3%), and septic shock (1.0%).

The most frequently reported (occurring in ≥ 1% of subjects in the KdD group) grade ≥ 3 adverse events that led to the discontinuation of daratumumab were pneumonia (1.3%) and septic shock (1.0%).

<div style=\"page-break-after: always\"></div>

Table 15 . Treatment-emergent Adverse Events Leading to Any Study Treatment Discontinuation by System Organ Class and Preferred Term - Reported for at Least 1% of Subjects in Either Group (Safety Population)

| System Organ Class Preferred Term                                                                              | Kd (N = 153) n (%)   | KdD (N = 308) n (%)   |
|----------------------------------------------------------------------------------------------------------------|----------------------|-----------------------|
| Number of subjects reporting treatment- emergent adverse events leading to any study treatment discontinuation | 38 (24.8)            | 69 (22.4)             |
| Blood and lymphatic system disorders                                                                           | 2 (1.3)              | 3 (1.0)               |
| Thrombotic thrombocytopenic purpura                                                                            | 2 (1.3)              | 2 (0.6)               |
| Cardiac disorders                                                                                              | 6 (3.9)              | 17 (5.5)              |
| Cardiac failure                                                                                                | 3 (2.0)              | 6 (1.9)               |
| General disorders and administration site conditions                                                           | 5 (3.3)              | 8 (2.6)               |
| Fatigue                                                                                                        | 1 (0.7)              | 6 (1.9)               |
| Asthenia                                                                                                       | 2 (1.3)              | 2 (0.6)               |
| Infections and infestations                                                                                    | 3 (2.0)              | 14 (4.5)              |
| Pneumonia                                                                                                      | 0 (0.0)              | 4 (1.3)               |
| Septic shock                                                                                                   | 0 (0.0)              | 3 (1.0)               |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps)                                            | 4 (2.6)              | 2 (0.6)               |
| Plasma cell myeloma                                                                                            | 2 (1.3)              | 2 (0.6)               |
| Renal and urinary disorders                                                                                    | 6 (3.9)              | 3 (1.0)               |
| Acute kidney injury                                                                                            | 3 (2.0)              | 2 (0.6)               |
| Proteinuria                                                                                                    | 2 (1.3)              | 1 (0.3)               |
| Respiratory, thoracic and mediastinal                                                                          | 3 (2.0)              | 10 (3.2)              |
| Dyspnoea                                                                                                       | 1 (0.7)              | 4 (1.3)               |
| Pulmonary oedema                                                                                               | 2 (1.3)              | 2 (0.6)               |
| Vascular disorders                                                                                             | 3 (2.0)              | 4 (1.3)               |
| Hypertension                                                                                                   | 3 (2.0)              | 4 (1.3)               |

Compared with the CANDOR primary analysis, the subject incidence of adverse events leading to carfilzomib discontinuation was nominally higher in the KdD group (23.4%) compared with the Kd group (21.6%) in the 120-day Safety Update.

## Adverse events leading to dose reduction

Adverse events that led to the reduction of carfilzomib are provided in Table 12.

<div style=\"page-break-after: always\"></div>

Table 16 . Treatment-emergent Adverse Events Leading to Reduction of Carfilzomib by Preferred Term

| Preferred Term                                                                                  | Kd (N = 153) n (%)   | KdD (N = 308) n (%)   |
|-------------------------------------------------------------------------------------------------|----------------------|-----------------------|
| Number of subjects reporting treatment-emergent adverse events leading to Carfilzomib reduction | 30 (19.6)            | 77 (25.0)             |
| Hypertension                                                                                    | 5 (3.3)              | 24 (7.8)              |
| Dyspnoea                                                                                        | 6 (3.9)              | 14 (4.5)              |
| Fatigue                                                                                         | 3 (2.0)              | 11 (3.6)              |
| Asthenia                                                                                        | 2 (1.3)              | 4 (1.3)               |
| Diarrhoea                                                                                       | 1 (0.7)              | 4 (1.3)               |
| Thrombocytopenia                                                                                | 1 (0.7)              | 4 (1.3)               |
| Anaemia                                                                                         | 0 (0.0)              | 4 (1.3)               |
| Lethargy                                                                                        | 1 (0.7)              | 3 (1.0)               |
| Hyperbilinubinaemia                                                                             | 0 (0.0)              | 3 (1.0)               |
| Muscle spasms                                                                                   | 2 (1.3)              | 2 (0.6)               |
| Neuropathy peripheral                                                                           | 1 (0.7)              | 2 (0.6)               |
| Alanine aminotransferase increased                                                              | 0 (0.0)              | 2 (0.6)               |
| Aspartate aminotransferase increased                                                            | 0 (0.0)              | 2 (0.6)               |
| Bronchitis                                                                                      | 0 (0.0)              | 2 (0.6)               |
| Cardiac failure                                                                                 | 0 (0.0)              | 2 (0.6)               |
| Peripheral motor neuropathy                                                                     | 0 (0.0)              | 2 (0.6)               |
| Peripheral sensory neuropathy                                                                   | 0 (0.0)              | 2 (0.6)               |
| Pneumonia                                                                                       | 0 (0.0)              | 2 (0.6)               |
| Polyneuropathy                                                                                  | 0 (0.0)              | 2 (0.6)               |
| Headache                                                                                        | 1 (0.7)              | 1 (0.3)               |
| Hepatic enzyme increased                                                                        | 1 (0.7)              | 1 (0.3)               |
| Hepatic function abnormal                                                                       | 1 (0.7)              | 1 (0.3)               |
| Liver disorder                                                                                  | 1 (0.7)              | 1 (0.3)               |
| Neutropenia                                                                                     | 1 (0.7)              | 1 (0.3)               |
| Abdominal pain                                                                                  | 0 (0.0)              | 1 (0.3)               |
| Acute kidney injury                                                                             | 0 (0.0)              | 1 (0.3)               |
| Alanine aminotransferase abnormal                                                               | 0 (0.0)              | 1 (0.3)               |
| Arteriospasm coronary                                                                           | 0 (0.0)              | 1 (0.3)               |
| Blood creatinine increased                                                                      | 0 (0.0)              | 1 (0.3)               |
| Cardiac failure congestive                                                                      | 0 (0.0)              | 1 (0.3)               |
| Cardiotoxicity                                                                                  | 0 (0.0)              | 1 (0.3)               |
| Chronic kidney disease                                                                          | 0 (0.0)              | 1 (0.3)               |
| Chronic obstructive pulmonary disease                                                           | 0 (0.0)              | 1 (0.3)               |

<div style=\"page-break-after: always\"></div>

<!-- image -->

| Preferred Term                  | Kd (N = 153) n (%)   | KdD (N = 308) n (%)   |
|---------------------------------|----------------------|-----------------------|
| Food aversion                   | 0 (0.0)              | 1 (0.3)               |
| Hypertransaminasaemia           | 0 (0.0)              | 1 (0.3)               |
| Liver function test increased   | 0 (0.0)              | 1 (0.3)               |
| Muscular weakness               | 0 (0.0)              | 1 (0.3)               |
| Neuralgia                       | 0 (0.0)              | 1 (0.3)               |
| Proteinuria                     | 0 (0.0)              | 1 (0.3)               |
| Pulmonary arterial hypertension | 0 (0.0)              | 1 (0.3)               |
| Pulmonary oedema                | 0 (0.0)              | 1 (0.3)               |
| Sepsis                          | 0 (0.0)              | 1 (0.3)               |
| Sinusitis                       | 0 (0.0)              | 1 (0.3)               |
| Tooth infection                 | 0 (0.0)              | 1 (0.3)               |
| Vertigo                         | 0 (0.0)              | 1 (0.3)               |
| Vomiting                        | 0 (0.0)              | 1 (0.3)               |
| Weight decreased                | 0 (0.0)              | 1 (0.3)               |
| Haemolysis                      | 2 (1.3)              | 0 (0.0)               |
| Blood bilirubin increased       | 1 (0.7)              | 0 (0.0)               |
| Cardiac failure acute           | 1 (0.7)              | 0 (0.0)               |
| Cough                           | 1 (0.7)              | 0 (0.0)               |
| Dyspnoea exertional             | 1 (0.7)              | 0 (0.0)               |
| Gastrointestinal disorder       | 1 (0.7)              | 0 (0.0)               |
| Pulmonary embolism              | 1 (0.7)              | 0 (0.0)               |
| Renal impaiment                 | 1 (0.7)              | 0 (0.0)               |
| Sinus tachycardia               | 1 (0.7)              | 0 (0.0)               |
| Transaminases increased         | 1 (0.7)              | 0 (0.0)               |

Kd: carfilzomib and dexamethasone; KdD: carfilzomib, dexamethasone, and daratumumab; Treatment-emergent adverse events are defined as any adverse events with an onset after the administration of the first dose of any study treatment and within the end of study or 30 days of the last dose of any study treatment, whichever occurs earlier. Adverse events were coded using MedDRA (version 22.0).

At the updated safety data and, consistent with the CANDOR primary analysis , adverse events leading to dose reduction of carfilzomib occurred at a higher subject incidence in the KdD group (27.3%) compared with the Kd group (20.9%) .

## Adverse events of interest

Adverse events of interest were prespecified medical concepts identified based on their known association with subjects with advanced myeloma, proteasome inhibition, or carfilzomib or daratumumab. Adverse events of interest for both carfilzomib and daratumumab include haemorrhage, tumour lysis syndrome, and hepatitis B reactivation.

## Carfilzomib adverse events of interest

## Cardiac arrythmias

Cardiac arrythmias (standardized MedDRA query, narrow scope [SMQN]) adverse events of interest were reported for 7.1 % of subjects in the KdD group and 5.9 % of subjects in the Kd group.

<div style=\"page-break-after: always\"></div>

Grade ≥ 3 cardiac arrythmias (SMQN) adverse events of interest were reported for a similar incidence of subjects in the KdD group (2.9 % ) compared with the Kd group (2.6 % ). The only preferred term with a ≥ 1 % higher subject incidence in the KdD group than in the Kd group was atrial fibrillation (KdD:  2.3 % , Kd: 0.7 % ). Serious cardiac arrythmias (SMQN) adverse events of interest were reported for a lower incidence of subjects in the KdD group (2.3 % ) compared with the Kd group (1.3 % ).

No fatal cardiac arrythmias events of interest occurred in either treatment group.

## Cardiac failure

Cardiac failure (SMQN) adverse events of interest were reported for 7.5 % of subjects in the KdD group compared with 10.5 % of subjects in the Kd group.

Grade ≥ 3 cardiac failure (SMQN) adverse events of interest were reported for a lower incidence of subjects in the KdD group (3.9 % ) compared with the Kd group (8.5 % ).

Fatal cardiac failure (SMQN) adverse events of interest were reported for 0.3 % of subjects in the KdD group and 0.0 % of subjects in the Kd group.

## Cardiomyopathy

Cardiomyopathy (SMQN) adverse events of interest were reported for 1.3 % of subjects in the KdD group and 2.6 % of subjects in the Kd group.

## Ischemic heart disease

Ischemic heart disease (SMQN) adverse events of interest were reported for a similar incidence of subjects in the KdD group (4.2 % ) compared with the Kd group (3.3 % ).

Grade ≥ 3 ischemic heart disease (SMQN) adverse events of interest were reported for 2.9 % of subjects in the KdD group and 2.6 % of subjects in the Kd group.

## Myocardial Infarction

Myocardial infarction (SMQN) adverse events of interest were reported for a similar incidence of subjects in the KdD group (1.3 % ) compared with the Kd group (0.7 % ). No fatal myocardial infarction (SMQN) events of interest were reported for either treatment group.

## Torsades de Pointes/QT Prolongation

Torsades de pointes/QT prolongation (SMQN) adverse events of interest were reported for 0.6 % of subjects in the KdD group and 0.0 % of subjects in the Kd group. No grade ≥ 3 or serious torsades de pointes/QT prolongation (SMQN) adverse events of interest occurred in either treatment group.

## Hematopoietic Erythropenia

Hematopoietic erythropenia (standardized MedDRA query, broad scope [SMQB]) adverse events of interest were reported for a similar incidence of subjects in the KdD group (33.1 % ) compared with the Kd group (32.7 % ).

Grade ≥ 3 hematopoietic erythropenia (SMQB) adverse events of interest were reported for a higher incidence of subjects in the KdD group (16.9 % ) compared with the Kd group (14.4 % ). The only preferred term with a ≥ 1 % higher subject incidence in the KdD group than in the Kd group was anemia (KdD:  16.6 % , Kd:  14.4 % ).

## Haematopoietic Leukopenia

<div style=\"page-break-after: always\"></div>

Hematopoietic leukopenia (SMQN) adverse events of interest were reported for a higher incidence of subjects in the KdD group (23.1 % ) compared with the Kd group (17.0 % ). Preferred terms that occurred with a ≥ 1 % higher subject incidence in the KdD group compared with the Kd group (KdD, Kd) were neutropenia (14.0 % , 9.8 % ), lymphopenia (8.8 % , 7.8 % ), and leukopenia (6.5 % , 3.9 % ).

Grade ≥ 3 hematopoietic leukopenia (SMQN) adverse events of interest were reported for a higher incidence of subjects in the KdD group (15.3 % ) compared with the Kd group (11.8 % ). Preferred terms that occurred with a ≥ 1 % higher subject incidence in the KdD group compared with the Kd group (KdD, Kd) were neutropenia (8.4 % , 5.9 % ) and leukopenia.

## Hematopoietic Thrombocytopenia

Hematopoietic thrombocytopenia (SMQN) adverse events of interest were reported for a higher incidence of subjects in the KdD group (37.3 % ) compared with the Kd group (30.1 % ). The only preferred term that occurred with a ≥ 1 % higher subject incidence in the KdD group compared with the Kd group was thrombocytopenia (KdD:  37.3 % , Kd:  29.4 % ).

Grade ≥ 3 hematopoietic thrombocytopenia (SMQN) adverse events of interest were reported for a higher incidence of subjects in the KdD group (24.7 % ) compared with the Kd group (16.3 % ). The only preferred term that occurred with a ≥ 1 % higher subject incidence in the KdD group compared with the Kd group was thrombocytopenia (KdD:  24.4 % , Kd:  16.3 % ).

## Hemorrhage adverse events

Hemorrhage terms (excluding laboratory terms) (SMQN) adverse events of interest were reported for 14.3 % of subjects in the KdD group and 11.8 % of subjects in the Kd group.

Grade ≥ 3 hemorrhage terms (excluding laboratory terms) (SMQN) adverse events of interest were reported for a similar incidence of subjects in the KdD group (1.9 % ) compared with the Kd group (2.6 % ).

## Hepatic adverse events

Hepatic failure, fibrosis and cirrhosis and other liver damage-related conditions (SMQN) adverse events of interest were reported for 1.9 % of subjects in the KdD group and 3.9 % of subjects in the Kd group. Liverrelated investigations, signs and symptoms (SMQN) adverse events of interest were reported for 11.4 % of subjects in the KdD group and 8.5 % of subjects in the Kd group

Grade ≥ 3 hepatic failure, fibrosis and cirrhosis and other liver damage-related conditions (SMQN) adverse events of interest were reported for a similar incidence of subjects in the KdD group (1.0 % ) compared with the Kd group (0.7 % ). Grade ≥ 3 liver-related investigations, signs and symptoms (SMQN) adverse events of interest were reported for a higher incidence of subjects in the KdD group (4.5 % ) compared with the Kd group (2.0 % ). The only preferred term that occurred with a ≥ 1 % higher subject incidence in the Kd group compared with the KdD group was increased aspartate aminotransferase (KdD:  0.3 % , Kd: 2.0 % ).

## Infection adverse events

Adverse events of the SOC of infections and infestations were reported for a higher incidence of subjects in the KdD group (81.2 % ) compared with the Kd group (66.7 % )( Table 13).

After adjusting for exposure, the risk estimate (95 % CI) of adverse events was higher in the KdD group compared with the Kd group (197.04 [174.07, 223.05] versus 166.72 [137.31, 202.43]; per 100 subject-years, respectively).

<div style=\"page-break-after: always\"></div>

Table 17.  Infections and Infestations Adverse Events Occurring in ≥ 2 % of Subjects in Either Group by Preferred Term (Safety Population)

| System Organ Class Preferred Term   | Kd (N = 153) n ( % )   | KdD (N = 308) n ( % )   |
|-------------------------------------|------------------------|-------------------------|
| Infections and Infestations         | 102 (66.7)             | 250 (81.2)              |
| Upper respiratory tract infection   | 35 (22.9)              | 90 (29.2)               |
| Pneumonia                           | 19 (12.4)              | 55 (17.9)               |
| Bronchitis                          | 18 (11.8)              | 52 (16.9)               |
| Influenza                           | 10 (6.5)               | 34 (11.0)               |
| Respiratory tract infection         | 8 (5.2)                | 31 (10.1)               |
| Nasopharyngitis                     | 13 (8.5)               | 27 (8.8)                |
| Urinary tract infection             | 4 (2.6)                | 18 (5.8)                |
| Lower respiratory tract infection   | 4 (2.6)                | 17 (5.5)                |
| Conjunctivitis                      | 3 (2.0)                | 16 (5.2)                |
| Sinusitis                           | 4 (2.6)                | 15 (4.9)                |
| Pharyngitis                         | 4 (2.6)                | 13 (4.2)                |
| Viral infection                     | 6 (3.9)                | 12 (3.9)                |
| Sepsis                              | 2 (1.3)                | 12 (3.9)                |
| Gastroenteritis                     | 5 (3.3)                | 9 (2.9)                 |
| Rhinitis                            | 4 (2.6)                | 8 (2.6)                 |
| Infection                           | 4 (2.6)                | 8 (2.6)                 |
| Lung infection                      | 3 (2.0)                | 8 (2.6)                 |
| Cellulitis                          | 4 (2.6)                | 4 (1.3)                 |
| Tracheitis                          | 3 (2.0)                | 4 (1.3)                 |

BIW = twice-weekly; Kd = carfilzomib plus dexamethasone; KdD = carfilzomib, dexamethasone, and daratumumab; MedDRA = Medical Dictionary for Regulatory Activities

Treatment-emergent adverse events were defined as any adverse events with an onset after the administration of the first dose of any study treatment and within the end of study or 30 days of the last dose of any study treatment, whichever occurred earlier.  Adverse events were coded using MedDRA (version 22.0).

Source:  Table 14-6.2.2 of Study 20160275

Overall, respiratory tract infections accounted for most treatment-emergent infections.  Additionally, the higher incidence of infections in the KdD group compared with the Kd group appears to be attributable to a higher incidence of respiratory tract infections.

The most frequently ( ≥ 10 % of subjects in either treatment group [KdD, Kd]) reported adverse events within the SOC of infections and infestations were the preferred terms of upper respiratory tract infection (29.2 % , 22.9 % ), pneumonia (17.9 % , 12.4 % ), bronchitis (16.9 % , 11.8 % ), influenza (11.0 % , 6.5 % ), and respiratory tract infection (10.1 % , 5.2 % ).

Analysis of the events using the respiratory tract infections (HLGT) adverse events of interest strategy showed a higher incidence in the KdD group (73.1 % ) compared with the Kd group (54.9 % ).

<div style=\"page-break-after: always\"></div>

The subject incidence of opportunistic infections and viral infections, which are events of interest for daratumumab, were also higher in the KdD group compared with the Kd group.  Opportunistic infections (JMQ) and viral infection (JMQ) adverse events of interest were reported for 9.1 % and 20.5 % of subjects in the KdD group compared with 3.9 % and 14.4 % in the Kd group.

Grade ≥ 3 adverse events of the SOC of infections and infestations were reported for a higher incidence of subjects in the KdD group (37.3 % ) compared with the Kd group (29.4 % ).

The most frequently ( ≥ 2 % of subjects in either treatment group [KdD, Kd]) reported grade ≥ 3 adverse events within the SOC of infections and infestations were of the preferred terms of pneumonia (13.3 % , 8.5 % ), sepsis (3.9 % , 1.3 % ), influenza (3.6 % , 0.7 % ), bronchitis (2.6 % , 1.3 % ), upper respiratory tract infection (2.6 % , 1.3 % ), lower respiratory tract infection (2.6 % , 0.7 % ), and urinary tract infection (1.3 % , 2.0 % ).

Fatal adverse events of the SOC of infections and infestations were reported for a higher incidence of subjects in the KdD group (4.5 % ) compared with the Kd group (2.6 % ). The preferred terms were septic shock (5 subjects [1.6 % ] in the KdD group, 1 subject [0.7 % ] in the Kd group), sepsis (3 subjects [1.0 % ] in the KdD group, 2 subjects [1.3 % ] in the Kd group), pneumonia (4 subjects [1.3 % ] in the KdD group), Acinetobacter infection (1 subject [0.3 % ] in the KdD group), respiratory tract infection (1 subject [0.3 % ] in the KdD group), and influenza (1 subject [0.7 % ] in the Kd group).  After adjusting for exposure, a higher risk estimate in the KdD group compared with the Kd group was reported for fatal adverse events (KdD:  4.24, Kd:  3.11; per 100 subject-years, respectively).

## Hepatitis B reactivation

Hepatitis B reactivation (AMQ) adverse events of interest were reported for 1 subject (0.3 % ) in the KdD group and 0.0 % of subjects in the Kd group.

## Respiratory tract infections

Respiratory tract infections (HLGT) adverse events of interest were reported for a higher incidence of subjects in the KdD group (73.1 % ) compared with the Kd group (54.9 % ). Preferred terms with a ≥ 1 % higher subject incidence in the KdD group than in the Kd group (KdD, Kd) were upper respiratory tract infection (29.2 % , 22.9 % ), pneumonia (17.9 % , 12.4 % ), bronchitis (16.9 % , 11.8 % ), influenza (11.0 % , 6.5 % ), respiratory tract infection (10.1 % , 5.2 % ), lower respiratory tract infection (5.5 % , 2.6 % ), sinusitis (4.9 % , 2.6 % ), pharyngitis (4.2 % , 2.6 % ), chronic sinusitis (1.6 % , 0.0 % ), respiratory syncytial virus infection (1.6 % , 0.0 % ), viral bronchitis (1.3 % , 0.0 % ), and tracheobronchitis (1.0 % , 0.0 % ).  The only preferred term with a ≥ 1 % higher subject incidence in the Kd group than in the KdD group was viral pneumonia (KdD:  0.0 % , Kd:  1.3 % ).

Grade ≥ 3 respiratory tract infections (HLGT) adverse events of interest were reported for a higher incidence of subjects in the KdD group (28.9 % ) compared with the Kd group (15.7 % ).

Fatal respiratory tract infections (HLGT) events of interest were reported for a higher incidence of subjects in the KdD group (1.6 % ) compared with the Kd group (0.7 % ). Fatal respiratory tract infections (HLGT) events of interest included pneumonia (4 subjects [1.3 % ]) and respiratory tract infection (1 subject [0.3 % ]) in the KdD group, and influenza (1 subject [0.7 % ]) in the Kd group.

## Infusion reaction adverse events

The adverse event infusion-related reaction was reported for a higher incidence of subjects in the KdD group (7.8 % ) compared with the Kd group (2.0 % ).

Grade ≥ 3 infusion-related reactions were reported for 0.6 % of subjects in the KdD group and 0.0 % of subjects in the Kd group.

<div style=\"page-break-after: always\"></div>

- Same date of first carfilzomib dosing: infusion reaction was reported for a higher incidence of subjects in the KdD group (12.7 % ) compared with the Kd group (0.7 % ). Grade ≥ 3 infusion reaction (AMQN) (event on same date of first carfilzomib dosing) adverse events of interest were reported for a similar incidence of subjects in the KdD group (1.6 % ) compared with the Kd group (0.7 % ).
- Any date of carfilzomib dosing: reported for a higher incidence of subjects in the KdD group (40.9 % ) compared with the Kd group (28.1 % ). Grade ≥ 3 infusion reaction (AMQN) (event on same date of any carfilzomib dosing) adverse events of interest were reported for a higher incidence of subjects in the KdD group (12.3 % ) compared with the Kd group (5.2 % ).

## Peripheral Neuropathy Adverse Events

Peripheral neuropathy (SMQN) adverse events of interest were reported for a higher incidence of subjects in the KdD group (17.2 % ) compared with the Kd group (8.5 % ). Grade ≥ 3 peripheral neuropathy (SMQN) adverse events of interest were reported for 1.0 % of subjects in the KdD group and 0.0 % of subjects in the Kd group.

## Dyspneas

Dyspneas (HLT) adverse events of interest were reported for 22.4 % of subjects in the KdD group and 24.2 % of subjects in the Kd group. Grade ≥ 3 dyspneas (HLT) adverse events of interest were reported for 3.9 % of subjects in the KdD group and 2.6 % of subjects in the Kd group.

## Interstitial lung disease

Interstitial lung disease (SMQN) adverse events of interest were reported for a similar incidence of subjects in the KdD group (1.9 % ) compared with the Kd group (1.3 % ). Grade ≥ 3 interstitial lung disease (SMQN) adverse events of interest were reported for 1.6 % of subjects in the KdD group and 0.0 % of subjects in the Kd group.

## Respiratory failure

Respiratory failure (SMQN) adverse events of interest were reported for a similar incidence of subjects in the KdD group (1.0 % ) compared with the Kd group (0.7 % ).

A fatal respiratory failure (SMQN) adverse event of interest was reported for 1 subject (0.3 % ) in the KdD group and 0.0 % of subjects in the Kd group.

## Renal adverse events

Acute renal failure (SMQN) adverse events of interest were reported for 5.8 % of subjects in the KdD group and 7.8 % of subjects in the Kd group.

Preferred terms with a ≥ 1 % higher subject incidence in the Kd group than in the KdD group (KdD, Kd) were acute kidney injury (3.9 % , 5.9 % ) and renal failure (1.0 % , 2.6 % ).

Grade ≥ 3 acute renal failure (SMQN) adverse events of interest were reported for a lower incidence of subjects in the KdD group (2.9 % ) compared with the Kd group (6.5 % ).

Preferred terms with a ≥ 1 % higher subject incidence in the Kd group than in the KdD group (KdD, Kd) were acute kidney injury (2.3 % , 4.6 % ), renal failure (0.3 % , 1.3 % ), and renal impairment (0.3 % , 1.3 % ).

## Reversible Posterior Leukoencephalopathy Syndrome Adverse Events

Reversible posterior leukoencephalopathy syndrome (AMQN) adverse events of interest were reported for a higher incidence of subjects in the KdD group (12.3 % ) compared with the Kd group (5.2 % ).

<div style=\"page-break-after: always\"></div>

Grade ≥ 3 reversible posterior leukoencephalopathy syndrome (AMQN) adverse events of interest were reported for 1.9 % of subjects in the KdD group and 0.0 % of subjects in the Kd group.

## Thromboembolic Adverse Events

Venous embolic and thrombotic events (SMQN) adverse events of interest were reported for 6.2 % of subjects in the KdD and 11.1 % of subjects in the Kd group.

Preferred terms with a ≥ 1 % higher subject incidence in the Kd group than in the KdD group (KdD, Kd) were pulmonary embolism (2.3 % , 4.6 % ) and deep vein thrombosis (1.6 % , 2.6 % ).

Grade ≥ 3 venous embolic and thrombotic events (SMQN) adverse events of interest were reported for a lower incidence of subjects in the KdD group (1.9 % ) compared with the Kd group (6.5 % ).

Fatal venous embolic and thrombotic events (SMQN) adverse event of interest were reported for a lower incidence of subjects in the KdD group (0.0 % ) compared with the Kd group (1 subject [0.7 % ]). The preferred term was pulmonary embolism.

## Thrombotic microangiopathy Adverse Events

Thrombotic thrombocytopenic purpura was reported for a similar incidence of subjects in the KdD group (0.6 % ) compared with the Kd group (1.3 % ), all grade ≥ 3 and serious.

## Tumor lysis syndrome

Tumor lysis syndrome (SMQN) adverse events of interest were reported for a similar incidence of subjects in the KdD group (1.0 % ) compared with the Kd group (0.7 % ), all grade ≥ 3.

Fatal tumor lysis syndrome (SMQN) adverse events of interest were reported for 1 subject (0.3 % ) in the KdD group and 0.0 % of subjects in the Kd group.

## Hypertension

Hypertension (SMQN) adverse events of interest were reported for 31.8 % of subjects in the KdD group and 28.8 % of subjects in the Kd group.

Grade ≥ 3 hypertension (SMQN) adverse events of interest were reported for a higher incidence of subjects in the KdD group (17.9 % ) compared with the Kd group (13.7 % ).

## Pulmonary hypertension

Pulmonary hypertension (SMQN) adverse events of interest were reported for a similar incidence of subjects in the KdD group (1.9 % ) compared with the Kd group (2.6 % ).

Grade ≥ 3 pulmonary hypertension (SMQN) adverse events of interest were reported for a similar incidence of subjects in the KdD group (1.0 % ) compared with the Kd group (0.0 % ).

## Daratumumab adverse events of interest

Hemorrhage, Hepatitis B reactivation and Tumor Lysis Syndrome are described above. No interference with cross-matching and red blood cell antibody screening (JMQ) adverse events of interest were reported for any treatment group.

## Oportunistic infection

Opportunistic infections (JMQ) adverse events of interest were reported for a higher incidence of subjects in the KdD group (9.1 % ) compared with the Kd group (3.9 % ). Grade ≥ 3 opportunistic infections (JMQ)

<div style=\"page-break-after: always\"></div>

adverse events of interest were reported for 1.0 % of subjects in the KdD group and 0.0 % of subjects in the Kd group.

## Viral infection

Reported for a higher incidence of subjects in the KdD group (20.5 % ) compared with the Kd group (14.4 % ). They included influenza, oral herpes and respiratory syncytial virus infection. Grade ≥ 3 viral infection (JMQ) adverse events of interest were reported for a higher incidence of subjects in the KdD group (6.2 % ) compared with the Kd group (2.0 % ), only for infuenza.

Fatal viral infection (JMQ) adverse events of interest were reported for 0.0 % of subjects in the KdD group and 1 subject (0.7 % ) in the Kd group (influenza).

## Infusion reaction

Infusion reaction (AMQ) adverse events for which the investigator considered there to be a reasonable possibility that the event may have been caused by daratumumab were considered as daratumumabrelated infusion reaction (AMQ) adverse events.

- Event on same date or next date of first daratumumab dosing: infusion reactions reported for 38 subjects (12.3 % ) in the KdD group. Grade ≥ 3 daratumumab-related infusion reaction (AMQN) (event on same date or next date of first daratumumab dosing) adverse events of interest were reported for 4 subjects (1.3 % ) in the KdD group.
- Event on same date or next date of any daratumumab dosing: reported for 56 subjects (18.2 % ) in the KdD group. Grade ≥ 3 daratumumab-related infusion reaction (AMQN) (event on same date or next date of any daratumumab dosing) adverse events of interest were reported for 7 subjects (2.3 % ) in the KdD group.

## Laboratory findings

The most frequently reported (reported for &gt; 10% of subjects in either treatment group) grade 3 laboratory toxicities in each treatment group (KdD, Kd) were decreases in lymphocytes (49.7%, 32.7%), decreases in leukocytes (18.2%, 8.5%), and decreases in hemoglobin (9.1%, 13.1%). The most frequently reported (reported for &gt; 5% of subjects in either treatment group) grade 4 laboratory toxicities in each treatment group were decreases in lymphocytes (KdD: 7.8%, Kd: 3.9%) (Table 14).

Table 14. Summary of Postbaseline Grade 3 or 4 Laboratory Toxicities (Safety Population)

<div style=\"page-break-after: always\"></div>

| Laboratory Panel Laboratory Parameter                    | Direction of Toxicity   | Post- baseline Grade   | Kd (N = 153) n(%)   | KdD (N = 308) n(%)   |
|----------------------------------------------------------|-------------------------|------------------------|---------------------|----------------------|
| Number of subjects with at least one laboratory toxicity | Any                     | Grade 3 or 4           | 82 (53.6)           | 210 (68.2)           |
| Hematology Panel                                         |                         |                        |                     |                      |
| Hemoglobin (g/L)                                         | Decrease                | Grade 3                | 20 (13.1)           | 28 (9.1)             |
| Lymphocytes (10^9/L)                                     | Decrease                | Grade 3                | 50 (32.7)           | 153 (49.7)           |
|                                                          |                         | Grade 4                | 6 (3.9)             | 24 (7.8)             |
| Neutrophils (10^9/L)                                     | Decrease                | Grade 3                | 12 (7.8)            | 28 (9.1)             |
|                                                          |                         | Grade 4                | 1 (0.7)             | 2(0.6)               |
| Platelets (10^9/L)                                       | Decrease                | Grade 3                | 11 (7.2)            | 47 (15.3)            |
|                                                          |                         | Grade 4                | 5 (3.3)             | 12 (3.9)             |
| Leukocytes (10^9/L)                                      | Decrease                | Grade 3                | 13 (8.5)            | 56 (18.2)            |
|                                                          |                         | Grade 4                | 1 (0.7)             | 2 (0.6)              |
| Chemistry Panel                                          |                         |                        |                     |                      |
| Albumin (g/L)                                            | Decrease                | Grade 3                | 3 (2.0)             | 1 (0.3)              |
| Alanine Aminotransferase (U/L)                           | Increase                | Grade 3                | 1 (0.7)             | 7 (2.3)              |
| Aspartate Aminotransferase (U/L)                         | Increase                | Grade 3                | 1 (0.7)             | 1 (0.3)              |
| Bilirubin (umol/L)                                       | Increase                | Grade 4                | 0 (0.0)             | 1 (0.3)              |
| Calcium (Corrected) (mg/dL)                              | Decrease                | Grade 3                | 1 (0.7)             | 2 (0.6)              |
|                                                          |                         | Grade 4                | 0 (0.0)             | 4 (1.3)              |
|                                                          | Increase                | Grade 3                | 2 (1.3)             | 0 (0.0)              |
|                                                          |                         | Grade 4                | 2 (1.3)             | 4 (1.3)              |
| Creatinine (umol/L)                                      | Increase                | Grade 3                | 2 (1.3)             | 6 (1.9)              |
| Potassium (mmol/L)                                       | Decrease                | Grade 3                | 0 (0.0)             | 11 (3.6)             |
|                                                          |                         | Grade 4                | 1 (0.7)             | 2(0.6)               |
|                                                          | Increase                | Grade 3                | 0 (0.0)             | 3 (1.0)              |
|                                                          |                         | Grade 4                | 0 (0.0)             | 2 (0.6)              |
| Sodium (mmol/L)                                          | Decrease                | Grade 3                | 8 (5.2)             | 8 (2.6)              |

CTCAE = Common Teminology Criteria for Adverse events; Kd = carfilzomib and dexamethasone; KdD = carfilzomib, dexamethasone, and daratumumab Laboratory abnormalities were graded using CTCAE version 4.03. Laboratory results from samples taken &gt; 30 days after the last administration of protocol therapy were excluded from the laboratory summaries.

Source:Table 14-7.5.1

## Adverse drug reactions

## Carfilzomib ADRs

Potential new adverse drug reactions (ADRs) for carfilzomib were evaluated based on the primary analysis of the KdD 20/56 mg/m 2  twice-weekly group from CANDOR but, according to the algorithm, no

<div style=\"page-break-after: always\"></div>

new ADRs for carfilzomib were identified. The ADRs on the prescribing information are based on the previously assessed trials with carfilzomib.

## Daratumumab ADRs

New ADRs for daratumumab were evaluated by Janssen's medical experts based on the safety data from CANDOR using the definition of ADRs from the ICH guideline. The only new ADR identified for daratumumab from CANDOR was sepsis (serious adverse event incidence:  KdD:  3.9 % , Kd:  1.3 % ). Sepsis does not represent a new important identified risk for daratumumab as sepsis is diagnosed, monitored, and managed through routine medical practice in these patients and the event does not require any additional risk minimization or additional pharmacovigilance activities.

## Safety in special populations

In CANDOR, the subject incidence of adverse events and serious adverse events was evaluated by age ( &lt; 65 years versus ≥ 65 years and &lt; 75 years versus ≥ 75 years).

## Subjects &lt; 65 Versus ≥ 65 Years

For subjects &lt; 65 years, adverse events were reported for a higher incidence of subjects in the KdD group (161 subjects [99.4 % ]) compared with the Kd group (72 subjects [93.5 % ]).

For subjects &lt; 65 years, adverse events of the SOCs with a ≥ 10 % higher subject incidence in the KdD group compared with the Kd group (KdD, Kd) were infections and infestations (82.1 % , 70.1 % ); general disorders and administration site conditions (58.0 % , 46.8 % ); and gastrointestinal disorders (54.3 % , 35.1 % ).  No SOC had a ≥ 10 % higher subject incidence in the Kd group compared with the KdD group.

For subjects ≥ 65 years, adverse events were reported for 145 subjects (99.3 % ) in the KdD group and 75 subjects (98.7 % ) in the Kd group.

For subjects ≥ 65 years, adverse events of the SOCs with a ≥ 10 % higher subject incidence in the KdD group compared with the Kd group (KdD, Kd) were infections and infestations (80.1 % , 63.2 % ); general disorders and administration site conditions (60.3 % , 50.0 % ); gastrointestinal disorders (56.8 % , 30.3 % ); and nervous system disorders (39.7 % , 25.0 % ).  No SOC had a ≥ 10 % higher subject incidence in the Kd group compared with the KdD group.

For subjects &lt; 65 years, serious adverse events were reported for a higher incidence of subjects in the KdD group (85 subjects [52.5 % ]) compared with the Kd group (31 subjects [40.3 % ]).

For subjects &lt; 65 years, serious adverse events of the SOCs with a ≥ 2 % higher subject incidence in the KdD group compared with the Kd group (KdD, Kd) were infections and infestations (25.3 % , 22.1 % ); respiratory, thoracic, and mediastinal disorders (8.6 % , 6.5 % ); cardiac disorders (7.4 % , 2.6 % ); blood and lymphatic system disorders (6.2 % , 3.9 % ); general disorders and administration site conditions (6.2 % , 3.9 % ); and musculoskeletal and connective tissue disorders (3.7 % , 1.3 % ).  For subjects &lt; 65 years, serious adverse events of the SOCs with a ≥ 2 % higher subject incidence in the Kd group compared with the KdD group (KdD, Kd) were renal and urinary disorders (2.5 % , 5.2 % ) and vascular disorders (1.9 % , 3.9 % ).

For subjects ≥ 65 years, serious adverse events were reported for a higher incidence of subjects in the KdD group (88 subjects [60.3 % ]) compared with the Kd group (39 subjects [51.3 % ]).

For subjects ≥ 65 years, serious adverse events of the SOCs with a ≥ 2 % higher subject incidence in the KdD group compared with the Kd group (KdD, Kd) were infections and infestations (34.2 % , 27.6 % );

<div style=\"page-break-after: always\"></div>

general disorders and administration site conditions (8.9 % , 3.9 % ); nervous system disorders (4.1 % , 0.0 % ); and investigations (3.4 % , 0.0 % ).  For subjects ≥ 65 years, serious adverse events of the SOCs with a ≥ 2 % higher subject incidence in the Kd group compared with the KdD group (KdD, Kd) were renal and urinary disorders (7.9 % , 2.7 % ); vascular disorders (1.4 % , 3.9 % ); and skin and subcutaneous tissue disorders (0.0 % , 2.6 % ).

## Subjects &lt; 75 Versus ≥ 75 Years

For subjects &lt; 75 years, adverse events were reported for 279 subjects (99.6 % ) in the KdD group and 125 subjects (95.4 % ) in the Kd group.

For subjects &lt; 75 years, adverse events of the SOCs with a ≥ 10 % higher subject incidence in the KdD group compared with the Kd group (KdD, Kd) were infections and infestations (81.8 % , 65.6 % ) and gastrointestinal disorders (56.1 % , 32.1 % ).  No SOC had a ≥ 10 % higher subject incidence in the Kd group compared with the KdD group.

For subjects ≥ 75 years, adverse events were reported for 27 subjects (96.4 % ) in the KdD group and 22 subjects (100 % ) in the Kd group.

For subjects ≥ 75 years, adverse events of the SOCs with a ≥ 10 % higher subject incidence in the KdD group compared with the Kd group (KdD, Kd) were general disorders and administration site conditions (71.4 % , 50.0 % ); gastrointestinal disorders (50.0 % , 36.4 % ); vascular disorders (46.4 % , 36.4 % ); nervous system disorders (46.4 % , 27.3 % ); injury, poisoning, and procedural complications (28.6 % , 18.2 % ); skin and subcutaneous tissue disorders (28.6 % , 9.1 % ); and renal and urinary disorders (17.9 % , 0.0 % ).  the SOCs with a ≥ 10 % higher subject incidence in the Kd group compared with the KdD group (KdD, Kd) were blood and lymphatic system disorders (42.9 % , 68.2 % ); psychiatric disorders (32.1 % , 45.5 % ); metabolism and nutrition disorders (22.7 % , 35.7 % ); and hepatobiliary disorders (3.6 % , 13.6 % ).

For subjects &lt; 75 years, serious adverse events were reported for 157 subjects (56.1 % ) in the KdD group and 58 subjects (44.3 % ) in the Kd group.

For subjects &lt; 75 years, serious adverse events of the SOCs with a ≥ 2 % higher subject incidence in the KdD group compared with the Kd group (KdD, Kd) were infections and infestations (28.9 % , 22.9 % ); respiratory, thoracic, and mediastinal disorders (10.7 % , 8.4 % ); cardiac disorders (8.2 % , 5.3 % ); general disorders and administration site conditions (6.8 % , 4.6 % ); and injury, poisoning, and procedural complications (4.3 % , 2.3 % ).  For subjects &lt; 75 years, serious adverse events of the SOCs with a ≥ 2 % higher subject incidence in the Kd group compared with the KdD group (KdD, Kd) were renal and urinary disorders (2.5 % , 7.6 % ) and vascular disorders (1.8 % , 4.6 % ).

For subjects ≥ 75 years, serious adverse events were reported for 16 subjects (57.1 % ) in the KdD group and 12 subjects (54.5 % ) in the Kd group.

For subjects ≥ 75 years, serious adverse events of the SOCs with a ≥ 2 % higher subject incidence in the KdD group compared with the Kd group (KdD, Kd) were general disorders and administration site conditions (14.3 % , 0.0 % ); and investigations; metabolism and nutrition disorders; nervous system disorders; and renal and urinary disorders (each 3.6 % , 0.0 % ).  For subjects ≥ 75 years, serious adverse events of the SOCs with a ≥ 2 % higher subject incidence in the Kd group compared with the KdD group (KdD, Kd) were respiratory, thoracic, and mediastinal disorders (14.3 % , 18.2 % ); gastrointestinal disorders (3.6 % , 9.1 % ); injury, poisoning, and procedural complications (3.6 % , 9.1 % ); blood and lymphatic system disorders (0.0 % , 4.5 % ); and psychiatric disorders (0.0 % , 4.5 % ).

<div style=\"page-break-after: always\"></div>

## Safety related to drug-drug interactions and other interactions

## Carfilzomib

No changes have been identified from the current carfilzomib product profile. Carfilzomib is primarily metabolized through peptidase and epoxide hydrolase activities, and as a result, the pharmacokinetic profile of carfilzomib is unlikely to be affected by concomitant administration of cytochrome P450 inhibitors and inducers. Carfilzomib is not expected to influence exposure of other drugs.

## Daratumumab

No interactions with concomitant medications are expected.

Daratumumab peak and trough concentrations at similar timepoints are comparable across monotherapy and combination therapy studies, including across different regimens within the same study, indicating that the regimen difference has no impact on the concentration of daratumumab.

## Post marketing experience

## Carfilzomib

The first approval for marketing worldwide for carfilzomib was in the United States on 20 July 2012. The EU approval for carfilzomib was granted on 19 November 2015. As of 17 October 2019, 66 countries (including the 28 EU member states) have granted marketing approval for carfilzomib with 1 or more indications.

## Daratumumab

Daratumumab first received marketing authorization in the United States on 16 November 2015. The EU approval for daratumumab was granted on 20 May 2016. As of 23 October 2019, daratumumab was approved in 88 countries with 1 or more indications.

## Postmarketing Reports

## Carfilzomib

As of 17 October 2019, Amgen received a total of 10330 ADRs cumulatively from medically confirmed and unconfirmed spontaneous sources, of which 4985 were serious and 5345 were nonserious. The MAH has also received a total of 7345 serious adverse reactions cumulatively from noninterventional postmarketing sources.

## Daratumumab

A cumulative review was performed on all postmarketing spontaneous cases of daratumumab and all events received by Janssen Global Medical Safety and entered into global safety database cumulatively through 04 March 2019. The results suggest that the drug's postmarketing safety profile is consistent with the known safety profile of daratumumab as a single agent or in combination therapy.

Overall, review of postmarketing spontaneous reports did not identify any new safety signal.

## Summary of Published Safety Data

## Carfilzomib

Literature through 19 January 2019 is summarized in Section 11 of PBRER; number 7. As of 17 October 2019, no new and significant safety findings have been identified from the literature.

## Daratumumab

<div style=\"page-break-after: always\"></div>

As of 15 May 2019, the overall rates and types of adverse events reported within the scientific and medical literature, including relevant published conference abstracts, were generally consistent with the known safety profile of either daratumumab or other anticancer agents used in the

## 2.5.1. Discussion on clinical safety

Carfilzomib has a known safety profile, based mainly on the results of ASPIRE and ENDEAVOR studies and other complementary studies. This new safety assessment, for the proposed new combination of Carfilzomib/Daratumumab/Dexamethasone for the treatment of multiple myeloma patients who have received, at least, one previous treatment, is based on the results of Study 20160275 (CANDOR).

Overall, the safety results from CANDOR study are similar to the previously known for carfilzomib but it should beborn  in mind that adding daratumumab to the combination, may increase the toxicity and change the management of adverse events during treatment.

In the CANDOR Study, carfilzomib exposure was longer in the KdD arm (58.36 vs 40.29 weeks), which could have had an impact on AEs incidence. After adjusting for exposure, the risk estimates for AEs remained higher in the KdD arm compared with the Kd arm as well as fatal AEs, however, serious adverse events appeared almost similar between treatment arms. Also, the median exposure is longer for daratumumab than carfilzomib in KdD arm (68.14 vs 58.36 weeks), with a difference of two cycles in the median number of them received. This suggests patients continued receiving daratumumab after discontinuing carfilzomib, which could have had an impact on the incidence and allocation of reported AEs. During the procedure, updated safety data with a data cut-off 19 Jan 2020 were provided. Exposureadjusted estimates were also included within the updated safety results and showed a similar trend than in the interim analysis, higher AEs incidences were reported in the KDd arm compared with the control arm, also related with the longer exposure reported in that arm.

Most common reported AEs (preferred term) for KdD in the CANDOR study were thrombocytopenia (37.3%), anaemia (32.8%), diarrhoea (31.5%), hypertension (30.5%), upper respiratory tract infection (29.2%) and fatigue (24.4%). Subject incidence highest differences in the KdD group compared with the Kd group (KdD, Kd) were thrombocytopenia (37.3%, 29.4%), diarrhea (31.5%, 14.4%), upper respiratory tract infection (29.2%, 22.9%), fatigue (24.4%, 18.3%), nausea (18.2%, 13.1%), pneumonia (17.9%, 12.4%), insomnia (17.9%, 11.1%), bronchitis (16.9%, 11.8%), back pain (16.2%, 9.8%), infusion-related reaction (7.8%, 2.0%), and peripheral sensory neuropathy (6.5%, 1.3%). The only ones not described on carfilzomib nor daratumumab SmPCs were insomnia and back pain. There were some AEs which subject incidences were higher in the Kd arm: asthenia, blood and lymphatic system disorders (SOC), dyspnoea, renal and urinary disorders (SOC). All of them are described on carfilzomib SmPC.

Grade ≥ 3 adverse events were reported for a higher incidence of subjects in the KdD group (82.1%) compared with the Kd group (73.9%). Higher incidence of grade ≥ 3 adverse events of the SOC of infections and infestations in KdD arm is remarkable (37.3% vs 29.4%). This appears to be attributable to a higher incidence of sepsis and lower and upper respiratory tract infections but all preferred terms had higher subject incidences in the KdD treatment arm except for urinary tract infections, which were higher for Kd arm. Differences between incidence of thrombocytopenia in both arms (16.3% vs 24.4%) in favour of KdD is worrying and could have an impact on haemorrhagic adverse events, which are an identified AESI for both carfilzomib and daratumumab. Having said that, an increase in haemorrhagic events was not observed in patients treated with KdD compared to Kd in the CANDOR study (14.3% vs 11.8%, respectively). On the contrary, deep vein thrombosis, cardiac failure and acute kidney injury reported higher incidences in Kd treatment arm.

<div style=\"page-break-after: always\"></div>

Regarding fatal AEs, 8 (5.2%) patients from Kd arm and 30 (9.7%) patients from KdD treatment arm died due to an TEAE, which means a 4.5% higher incidence for fatal AEs in KdD arm. The imbalance in the overall fatal adverse events appear to be attributable mainly to events in the SOC infections and infestations, where higher incidences of deaths were reported for all preferred terms in this group except for sepsis and influenza. Also, cardiac disorders (cardiac arrest, cardio-respiratory arrest and cardiac failure), as cause of deaths, were reported for 4 (1.3%) patients in the KdD arm while none for the Kd group. Among subjects with fatal adverse events, the median age of subjects with fatal adverse events was higher in the KdD group (68.5 years) compared with the Kd group (61.0 years), while in the ITT population, median age between groups was similar. Considering frailty status of the subjects with a fatal adverse event, a lower proportion of subjects in the KdD group (46.7 % ) compared with the Kd group (75.0 % ) had a frailty status of fit at baseline. Of note, in the ITT population, a higher proportion of subjects in the KdD group (56.4 % ) compared with the Kd group (44.2 % ) had a frailty status of fit at baseline.

Regarding medical history, it is worthy pointing out the following slightly unbalances between arms (Kd, KdD): vascular disorders (59.7%, 49.7%), an abnormal baseline electrocardiogram interpretation (34.4%, 26.2%), baseline history of hypertension (54.5%, 43.3%). These unbalances could have impact on safety finding, especially regarding cardiac AEs and fatal AEs due to cardiac events. An increased risk of cardiac adverse events and/or fatal cardiac adverse events was observed in patients treated with KdD compared with Kd, particularly in patients with baseline characteristics of vascular disorders, hypertension and abnormal ECG, although reported rates for all cardiac and vascular-related AEs did not show any particular trend based on the D120 updated safety data. For instance, regarding common AEs, cardiac arrest (1% vs 0%), atrial fibrillation (1.6% vs 0.7%) and acute myocardial infarction (1% vs 0.7%) were reported in higher incidences in KdD arm, while, on the contrary, cardiac failure (1.3% vs 2.6%), deep vein thrombosis (0.3% vs 1.3%) and angina pectoris (0.3% vs 1.3%) showed higher rates in the Kd arm (data from updated safety cutoff date). In comparison with the primary analysis, there were 5 additional serious ischemic heart disease eventsreported. Most of the subjects presented preexisting risk factors such as prior cardiac disease and hypertension.  Information on the increased incidence of cardiac events and/or fatal cardiac adverse events in patiets treated with KdD compared with Kd in patients with baseline characteristics or vascular disorders, hypertension and abnormal ECG is reflected in the SmPC (see sections 4.4 and 4.8).

By previously stablished criteria, additional ADRs for daratumumab have been identified in this new safety data cutoff, being hypertension one of them. No new ADRs have been identified for carfilzomib.

In the KdD group, 76.7% of subjects with fatal adverse events were refractory to the last prior line of therapy, compared with 37.5% in the Kd group. In comparison, in the intent-to-treat population, 52.9% of subjects in the KdD group and 61.7% of subjects in the Kd group were refractory to the last prior line of therapy. It was suspected that being refractory to the prior treatment line could have consequences on the tolerability to this combination but focusing on AEs leading to treatment discontinuation or dose reduction, no clear trend towards either of the arms was identified.

Similar incidence of AEs that led to discontinuation of carfilzomib were reported in both treatment arms. For carfilzomib dose reductions, 30 (19.6%) patients from Kd arm and 77 (25%) patients in the KdD arms suffered any AEs that led to carfilzomib dose reduction. The most common reported motives for these reductions, for both arms, were: hypertension, dyspnoea and fatigue. The incidences of treatmentemergent adverse events leading to any study treatment discontinuation for the refractory KdD and Kd subgroups and the nonrefractory KdD and Kd subgroups were higher in the updated safety analyses: 25.2 % , 22.1 % , 23.4 % and 27.6 % , respectively. The incidences of adverse events leading to carfilzomib discontinuation for the refractory KdD and Kd subgroups and the nonrefractory KdD and Kd subgroups were 23.9 % , 18.9 % , 22.8 % , and 25.9 % . However, the proportion of patient that discontinued dexamethasone was more than double in the Kd arm compared to the KdD arm (24.2% vs. 10.7%),

<div style=\"page-break-after: always\"></div>

probably due to the fact that some patients from the KDd arm maintained treatment with daratumumab (and dexamethasone) while discontinuated carfilzomib treatment.

Adverse events of interest for both carfilzomib and daratumumab include haemorrhage, tumor lysis syndrome, and hepatitis B reactivation. One subject of the KdD arm suffered fatal tumor lysis syndrome. Regarding AESI for carfilzomib, some differences could be clinically relevant, especially the ones found for cardiac events, leukopenia (mainly neutropenia), thrombocytopenia and infections, including opportunistic and viral infections. Besides, some other AESI for carfilzomib were more frequently reported in the KdD arm, such as infusion related reactions (7.8% KdD vs 2.0% Kd) and peripheral neuropathy (17.2% KdD vs 8.5% Kd). Overall, these differences may be expected to some extent taking into account the added effect of daratumumab. However, it is striking the higher rate, more than double, of PRES reported in the KdD arm compared to the Kd (12.3% vs. 5.2%). However, according to the MAH, only two cases met the case definition for PRES (presence of 4 classic symptons). In addition, a search from the daratumumab global database was performed by the MAH, where some cases were reported, and from the registrational trials, where no association between this event and the treatment with daratumumab was identified. PRES is already included as an ADR for carfilzomib.

Sepsis was identified as a new ADR for daratumumab based on CANDOR results, while no new ADRs for carfilzomib were identified through this study.

Being infections and infestations the most common reported AEs (by SOC), baseline demographics of patients who suffered them were included in the CSR but this data does not show any specific trend.

In CANDOR, the subject incidence of adverse events and serious adverse events was evaluated by age ( &lt; 65 years versus ≥ 65 years and &lt; 75 years versus ≥ 75 years) and conclusions were similar to the ones extracted from the overall safety population, apart from a higher number of fatal AEs reported in this population of elderly patients. Information on the higher incidence of fatal adverse events in elderly patients has been included in the PI (section 4.8).

Section 4.8 of the SmPC has been updated to include safety findings from CANDOR trial.

## 2.5.2. Conclusions on clinical safety

In safety terms, adding daratumumab to carfilzomib/dexamethasone in the target population results in predictable increased toxicity corresponding to the known safety profile of both medicinal products.

Safety results were worse for KdD arm vs. Kd arm, for all analysed levels: incidence AEs (96.1% vs 99.4%), Grade ≥ 3 (73.9% vs 82.1%), serious AEs (45.8% vs 56.2%) and fatal (5.2% vs 9.7%) although longer exposure in the KdD treatment arm could have had an impact on this data.

An increased risk of different types of infections has been reported in the CANDOR study and patients should be closely monitored.

Overall, the toxicity profile of KdD, based on the results form CANDOR study, is more pronounced than the Kd combination but manageable in clinical practice.

## 2.5.3. PSUR cycle

The requirements for submission of periodic safety update reports for this medicinal product are set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC and any subsequent updates published on the European medicines web-portal.

<div style=\"page-break-after: always\"></div>

## 2.6. Risk management plan

The CHMP endorsed the Risk Management Plan version 12.0 with the following content:

## Safety concerns

Table  15. Summary of the safety concerns

| Importantidentifiedrisks                      | Cardiac toxicity (cardiac failure, cardiomyopathy, myocardial ischemia, myocardial infarction and cardiac arrest) Pulmonary toxicities   |
|-----------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------|
| Important potential risks Missing information | Progressive multifocal leukoencephalopathy None                                                                                          |

## Pharmacovigilance plan

There are currently no additional pharmacovigilance activities for carfilzomib.

<div style=\"page-break-after: always\"></div>

## Risk minimisation measures

Table 16. Summary Table of Pharmacovigilance Activities and Risk Minimization Activities by Safety Concern

<!-- image -->

| Safety Concem                                                                                                     | Risk Minimization Measures                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | PharmacovigilanceAclivities                                                                                                                                                                                                                               |
|-------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Imporlant Identified Risks                                                                                        | Imporlant Identified Risks                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |                                                                                                                                                                                                                                                           |
| Cardiac toxicity (cardiac failure, cardiomyopathy. myocardial ischemia, myocardial infarction and cardiac arrest) | Routine risk minimization measures: SmPCSeclions 4.2and4.4 where advice is given on adjuslment of hydration and monitoring for volume SmPC Section 4.4 where slopping carfilzomib until recovery recommendation is given for SmPC Seclion 4.4 where recommendation is given to perfom a comprehensive cardiological assessment prior to starting treatmentwithcarfilzomibin patienls with signs or symptoms of NYHA Class Ill or IV cardiac failure, recent myo cardial infarction, or uncontrolled angina or arrhythmias and that suchpalients should be treatedwith cautionand remain under close follow-up SmPC Sections 4.8 and 5.3 PL Sections 2 and 4 Additional risk minimization measures: None | Routine pharmacovigilance activities beyond adverse reaclions reporting and signal deteclion: Adverse event follow-up form for acute myocardial infarclion, and congestive heart failure and cardiomyopathy Additional pharmacovigilance activities: None |
| Pulmonary toxicities                                                                                              | Routineriskminimization measures: SmPC Section 4.4 where recommendationisgiven to evaluale and stop carfilzomib until recovery. SmPC Seclions 4.8 and 5.3 PL Sections 2 and4 Additional risk minimization measures: None                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | Routinepharmacovigilance activitiesbeyond adverse reaclions reporting and signal deteclion: Adverse event follow-up fom for acute central respiratory disease and interstitial lung disease Additionalpharmacovigilance activities: None                  |

| Safety Concerm                             | Risk Minimization Measures                                                                                                                                                                                                                                                                                             | Pharmacovigilance Activities                                                                                                                                                                       |
|--------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Important Identified Risks (continued)     | Important Identified Risks (continued)                                                                                                                                                                                                                                                                                 | Important Identified Risks (continued)                                                                                                                                                             |
| Pulmonary hypertension                     | Routine risk minimization measures: SmPC Seclion4.4 where recommendation is given for slopping carfilzomib until recovery SmPC Seclion 4.8 PL Sections 2 and 4 Additional risk minimization measures: None                                                                                                             | Routinepharmacovigilance activities beyond adverse reaclions reporting and signal deteclion: Adverse event follow-up form for pulmonary hyperlension Additional pharmacovigilance activities: None |
| Dyspnea                                    | Routine risk minimization measures: SmPC Seclion 4.4 where advice is given to evaluate dyspnea to exclude cardiopulmonary conditions and stop carfilzomib in subjects with grade 3 or 4 dyspnea until resolved or retumed to baseline SmPC Seclion 4.8 PL Seclions 2 and 4 Additional risk minimization measures: None | None                                                                                                                                                                                               |
| Hypertension including hypertensive crises | Routine risk minimization measures: SmPC Section 4.4 where advice is given to control hypertension prior to carfilzomib treatment, routinely evaluate for hypertension,and reduce or stop carfilzomib until resolved SmPC Seclion 4.8 PL Sections 2 and 4 Additional risk minimization measures: None                  | None                                                                                                                                                                                               |

<div style=\"page-break-after: always\"></div>

<!-- image -->

| Salely Concern                                      | Risk Minimization Measures                                                                                                                                                                                                                                                                                                                                                                                       | Pharmacovigilance Activities                                                                                                                                                                     |
|-----------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Important Identified Risks (continued)              | Important Identified Risks (continued)                                                                                                                                                                                                                                                                                                                                                                           |                                                                                                                                                                                                  |
|                                                     | Acute renal failureRoutine risk minimizationmeasures: SmPCSeclion 4.2whereadvice is given regarding reductionfor starting dose of lenalidomide in patients with baseline renal impairment and monitoring during carfilzomib treatment SmPC Seclion 4.4 where recommendation is given for monitoring of renal failure SmPC Seclions4.8,5.2,and5.3 PL Seclions 2 and 4 Additional risk minimization measures: None | Routine pharmacovigilance aclivities beyond adverse reaclions reporting and signal deteclion: Adverse event follow-up fomm for acute renal failure Additional pharmacovigilance aclivities: None |
| Thrombotic microangiopathy                          | Routine risk minimization measures: SmPCSection 4.4whereadvice is given for monitoring events and to discontinue carfilzomib if diagnosis suspecled SmPC Section4.8 PL Sections 2and4 Additional risk minimization measures: None                                                                                                                                                                                | None                                                                                                                                                                                             |
| Posterior reversible encephalopathy syndrome (PRES) | Routine risk minimization measures: SmPC Section 4.4where advice is given to stop carfilzomib treatment if diagnosis suspected SmPC Section4.8 ·PL Seclions 2 and4 Additional risk minimization measures: None                                                                                                                                                                                                   | Routine pharmacovigilance aclivitiesbeyond adverse reaclions reporting and signal detection: Adverse event follow-up fom for PRES Additional pharmacovigilance activities: None                  |
| Safety Concern                                      | Risk Minimizalion Measures                                                                                                                                                                                                                                                                                                                                                                                       | Pharmacovigilance Activities                                                                                                                                                                     |
| Important Identified Risks (continued)              | Important Identified Risks (continued)                                                                                                                                                                                                                                                                                                                                                                           |                                                                                                                                                                                                  |
| Hepatitis B virus reactivation                      | Routine risk minimization measures: SmPC Section4.4 where advice is given to screen patienlsforHBV infection, consider prophylaxis with antivirals,monitor for signs of HBV reactivation,and to consult experts asnecessary SmPC Seclion 4.8 PL Seclions 2 and 4 Additional risk minimizationmeasures: None                                                                                                      | Routine pharmacovigilance activitiesbeyondadverse reactions reporling and signal detection: None Additional pharmacovigilance activities: None                                                   |
| Important Potential Risks                           | Important Potential Risks                                                                                                                                                                                                                                                                                                                                                                                        |                                                                                                                                                                                                  |
| Progressive multifocal leukoencephalopalhy          | Routine risk minimization measures. SmPC Section4.4 where advice is given to monitor patients for any new or worsening signs and symptoms of PML, suspend administration until PML has been excluded by a specialist, and discontinue carfilzomib if a PML dagnosis is confinmed PL Secion 2 None                                                                                                                | Routine pharmacovigilance aclivities beyond adverse reacions reporting and signal detection: Adverse event follow-up form for PML Additional pharmacovigilance activities: None                  |
| Missing Infomation                                  | Missing Infomation                                                                                                                                                                                                                                                                                                                                                                                               |                                                                                                                                                                                                  |
| None                                                | Additional risk minimization measures:                                                                                                                                                                                                                                                                                                                                                                           |                                                                                                                                                                                                  |

Page 4 of 4

<div style=\"page-break-after: always\"></div>

## 2.7. Update of the Product information

Please refer to Attachment 1 which includes all agreed changes to the Product Information.

## 2.7.1. User consultation

A justification for not performing a full user consultation with target patient groups on the package leaflet has been submitted by the MAH and has been found acceptable.

## 3. Benefit-Risk Balance

## 3.1. Therapeutic Context

## 3.1.1. Disease or condition

Multiple myeloma, an oligoclonal neoplastic proliferation of plasma cells, is the second most common hematologic malignancy with an estimated incidence worldwide in 2018 of 159 985 persons (Ferlay et al, 2018).  The 5-year prevalence of multiple myeloma worldwide was estimated at 376 005 persons.

The primary goals of treatment for relapsed or refractory multiple myeloma are to achieve deep and durable response and subsequently longer survival with an acceptable level of toxicity.  Additional goals are to prevent or delay disease-related morbidity (including bone fractures and renal insufficiency), to provide relief from pain and other disease-related symptoms, and to maintain the best possible quality of life (World Health Organization, 2019; Landgren and Iskander, 2017; Durie, 2010; Durie, 2005).

Multiple myeloma may represent less than 1 % of all cancer diagnoses but contributes to significant disease burden with over 2 million disability-adjusted life-years (Cowan et al, 2018; Bray et al, 2013). Despite recent therapeutic advances which have prolonged survival, multiple myeloma remains a fatal disease with nearly 100 000 annual deaths worldwide (1 % of cancer deaths) (Cowan et al, 2018; Kazandjian, 2016; Ferlay et al, 2015).  Multiple myeloma is a disease of older adults, with a median age at diagnosis of 69 years (Surveillance, Epidemiology, and End Results Cancer Stat Facts, 2019).

## 3.1.2. Available therapies and unmet medical need

Regimens used and/or approved for the treatment of multiple myeloma incorporate conventional agents such as alkylating agents, anthracyclines, and corticosteroids, as well as novel agents including immunomodulatory drugs (IMiDs), proteasome inhibitors, monoclonal antibodies, and histone deacetylase inhibitors (National Comprehensive Cancer Network [NCCN], 2020; Moreau et al, 2017).  The novel and conventional agents are typically combined as doublet or triplet regimens and are sequenced across multiple lines of therapy.

Current treatment guidelines by NCCN and ESMO recommend regimens containing an IMiD for frontline therapy as well as lenalidomide for maintenance therapy, which has become standard of care (NCCN, 2020; Facon et al, 2018; Pulte et al, 2018; Moreau et al, 2017; McCarthy et al, 2017).

Despite recent therapeutic advances, relapse is virtually inevitable and patients can become refractory to IMiDs (Nijhof et al, 2018; Sonneveld et al, 2017; Cornell and Kassim, 2016).  Outcomes tend to be worse for patients who are refractory to lenalidomide than the overall population (Moreau et al, 2019).

<div style=\"page-break-after: always\"></div>

## 3.1.3. Main clinical studies

The CANDOR study was designed to allow the recruitment of patients with MM previously treated with at least one prior line (transplant is considered as 1 line of therapy) but not more than three. Patients were 2:1 randomized to KdD and Kd arms, using as stratification factors: original ISS stage, lines of therapy, prior PI exposure and prior CD38 Ab exposure. Prior therapy with carfilzomib and anti-CD38 antibodies were allowed as previous treatment, provided at least PR was obtained and there was a treatment-free interval of 6 months. Patients refractory to any prior lenalidomide treatment and any prior PI-including regimen were allowed.

Posology used for Kyprolis is in line with posology authorized based Endeavor study in the same population. Posology for daratumumab is in line with posology reflected in the SmPC.

The rational for the selected dose of 56 mg/m 2  twice-weekly was based on the available mature safety long-term data for Kd from the ENDEAVOR study and the fact that daratumumab had already been added to other doublets, including proteasome inhibitors without adding considerable toxicity.

PFS was the primary endpoint, with ORR, MRD(-)CR and OS as key secondary endpoints. The use of PFS as main outcome variable is acceptable, given that there are different efficacious treatment alternatives that patients could receive, which will likely modify the expected survival.

Although the design of the study is unblinded, the use of an IRC to assess response (as defined by IMWGURC) is endorsed. In addition, the different sensitive analyses planned increase the level of robustness of the results.

## 3.2. Favourable effects

The population recruited in the study is the one expected at relapse.

A statistically significant difference was observed for PFS (as assessed by the IRC) between the KdD and Kd groups (HR = 0.630; 95% CI: 0.464, 0.854; p = 0.0014) in the final PFS analysis. This result seems robust as the different sensitive analyses (investigator and ORCA among others) offer similar results.

The other secondary key variables ORR and MRD(-)CR at 12 months (at a 10-5 level) according to IRC support the PFS results. The ORR as assessed by IRC was 84.3% (95% CI: 79.8, 88.1) in the KdD group and 74.7% (95% CI: 67.0, 81.3) in the Kd group (odds ratio: 1.925 [95% CI: 1.184, 3.129]; p = 0.0040). The MRD[-]CR rate at 12 months (at a 10-5 level) based on IRC assessment was 12.5% (95% CI: 9.0, 16.7) in the KdD group and 1.3% (95% CI: 0.2, 4.6) in the Kd group (odds ratio: 11.329 [95% CI: 2.703, 47.476]; p &lt; 0.0001). The sensitive analyses (investigator and ORCA among others) for ORR and MDR(-)CR offer similar results.

Additional secondary endpoints such as DoR and time to next treatment are overall in line with PFS.

## 3.3. Uncertainties and limitations about favourable effects

Data from only 1 patient in KdD arm received previous CD38 therapy are included in this submission which does not allow assessment of previous exposure effect. This information is included in section 5.1 of the SmPC.

Lenalidomide and IMiD was administered to 42.3% and 67.8%, respectively with slightly differences between arms (lenalidomide: 48.1% in Kd and 39.4% in KdD and IMiD: 71.4% in Kd and 66.0% in KdD). These unbalances are lower for the refractory populations, maximum 4% in favour of KdD between arms. That could be a confounding factor on results observed, especially on subgroups analyses.

<div style=\"page-break-after: always\"></div>

Overall survival data were not mature at the time of the analysis, and while, a trend toward longer OS in the KdD arm compared with Kd armin the overall population and even in elderly patients for OS could be observed. Current OS data are not mature. The first OS interim analysis offered a positive trend for KdD vs Kd (HR 0.745 (95% CI: 0.491, 1.131; p = 0.0836). The OS event-free rate was 84.5% in the KdD group and 85.2% in the Kd group at 12 months and 79.9% in the KdD group and 74.4% in the Kd group at 18 months. Results from a second IA were overall consistent with the first IA. A trend in favour of KdD was observed although statistical significance was not reached (HR 0.758; 95% CI: 0.536, 1.073; p = 0.0590). The MAH has accepted a recommendation from the CHMP to provide data from an additional interim analysis for OS and the final analysis post authorization.

Overall, the subgroups analyses suggested a potential benefit of KdD vs Kd in most subgroups. However, results should be interpreted with caution since there are several subgroups with categories crossing 1 and there are several inconsistences in some subgroups between PFS and ORR analysis. There are two subgroups in which the benefit of KdD vs Kd seems to be less clear in all subgroup analyses: patients &gt; 75 and patients refractory to bortezomib and ixazomib. It is noted that the percentage of subjects aged 75 to 84 years was lower in the KdD group (9.0%) than in the Kd group (14.3%) and no patients ≥ 85 years have been included in this study. It is considered that the small size of the subgroup of patients over 75 years of age precludes any firm conclusion, the available information is reflected in the PI, to make it available to the prescribing physician. Furthermore, while a trend in favour of KdD is observed in the overall population and even in elderly patients for OS, according to the KM curves there was a higher rate of deaths in elderly patients treated with KdD compared with those receiving Kd during (approximately) the first year of treatment. This could be related to the higher rate of fatal adverse events reported in subjects ≥ 65 years of age . A statement in this regard is included in the PI.

In the same way, only a non-statistically significant positive trend was observed in PFS for the European region subgroup (HR= 0.857 [95% CI: 0.596 - 1.231], 66% of the subjects) whereas results were highly statistically significant for the North-America region (HR= 0.041 [95% CI=0.005; 0.339], 7% of the subjects). Baseline disease characteristics were further explored in both groups to clarify if a worse disease prognosis of European subjects at randomization could have impacted the results but no clear trend was identified. Moreover, the small size of the North America subgroup and the fact that region was not a stratification factor preclude any definitive interpretation of these results.

## 3.4. Unfavourable effects

In CANDOR, 306 subjects (99.4 % ) in the KdD group and 147 subjects (96.1 % ) in the Kd group had at least 1 adverse event. A higher subject incidence in the KdD group compared with the Kd group was reported (KdD, Kd) for grade ≥ 3 adverse events (82.1 % , 73.9 % ), serious adverse events (56.2 % , 45.8 % ), and fatal adverse events (9.7 % , 5.2 % ).  A similar subject incidence in the KdD group and the Kd group was reported for adverse events that led to the discontinuation of carfilzomib (KdD:  21.1 % , Kd:  21.6 % ).

Adverse events that occurred with a ≥ 5% higher subject incidence in the KdD group compared with the Kd group (KdD, Kd) were thrombocytopenia (37.3%, 29.4%), diarrhea (31.5%, 14.4%), upper respiratory tract infection (29.2%, 22.9%), fatigue (24.4%, 18.3%), nausea (18.2%, 13.1%), pneumonia (17.9%, 12.4%), insomnia (17.9%, 11.1%), bronchitis (16.9%, 11.8%), back pain (16.2%, 9.8%), infusion-related reaction (7.8%, 2.0%), and peripheral sensory neuropathy (6.5%, 1.3%). No adverse even ts occurred with a ≥ 5% higher subject incidence in the Kd group than in the KdD group.

Grade ≥ 3 adverse events of the SOC of infections and infestations occurred more frequently (≥ 5% difference in subject incidence) in the KdD group (37.3%) compared wit h the Kd group (29.4%). Grade ≥ 3 adverse events that occurred with a ≥ 2% higher subject incidence in the KdD group compared wi th the Kd group (KdD, Kd) were thrombocytopenia (24.4%, 16.3%), anemia (16.6%, 14.4%), neutropenia

<div style=\"page-break-after: always\"></div>

(8.4%, 5.9%), pneumonia (13.3%, 8.5%), sepsis (3.9%, 1.3%), influenza (3.6%, 0.7%), hypertension (17.5%, 13.1%), fatigue (7.8%, 4.6%), and diarrhea (3.9%, 0.7%).

Pneumonia and thrombocytopenia were grade ≥ 3 adverse events that occurred more frequently ( ≥ 5% difference) in the Kd group than in the KdD group (24.4 versus 16.3%).

It should also be pointed out that incidence of reversible posterior leucoencephalopathy syndrome (PRES), already reported with carfilzomib, was higher in the KdD arm (12.3% versus 5.2%).

Serious adverse events of the SOCs with a ≥ 2 % difference in the KdD group compared with the Kd group (KdD, Kd) were infections and infestations (29.5 % , 24.8 % ) and general disorders and administration site conditions (7.5 % , 3.9 % ).

Fatal adverse events of the SOCs with a ≥ 1 % difference in the KdD group compared with the Kd group (KdD, Kd) were infections and infestations (4.5 % , 2.6 % ) and cardiac disorders (1.3 % , 0.0 % ). Events from the SOC infections and infestations accounted for most fatal adverse events in the KdD group and included septic shock (5 subjects [1.6 % ]), pneumonia (4 subjects [1.3 % ]), and sepsis (3 subjects [1.0 % ]).

The most frequently reported (occurring in ≥ 2% of subjects in either treatment group [KdD, Kd]) adverse events that led to treatment discontinuation of carfilzomib were cardiac failure (1.9%, 2.0%), hypertension (1.3%, 2.0%), and acute kidney injury (0.3%, 2.0%). The most frequently reported (occurring in ≥ 1% of subjects in either treatment group [KdD, Kd]) grade ≥ 3 adverse events that led to discontinuation of carfilzomib were fatigue (1.9%, 0.7%), hypertension (1.3%, 1.3%), cardiac failure (1.0%, 1.3%), acute kidney injury (0.3%, 2.0%), thrombotic thrombocytopenic purpura (0.6%, 1.3%), plasma cell myeloma (0.6%, 1.3%), pulmonary oedema (0.6%, 1.3%), pneumonia (1.3%, 0.0%), proteinuria (0.3%, 1.3%), and septic shock (1.0%, 0.0%).

Overall, 9.1% of subjects in the KdD group had at least 1 adverse event leading to the discontinuation of daratumumab. The most frequently reported (occurring in ≥ 1% of subjec ts) adverse events that led to the discontinuation of daratumumab were cardiac failure (1.0%), pneumonia (1.3%), and septic shock (1.0%).

The most frequently reported (occurring in ≥ 1% of subjects in the KdD group) grade ≥ 3 adverse events that led to the discontinuation of daratumumab were pneumonia (1.3%) and septic shock (1.0%).

Updated safety data provided showed similar trends. Higher AEs incidences were found for KDd arm in all the above-mentioned categories, in relation with the significant longer exposure reported for the experimental arm.

## 3.5. Uncertainties and limitations about unfavourable effects

Regarding medical history, some unbalances were observed between arms (Kd, KdD): vascular disorders (59.7%, 49.7%), an abnormal baseline electrocardiogram interpretation (34.4%, 26.2%), baseline history of hypertension (54.5%, 43.3%). These unbalances could have impact on safety finding, especially regarding cardiac AEs and fatal AEs due to cardiac events. An increased risk of cardiac adverse events and/or fatal cardiac adverse events was observed in patients treated with KdD compared with Kd, particularly in patients with baseline characteristics of vascular disorders, hypertension and abnormal ECG, although no clear trend was identified when analysing by SOC and PT. This information is included in the PI.

A higher rate of fatal AEs was reported in the KdD arm compared to the Kd arm (9.7% vs.5.2%), mainly driven by infections (particularly septic shock and pneumonia) and cardiac disorders. The latter is of concern taking into account the apparently better 'cardiovascular status' of patients treated with KdD, as

<div style=\"page-break-after: always\"></div>

stated before. Furthermore, more than a half of the reported deaths in the KdD arm occurred in elderly patients (i.e. ≥65 years). KdD should be used wit h caution in patients ≥75 years after careful consideration of the potential benefit/risk on an individual basis.

In the KdD group, 76.7% of subjects with fatal adverse events were refractory to the last prior line of therapy, compared with 37.5% in the Kd group. In comparison, in the intent-to-treat population, 52.9% of subjects in the KdD group and 61.7% of subjects in the Kd group were refractory to the last prior line of therapy. This could have consequences on the tolerability to this combination but incidences of AEs leading to treatment discontinuation and dose reductions were similar across all subgroups when compared to overall population, although were higher for KDd arm in almost all cases.

## 3.6. Effects Table

Table 2. Effects Table for Kyprolis in combination with dexamethasone and daratumumab for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma (data cut-off: 14 July 2019)

| Effect                                                 | Short description                                                            | Unit                                                   | Treatment (KdD)                                        | Control (Kd)                                           | Uncertainties / Strength of evidence                                                                                                                                | References                                             |
|--------------------------------------------------------|------------------------------------------------------------------------------|--------------------------------------------------------|--------------------------------------------------------|--------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------|
| Favourable Effects                                     | Favourable Effects                                                           | Favourable Effects                                     | Favourable Effects                                     | Favourable Effects                                     | Favourable Effects                                                                                                                                                  | Favourable Effects                                     |
| PFS (IRC)                                              | time from randomization until disease progression or death from any cause    | Median (months)                                        | NE                                                     | 15.8                                                   | HR = 0.630; 95% CI: 0.464, 0.854; p = 0.0014 Result not consistent among subgroups analysis Sensitivity analyses support the main result                            |                                                        |
| ORR (IRC)                                              | Proportion of subjects who achieved best response (sCR, CR, VGPR, PR)        | %of patients                                           | 84.3                                                   | 74.7                                                   | Result not consistently reported in the subgroup analysis                                                                                                           |                                                        |
| MRD[- ]CR (IRC)                                        | Proportion of subjects who achieved complete response (CR) and MRD[-] status | %of patients                                           | 12.5                                                   | 1.3                                                    | Result inconsistent among subgroups                                                                                                                                 |                                                        |
| OS                                                     | Overall survival                                                             | Median (months)                                        | NE                                                     | NE                                                     | Immaturity of data (1 st Interim Analysis) HR = 0.745 (95% CI: 0.491, 1.131); p = 0.0836 (2 nd IA -DCO: 15 Jun 2020) HR = 0.758 (95% CI: 0.536, 1.073); p = 0.0590) |                                                        |
| Unfavourable Effects (safety data cutoff: 20 Jan 2020) | Unfavourable Effects (safety data cutoff: 20 Jan 2020)                       | Unfavourable Effects (safety data cutoff: 20 Jan 2020) | Unfavourable Effects (safety data cutoff: 20 Jan 2020) | Unfavourable Effects (safety data cutoff: 20 Jan 2020) | Unfavourable Effects (safety data cutoff: 20 Jan 2020)                                                                                                              | Unfavourable Effects (safety data cutoff: 20 Jan 2020) |
| AEs                                                    |                                                                              | n (%)                                                  | 307 (99.7)                                             | 148 (96.7)                                             |                                                                                                                                                                     |                                                        |
| G3/4 AEs                                               |                                                                              | n (%)                                                  | 261 (84.7)                                             | 114 (74.5)                                             |                                                                                                                                                                     |                                                        |
| Serious AEs                                            |                                                                              | n (%)                                                  | 188 (61)                                               | 72 (47.1)                                              |                                                                                                                                                                     |                                                        |
| fatal AEs                                              | infections and infestations (4.5%, 2.6%) and cardiac disorders (1.3%,        | n (%)                                                  | 8 (5.2)                                                | 30 (9.7)                                               |                                                                                                                                                                     |                                                        |

<div style=\"page-break-after: always\"></div>

| Effect                                                   | Short description                                                                             | Unit   | Treatment (KdD)   | Control (Kd)   | Uncertainties / Strength of evidence   | References   |
|----------------------------------------------------------|-----------------------------------------------------------------------------------------------|--------|-------------------|----------------|----------------------------------------|--------------|
|                                                          | 0.0%)                                                                                         |        |                   |                |                                        |              |
| AEs leading to treatment discontinuat ion (carfilzomib ) | cardiac failure (1.9%, 2.0%), hypertension (1.3%, 2.0%), and acute kidney injury (0.3%, 2.0%) | n (%)  | 72 (23.4)         | 33 (21.6)      |                                        |              |

Abbreviations:

Notes:

## 3.7. Benefit-risk assessment and discussion

## 3.7.1. Importance of favourable and unfavourable effects

Results on PFS, ORR and MRD(-)CR at 12 months seem to be consistent and robust.

Overall, the subgroups analyses suggested a potential benefit of KdD vs Kd in most subgroups. However, results should be interpreted with caution since there are several subgroups with categories crossing 1 and there are several inconsistences in some subgroups between PFS and ORR analysis. There are two subgroups in which the benefit of KdD vs Kd seems to be less clear in all subgroup analyses: patients &gt; 75 and refractory to bortezomib and ixazomib. The (limited) available information in the subgroup of patients over 75 years of age should be reflected in section 5.1 of the SmPC.

From a safety point of view, the addition of daratumumab to Kd results in a predictable increased toxicity corresponding to the known safety profile of both medicinal products. This increase is particularly noticeable for cardiac disorders, haematological toxicity and infections, some of them with a fatal outcome. Moreover, it is of concern the higher rate of fatal adverse events observed in elderly patients treated with KdD.

## 3.7.2. Balance of benefits and risks

The superiority of the new combination of carfilzomib plus dexamethasone plus daratumumab (KdD) vs. carfilzomib plus dexamethasone (Kd) has been shown in terms of improved PFS and improved depth of response. OS results showed an apparently significant benefit for those patients treated with KdD.

## 3.8. Conclusions

The overall B/R of Kyprolis is considered positive.

## 4. Recommendations

## Outcome

Based on the review of the submitted data, the CHMP considers the following variation acceptable and therefore recommends the variation to the terms of the Marketing Authorisation, concerning the following change:

<div style=\"page-break-after: always\"></div>

| Variation accepted   | Variation accepted                                                                                                             | Type    | Annexes affected   |
|----------------------|--------------------------------------------------------------------------------------------------------------------------------|---------|--------------------|
| C.I.6.a              | C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one | Type II | I and IIIB         |

Extension of existing indication to include combination of Kyprolis with daratumumab and dexamethasone; as a consequence, sections 4.1, 4.2, 4.8 and 5.1 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 12.0 of the RMP has also been submitted.

The variation leads to amendments to the Summary of Product Characteristics and Package Leaflet.

## Amendments to the marketing authorisation

In view of the data submitted with the variation, amendments to Annex(es) I and IIIB are recommended.

## Similarity with authorised orphan medicinal products

The CHMP by consensus is of the opinion that Kyprolis is not similar to Imnovid, Farydak, Darzalex, Ninlaro and Blenrep within the meaning of Article 3 of Commission Regulation (EC) No. 847/200.

## 5. EPAR changes

The EPAR will be updated following Commission Decision for this variation. In particular the EPAR module 8 \" steps after the authorisation \" will be updated as follows:

## Scope

Please refer to the Recommendations section above.

## Summary

Please refer to Scientific Discussion Kyprolis-H-C-003790-II-0045